| 1 |
Talebzadeh AT, Talebzadeh N. Facial Presentation of Crohn’s Disease: Report of a Case. Cureus 2023. [DOI: 10.7759/cureus.36024] [Reference Citation Analysis]
|
| 2 |
Roncaioli JL, Babirye JP, Chavez RA, Liu FL, Turcotte EA, Lee AY, Lesser CF, Vance RE. A hierarchy of cell death pathways confers layered resistance to shigellosis in mice. Elife 2023;12. [PMID: 36645406 DOI: 10.7554/eLife.83639] [Reference Citation Analysis]
|
| 3 |
Leeds IL, Lightner AL, Kurowski JA. Perioperative Immunosuppression in Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease 2023. [DOI: 10.1007/978-3-031-14744-9_43] [Reference Citation Analysis]
|
| 4 |
Nasab AS, Finkler M, Delozier S, Sferra TJ, Splawski J, Moses J. Comparison of Short-Term Outcomes for Standard Versus Nonstandard Induction Dosing of Infliximab for Pediatric Inflammatory Bowel Disease. The Journal of Pediatric Pharmacology and Therapeutics 2022;27:732-738. [DOI: 10.5863/1551-6776-27.7.732] [Reference Citation Analysis]
|
| 5 |
Nakanishi A, Toyama S, Onozato D, Watanabe C, Hashita T, Iwao T, Matsunaga T. Effects of human induced pluripotent stem cell-derived intestinal organoids on colitis-model mice. Regen Ther 2022;21:351-61. [PMID: 36161099 DOI: 10.1016/j.reth.2022.08.004] [Reference Citation Analysis]
|
| 6 |
Roncaioli JL, Babirye JP, Chavez RA, Liu FL, Turcotte EA, Lee AY, Lesser CF, Vance RE. A hierarchy of cell death pathways confers layered resistance to shigellosis in mice.. [DOI: 10.1101/2022.09.21.508939] [Reference Citation Analysis]
|
| 7 |
Zhang C, Li W, Chen L, Chen Z, Wang X, Xu Q, Zhang H, Chen H, Liu J. Oregano Oil Combined with Macleaya Cordata Oral Solution Improves the Growth Performance and Immune Response of Broilers. Animals 2022;12:2480. [DOI: 10.3390/ani12182480] [Reference Citation Analysis]
|
| 8 |
Lee J, Chung K, Shin J, Jung S, Lee S, Lee M, Hong H, Rhee YK, Lee K. Anti-Colitic Effect of an Exopolysaccharide Fraction from Pediococcus pentosaceus KFT-18 on Dextran Sulfate Sodium-Induced Colitis through Suppression of Inflammatory Mediators. Polymers 2022;14:3594. [DOI: 10.3390/polym14173594] [Reference Citation Analysis]
|
| 9 |
Stange EF. Current and future aspects of IBD research and treatment: The 2022 perspective. Front Gastroenterol 2022;1. [DOI: 10.3389/fgstr.2022.914371] [Reference Citation Analysis]
|
| 10 |
Mojtabavi S, Saed A, Aboulfazli S, Kheirandsih A, Najafi M, Jafari-sabet M, Ziar A, Ebrahimi N, Mirmajidi SH, Ataee R. Evaluation of curcumin effect on Il6, Sirt1, TNFα and NFkB expression of liver tissues in diabetic mice with STZ. J Diabetes Metab Disord. [DOI: 10.1007/s40200-022-01090-4] [Reference Citation Analysis]
|
| 11 |
Alexdottir MS, Bourgonje AR, Karsdal MA, Pehrsson M, Loveikyte R, van Dullemen HM, Visschedijk MC, Festen EAM, Weersma RK, Faber KN, Dijkstra G, Mortensen JH. Serological Biomarkers of Intestinal Collagen Turnover Identify Early Response to Infliximab Therapy in Patients With Crohn’s Disease. Front Med 2022;9. [DOI: 10.3389/fmed.2022.933872] [Reference Citation Analysis]
|
| 12 |
Uchiyama K, Takagi T, Mizushima K, Asaeda K, Kajiwara M, Kashiwagi S, Toyokawa Y, Hotta Y, Tanaka M, Inoue K, Dohi O, Okayama T, Yoshida N, Katada K, Kamada K, Ishikawa T, Yasuda H, Konishi H, Kishimoto M, Naito Y, Itoh Y. Mucosal interleukin-8 expression as a predictor of subsequent relapse in ulcerative colitis patients with Mayo endoscopic subscore 0. J Gastroenterol Hepatol 2022;37:1034-42. [PMID: 35233808 DOI: 10.1111/jgh.15813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 13 |
Cai SQ, Tang ZM, Xiong C, Wu FF, Zhao JR, Zhang Q, Wang L, Zhang XN, Zhao XH. The anti-inflammatory effects of apigenin and genistein on the rat intestinal epithelial (IEC-6) cells with TNF-α stimulation in response to heat treatment. Curr Res Food Sci 2022;5:918-26. [PMID: 36686365 DOI: 10.1016/j.crfs.2022.05.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 14 |
Nie K, Zhang C, Deng M, Luo W, Ma K, Xu J, Wu X, Yang Y, Wang X. A Series of Genes for Predicting Responses to Anti-Tumor Necrosis Factor α Therapy in Crohn's Disease. Front Pharmacol 2022;13:870796. [PMID: 35517818 DOI: 10.3389/fphar.2022.870796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Raine T, Danese S. Breaking Through the Therapeutic Ceiling: What Will It Take? Gastroenterology 2022;162:1507-11. [PMID: 34995533 DOI: 10.1053/j.gastro.2021.09.078] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 16 |
Bossuyt P, Pouillon L, Claeys S, D'Haens S, Hoefkens E, Strubbe B, Marichal D, Peeters H. Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial. J Crohns Colitis 2022;16:199-206. [PMID: 34297099 DOI: 10.1093/ecco-jcc/jjab127] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 17 |
Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn's disease. Therap Adv Gastroenterol 2022;15:17562848221078456. [PMID: 35198041 DOI: 10.1177/17562848221078456] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 18 |
Kleinhenz J, Wagner E. Biologics in Pediatric Inflammatory Bowel Disease. Pediatr Ann 2022;51:e77-81. [PMID: 35156888 DOI: 10.3928/19382359-20220113-01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Shen JL, Zhou Z, Cao JS, Zhang B, Hu JH, Li JY, Liu XM, Juengpanich S, Li MS, Feng X. Biologic therapy for Crohn’s disease over the last 3 decades. World J Clin Cases 2022; 10(2): 594-606 [DOI: 10.12998/wjcc.v10.i2.594] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Liso M, Sila A, Verna G, Scarano A, Donghia R, Castellana F, Cavalcanti E, Pesole PL, Sommella EM, Lippolis A, Armentano R, Giudetti AM, Vergara D, Campiglia P, Sardone R, Curlo M, Mastronardi M, Petroni K, Tonelli C, Santino A, Chieppa M. Nutritional Regimes Enriched with Antioxidants as an Efficient Adjuvant for IBD Patients under Infliximab Administration, a Pilot Study. Antioxidants 2022;11:138. [DOI: 10.3390/antiox11010138] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 21 |
Kroenke MA, Barger TE, Hu J, Miller MJ, Kalenian K, He L, Hsu H, Bartley Y, Chow VF, Teixeira Dos Santos MC, Sullivan BA, Cheng LE, Parnes JR, Padaki R, Kuhns S, Mytych DT. Immune Complex Formation Is Associated With Loss of Tolerance and an Antibody Response to Both Drug and Target. Front Immunol 2021;12:782788. [PMID: 34970265 DOI: 10.3389/fimmu.2021.782788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 22 |
Markovics A, Rosenthal KS, Mikecz K, Carambula RE, Ciemielewski JC, Zimmerman DH. Restoring the Balance between Pro-Inflammatory and Anti-Inflammatory Cytokines in the Treatment of Rheumatoid Arthritis: New Insights from Animal Models. Biomedicines 2022;10:44. [DOI: 10.3390/biomedicines10010044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 23 |
Clark I. Basic Scientific Evidence Consistent with Etanercept Efficacy Against Alzheimer's Disease. Neuroscience 2021. [DOI: 10.1016/j.neuroscience.2021.11.002] [Reference Citation Analysis]
|
| 24 |
Papalia I, Tjandra D, Quah S, Tan C, Gorelik A, Sivanesan S, Macrae F. Colon Capsule Endoscopy in the Assessment of Mucosal Healing in Crohn's Disease. Inflamm Bowel Dis 2021;27:S25-32. [PMID: 34791289 DOI: 10.1093/ibd/izab180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 25 |
Fiocchi C, Dragoni G, Iliopoulos D, Katsanos K, Ramirez VH, Suzuki K; Scientific Workshop Steering Committee. Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-What, Why, and How. J Crohns Colitis 2021;15:1410-30. [PMID: 33733656 DOI: 10.1093/ecco-jcc/jjab051] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 26 |
Meyer F, Weil-Verhoeven D, Prati C, Wendling D, Verhoeven F. Safety of biologic treatments in solid organ transplant recipients: A systematic review. Semin Arthritis Rheum 2021;51:1263-73. [PMID: 34507811 DOI: 10.1016/j.semarthrit.2021.08.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 27 |
Song HY, Seo GS. Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies. J Korean Med Assoc 2021;64:605-13. [DOI: 10.5124/jkma.2021.64.9.605] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 28 |
Malkov MI, Lee CT, Taylor CT. Regulation of the Hypoxia-Inducible Factor (HIF) by Pro-Inflammatory Cytokines. Cells 2021;10:2340. [PMID: 34571989 DOI: 10.3390/cells10092340] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 29 |
Caballol B, Gudiño V, Panes J, Salas A. Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development. Expert Opin Investig Drugs 2021;:1-16. [PMID: 34365869 DOI: 10.1080/13543784.2021.1965122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 30 |
Sturm L, Schwemberger B, Menzel U, Häckel S, Albers CE, Plank C, Rip J, Alini M, Traweger A, Grad S, Basoli V. In Vitro Evaluation of a Nanoparticle-Based mRNA Delivery System for Cells in the Joint. Biomedicines 2021;9:794. [PMID: 34356857 DOI: 10.3390/biomedicines9070794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 31 |
D'Haens GR, van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut 2021;70:1396-405. [PMID: 33431575 DOI: 10.1136/gutjnl-2019-320022] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 32 |
Haring E, Zeiser R, Apostolova P. Interfering With Inflammation: Heterogeneous Effects of Interferons in Graft-Versus-Host Disease of the Gastrointestinal Tract and Inflammatory Bowel Disease. Front Immunol 2021;12:705342. [PMID: 34249014 DOI: 10.3389/fimmu.2021.705342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 33 |
Lv H, Tang Y, Zhang H, Li S, Fan Z. Astragalus polysaccharide supplementation improves production performance, egg quality, serum biochemical index and gut microbiota in Chongren hens. Anim Sci J 2021;92:e13550. [PMID: 33899985 DOI: 10.1111/asj.13550] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 34 |
Mezghiche I, Yahia-Cherbal H, Rogge L, Bianchi E. Novel approaches to develop biomarkers predicting treatment responses to TNF-blockers. Expert Rev Clin Immunol 2021;17:331-54. [PMID: 33622154 DOI: 10.1080/1744666X.2021.1894926] [Reference Citation Analysis]
|
| 35 |
Cho T, Sato H, Wakamatsu A, Ohashi R, Ajioka Y, Uchiumi T, Goto S, Narita I, Kaneko Y. Mood Disorder in Systemic Lupus Erythematosus Induced by Antiribosomal P Protein Antibodies Associated with Decreased Serum and Brain Tryptophan. J Immunol 2021;206:1729-39. [PMID: 33789980 DOI: 10.4049/jimmunol.2000260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 36 |
Guo S, Lei J, Liu L, Qu X, Li P, Liu X, Guo Y, Gao Q, Lan F, Xiao B, He C, Zou X. Effects of Macleaya cordata extract on laying performance, egg quality, and serum indices in Xuefeng black-bone chicken. Poult Sci 2021;100:101031. [PMID: 33684648 DOI: 10.1016/j.psj.2021.101031] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 37 |
Hou Q, Huang J, Ayansola H, Masatoshi H, Zhang B. Intestinal Stem Cells and Immune Cell Relationships: Potential Therapeutic Targets for Inflammatory Bowel Diseases. Front Immunol 2020;11:623691. [PMID: 33584726 DOI: 10.3389/fimmu.2020.623691] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 38 |
Cruz E, Kayser V. Major Classes of Biotherapeutics. Biologics, Biosimilars, and Biobetters 2020. [DOI: 10.1002/9781119564690.ch4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 39 |
Raja TW, Veeramuthu D, Savarimuthu I, Al-Dhabi NA. Current Trends in the Treatment of Systemic Lupus Erythematosus. Curr Pharm Des 2020;26:2602-9. [PMID: 32066358 DOI: 10.2174/1381612826666200211122633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 40 |
Hwang J, Jin J, Jeon S, Moon SH, Park MY, Yum DY, Kim JH, Kang JE, Park MH, Kim EJ, Pan JG, Kwon O, Oh GT. SOD1 suppresses pro-inflammatory immune responses by protecting against oxidative stress in colitis. Redox Biol 2020;37:101760. [PMID: 33096425 DOI: 10.1016/j.redox.2020.101760] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 41 |
Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 42 |
Ghimire H, Hu X, Qin G, Unil Perera AG. Optimizing infrared spectral discrimination to enhance disease diagnostics: monitoring the signatures of inflammatory bowel diseases with anti-TNFα therapy. Biomed Opt Express 2020;11:4679. [DOI: 10.1364/boe.394895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 43 |
Chulkina MM, Pichugin AV, Ataullakhanov RI. Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G+ granulocytes and Ly6C+ monocytes. Peptides 2020;132:170364. [PMID: 32621844 DOI: 10.1016/j.peptides.2020.170364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 44 |
Donald LJ, Spearman M, Mishra N, Komatsu E, Butler M, Perreault H. Mass spectrometric analysis of core fucosylation and sequence variation in a human-camelid monoclonal antibody. Mol Omics 2020;16:221-30. [PMID: 32163054 DOI: 10.1039/c9mo00168a] [Reference Citation Analysis]
|
| 45 |
Fiocchi C, Iliopoulos D. What's new in IBD therapy: An "omics network" approach. Pharmacol Res 2020;159:104886. [PMID: 32428668 DOI: 10.1016/j.phrs.2020.104886] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 46 |
Leppkes M, Neurath MF. Cytokines in inflammatory bowel diseases - Update 2020. Pharmacol Res 2020;158:104835. [PMID: 32416212 DOI: 10.1016/j.phrs.2020.104835] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 15.7] [Reference Citation Analysis]
|
| 47 |
Cucchiara S, D'Arcangelo G, Isoldi S, Aloi M, Stronati L. Mucosal healing in Crohn's disease: new insights. Expert Rev Gastroenterol Hepatol 2020;14:335-45. [PMID: 32315209 DOI: 10.1080/17474124.2020.1759416] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 48 |
Atretkhany KN, Gogoleva VS, Drutskaya MS, Nedospasov SA. Distinct modes of TNF signaling through its two receptors in health and disease. J Leukoc Biol 2020;107:893-905. [PMID: 32083339 DOI: 10.1002/JLB.2MR0120-510R] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 49 |
Biancone L, Armuzzi A, Scribano ML, Castiglione F, D'Incà R, Orlando A, Papi C, Daperno M, Vecchi M, Riegler G, Fries W, Alvisi P, Meucci G, Mocciaro F, Rogai F, Festa S, Guidi L, Testa A, Spina L, Renna S, Viola A, Patturelli M, Di Mitri R, Frankovic I, Calabrese E, Petruzziello C, De Cristofaro E, Sena G, Ruffa A, Neri B, Rossi A. Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study. Inflamm Bowel Dis 2020;26:450-9. [PMID: 31498388 DOI: 10.1093/ibd/izz155] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 50 |
Jung HJ, Kang JH, Pak S, Lee K, Seong JK, Oh SH. Detrimental Role of Nerve Injury-Induced Protein 1 in Myeloid Cells under Intestinal Inflammatory Conditions. Int J Mol Sci 2020;21:E614. [PMID: 31963519 DOI: 10.3390/ijms21020614] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 51 |
Griffiths OR, Landon J, Coxon RE, Morris K, James P, Adams R. Inflammatory bowel disease and targeted oral anti-TNFα therapy. Adv Protein Chem Struct Biol 2020;119:157-98. [PMID: 31997768 DOI: 10.1016/bs.apcsb.2019.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 52 |
Malakar S. C-Reactive Protein in Inflammatory Bowel Disease. Clinical Significance of C-reactive Protein 2020. [DOI: 10.1007/978-981-15-6787-2_3] [Reference Citation Analysis]
|
| 53 |
Sy R, Chan MM. Absorption and Secretion, General Symptoms, and Pharmacology. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.65622-2] [Reference Citation Analysis]
|
| 54 |
Jung Y. Anti-tumor Necrosis Factor Agents and Tuberculosis in Inflammatory Bowel Disease. Korean J Gastroenterol 2020;75:1. [DOI: 10.4166/kjg.2020.75.1.1] [Reference Citation Analysis]
|
| 55 |
Kaieda A, Takahashi M, Fukuda H, Okamoto R, Morimoto S, Gotoh M, Miyazaki T, Hori Y, Unno S, Kawamoto T, Tanaka T, Itono S, Takagi T, Sugimoto H, Okada K, Lane W, Sang BC, Saikatendu K, Matsunaga S, Miwatashi S. Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]Pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 2. ChemMedChem 2019;14:2093-101. [PMID: 31697454 DOI: 10.1002/cmdc.201900373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 56 |
Groux-Degroote S, Cavdarli S, Uchimura K, Allain F, Delannoy P. Glycosylation changes in inflammatory diseases. Adv Protein Chem Struct Biol 2020;119:111-56. [PMID: 31997767 DOI: 10.1016/bs.apcsb.2019.08.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 57 |
Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:1075-106. [PMID: 29512050 DOI: 10.1007/s40262-018-0639-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 58 |
Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics 2019;13:139-78. [PMID: 31440029 DOI: 10.2147/BTT.S207246] [Cited by in Crossref: 25] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 59 |
Chen X, Yang K, Xu Y, Li K. Top-100 highest-cited original articles in inflammatory bowel disease: A bibliometric analysis. Medicine (Baltimore) 2019;98:e15718. [PMID: 31096525 DOI: 10.1097/MD.0000000000015718] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 60 |
Kalb DM, Adikari SH, Hong-Geller E, Werner JH. Single-cell correlations of mRNA and protein content in a human monocytic cell line after LPS stimulation. PLoS One 2019;14:e0215602. [PMID: 31002726 DOI: 10.1371/journal.pone.0215602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 61 |
Kaieda A, Takahashi M, Fukuda H, Okamoto R, Morimoto S, Gotoh M, Miyazaki T, Hori Y, Unno S, Kawamoto T, Tanaka T, Itono S, Takagi T, Sugimoto H, Okada K, Snell G, Bertsch R, Nguyen J, Sang BC, Miwatashi S. Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 1. ChemMedChem 2019;14:1022-30. [PMID: 30945818 DOI: 10.1002/cmdc.201900129] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 62 |
Fehaid A, Taniguchi A. Size-Dependent Effect of Silver Nanoparticles on the Tumor Necrosis Factor α-Induced DNA Damage Response. Int J Mol Sci 2019;20:E1038. [PMID: 30818829 DOI: 10.3390/ijms20051038] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 63 |
Ke Q, Li C, Wu M, Ge L, Yao C, Yao C, Mi Y. Electrofusion by a bipolar pulsed electric field: Increased cell fusion efficiency for monoclonal antibody production. Bioelectrochemistry 2019;127:171-9. [PMID: 30831355 DOI: 10.1016/j.bioelechem.2019.02.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 64 |
Xu P, Elamin E, Elizalde M, Bours PPHA, Pierik MJ, Masclee AAM, Jonkers DMAE. Modulation of Intestinal Epithelial Permeability by Plasma from Patients with Crohn's Disease in a Three-dimensional Cell Culture Model. Sci Rep 2019;9:2030. [PMID: 30765731 DOI: 10.1038/s41598-018-38322-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 65 |
Schubert K, Collins LE, Green P, Nagase H, Troeberg L. LRP1 Controls TNF Release via the TIMP-3/ADAM17 Axis in Endotoxin-Activated Macrophages. J Immunol 2019;202:1501-9. [PMID: 30659107 DOI: 10.4049/jimmunol.1800834] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 66 |
Dostert C, Grusdat M, Letellier E, Brenner D. The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond. Physiological Reviews 2019;99:115-60. [DOI: 10.1152/physrev.00045.2017] [Cited by in Crossref: 166] [Cited by in F6Publishing: 175] [Article Influence: 41.5] [Reference Citation Analysis]
|
| 67 |
Van den Bosch F, Carron P, Mease P. Biologic Treatment of Axial Spondyloarthritis. Axial Spondyloarthritis. Elsevier; 2019. pp. 227-42. [DOI: 10.1016/b978-0-323-56800-5.00015-1] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 68 |
Atretkhany KN, Mufazalov IA, Dunst J, Kuchmiy A, Gogoleva VS, Andruszewski D, Drutskaya MS, Faustman DL, Schwabenland M, Prinz M, Kruglov AA, Waisman A, Nedospasov SA. Intrinsic TNFR2 signaling in T regulatory cells provides protection in CNS autoimmunity. Proc Natl Acad Sci U S A 2018;115:13051-6. [PMID: 30498033 DOI: 10.1073/pnas.1807499115] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 69 |
Fernández-Ruiz M, Aguado JM. Risk of infection associated with anti-TNF-α therapy. Expert Rev Anti Infect Ther 2018;16:939-56. [PMID: 30388900 DOI: 10.1080/14787210.2018.1544490] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 70 |
Metcalfe C, Dougall T, Bird C, Rigsby P, Behr-Gross ME, Wadhwa M, Study POT. The first World Health Organization International Standard for infliximab products: A step towards maintaining harmonized biological activity. MAbs 2019;11:13-25. [PMID: 30395763 DOI: 10.1080/19420862.2018.1532766] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 71 |
Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol 2018;11:1558-70. [PMID: 29907872 DOI: 10.1038/s41385-018-0050-3] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 12.4] [Reference Citation Analysis]
|
| 72 |
Fukata T, Mizushima T, Nishimura J, Okuzaki D, Wu X, Hirose H, Yokoyama Y, Kubota Y, Nagata K, Tsujimura N, Inoue A, Miyoshi N, Haraguchi N, Takahashi H, Hata T, Matsuda C, Kayama H, Takeda K, Doki Y, Mori M, Yamamoto H. The Supercarbonate Apatite-MicroRNA Complex Inhibits Dextran Sodium Sulfate-Induced Colitis. Mol Ther Nucleic Acids 2018;12:658-71. [PMID: 30092402 DOI: 10.1016/j.omtn.2018.07.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 73 |
Bauer E, Thiele I. From metagenomic data to personalized in silico microbiotas: predicting dietary supplements for Crohn's disease. NPJ Syst Biol Appl 2018;4:27. [PMID: 30083388 DOI: 10.1038/s41540-018-0063-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 74 |
Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF Therapy in Crohn's Disease. Int J Mol Sci 2018;19:E2244. [PMID: 30065229 DOI: 10.3390/ijms19082244] [Cited by in Crossref: 119] [Cited by in F6Publishing: 126] [Article Influence: 23.8] [Reference Citation Analysis]
|
| 75 |
Azer SA, Azer S. What can we learn from top-cited articles in inflammatory bowel disease? A bibliometric analysis and assessment of the level of evidence. BMJ Open. 2018;8:e021233. [PMID: 30002009 DOI: 10.1136/bmjopen-2017-021233] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 76 |
Gong SS, Fan YH, Wang SY, Han QQ, Lv B, Xu Y, Chen X, He YE. Mucosa repair mechanisms of Tong-Xie-Yao-Fang mediated by CRH-R2 in murine, dextran sulfate sodium-induced colitis. World J Gastroenterol 2018; 24(16): 1766-1778 [PMID: 29713130 DOI: 10.3748/wjg.v24.i16.1766] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 77 |
Römkens TEH, Kranenburg P, Tilburg AV, Bronkhorst C, Nagtegaal ID, Drenth JPH, Hoentjen F. Assessment of Histological Remission in Ulcerative Colitis: Discrepancies Between Daily Practice and Expert Opinion. J Crohns Colitis 2018;12:425-31. [PMID: 29240880 DOI: 10.1093/ecco-jcc/jjx165] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 78 |
Park HJ, Kim J, Saima FT, Rhee KJ, Hwang S, Kim MY, Baik SK, Eom YW, Kim HS. Adipose-derived stem cells ameliorate colitis by suppression of inflammasome formation and regulation of M1-macrophage population through prostaglandin E2. Biochem Biophys Res Commun 2018;498:988-95. [PMID: 29550474 DOI: 10.1016/j.bbrc.2018.03.096] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 79 |
Balbas-Martinez V, Ruiz-Cerdá L, Irurzun-Arana I, González-García I, Vermeulen A, Gómez-Mantilla JD, Trocóniz IF. A systems pharmacology model for inflammatory bowel disease. PLoS One 2018;13:e0192949. [PMID: 29513758 DOI: 10.1371/journal.pone.0192949] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 80 |
Bourgonje AR, von Martels JZH, de Vos P, Faber KN, Dijkstra G. Increased fecal calprotectin levels in Crohn's disease correlate with elevated serum Th1- and Th17-associated cytokines. PLoS One 2018;13:e0193202. [PMID: 29466406 DOI: 10.1371/journal.pone.0193202] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 81 |
Hoffman JM, Sideri A, Ruiz JJ, Stavrakis D, Shih DQ, Turner JR, Pothoulakis C, Karagiannides I. Mesenteric Adipose-derived Stromal Cells From Crohn's Disease Patients Induce Protective Effects in Colonic Epithelial Cells and Mice With Colitis. Cell Mol Gastroenterol Hepatol 2018;6:1-16. [PMID: 29928668 DOI: 10.1016/j.jcmgh.2018.02.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 82 |
Zhou Y, Xu ZZ, He Y, Yang Y, Liu L, Lin Q, Nie Y, Li M, Zhi F, Liu S, Amir A, González A, Tripathi A, Chen M, Wu GD, Knight R, Zhou H, Chen Y. Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction. mSystems 2018;3:e00188-17. [PMID: 29404425 DOI: 10.1128/mSystems.00188-17] [Cited by in Crossref: 127] [Cited by in F6Publishing: 137] [Article Influence: 25.4] [Reference Citation Analysis]
|
| 83 |
Hildner K, Waldschmitt N, Haller D. Microbiome and Diseases: Inflammatory Bowel Diseases. The Gut Microbiome in Health and Disease 2018. [DOI: 10.1007/978-3-319-90545-7_11] [Reference Citation Analysis]
|
| 84 |
Vaughn BP. Antitumor Necrosis Factor Agents in Crohn’s Disease. Treatment of Inflammatory Bowel Disease with Biologics 2018. [DOI: 10.1007/978-3-319-60276-9_3] [Reference Citation Analysis]
|
| 85 |
Nold-Petry CA, Nold MF, Levy O, Kliger Y, Oren A, Borukhov I, Becker C, Wirtz S, Sandhu MK, Neurath M, Dinarello CA. Gp96 Peptide Antagonist gp96-II Confers Therapeutic Effects in Murine Intestinal Inflammation. Front Immunol 2017;8:1531. [PMID: 29312281 DOI: 10.3389/fimmu.2017.01531] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 86 |
Kempski J, Brockmann L, Gagliani N, Huber S. TH17 Cell and Epithelial Cell Crosstalk during Inflammatory Bowel Disease and Carcinogenesis. Front Immunol 2017;8:1373. [PMID: 29118756 DOI: 10.3389/fimmu.2017.01373] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 87 |
Vadstrup K, Bendtsen F. Anti-NKG2D mAb: A New Treatment for Crohn's Disease? Int J Mol Sci 2017;18:E1997. [PMID: 28926962 DOI: 10.3390/ijms18091997] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 88 |
Szollosi DE, Manzoor MK, Aquilato A, Jackson P, Ghoneim OM, Edafiogho IO. Current and novel anti-inflammatory drug targets for inhibition of cytokines and leucocyte recruitment in rheumatic diseases. Journal of Pharmacy and Pharmacology 2018;70:18-26. [DOI: 10.1111/jphp.12811] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 89 |
Miranda S, Roux ME. Acoustic stress induces long term severe intestinal inflammation in the mouse. Toxicol Lett 2017;280:1-9. [PMID: 28774831 DOI: 10.1016/j.toxlet.2017.07.898] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 90 |
Chitul A, Voiosu AM, Marinescu M, Caraiola S, Nicolau A, Badea GC, Pârvu MI, Ionescu RA, Mateescu BR, Voiosu MR, Băicuş CR, Rimbaş M. Different effects of anti-TNF-alpha biologic drugs on the small bowel macroscopic inflammation in patients with ankylosing spondylitis. Rom J Intern Med 2017;55:44-52. [PMID: 28103201 DOI: 10.1515/rjim-2017-0001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 91 |
Østgård R, Deleuran B, Dam M, Hansen I, Jurik A, Glerup H. Faecal calprotectin detects subclinical bowel inflammation and may predict treatment response in spondyloarthritis. Scandinavian Journal of Rheumatology 2018;47:48-55. [DOI: 10.1080/03009742.2017.1299216] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 92 |
Attarwala H, Han M, Kim J, Amiji M. Oral nucleic acid therapy using multicompartmental delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2018;10. [PMID: 28544521 DOI: 10.1002/wnan.1478] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 93 |
Higa LH, Jerez HE, de Farias MA, Portugal RV, Romero EL, Morilla MJ. Ultra-small solid archaeolipid nanoparticles for active targeting to macrophages of the inflamed mucosa. Nanomedicine 2017;12:1165-75. [DOI: 10.2217/nnm-2016-0437] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 94 |
Celiberto LS, Bedani R, Dejani NN, Ivo de Medeiros A, Sampaio Zuanon JA, Spolidorio LC, Tallarico Adorno MA, Amâncio Varesche MB, Carrilho Galvão F, Valentini SR, Font de Valdez G, Rossi EA, Cavallini DCU. Effect of a probiotic beverage consumption (Enterococcus faecium CRL 183 and Bifidobacterium longum ATCC 15707) in rats with chemically induced colitis. PLoS One 2017;12:e0175935. [PMID: 28437455 DOI: 10.1371/journal.pone.0175935] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 95 |
Sofia MA, Rubin DT. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. Dig Dis Sci 2017;62:833-42. [PMID: 28197743 DOI: 10.1007/s10620-017-4479-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 96 |
Woody A, Figueroa WS, Benencia F, Zoccola PM. Stress-Induced Parasympathetic Control and Its Association With Inflammatory Reactivity. Psychosom Med 2017;79:306-10. [PMID: 28002383 DOI: 10.1097/PSY.0000000000000426] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 97 |
Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis 2017;49:338-58. [PMID: 28161290 DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 98 |
Solhi R, Alebouyeh M, Khafri A, Rezaeifard M, Aminian M. In vitro evaluation of cross-strain inhibitory effects of IgY polyclonal antibody against H. pylori. Microb Pathog 2017;110:682-7. [PMID: 28351713 DOI: 10.1016/j.micpath.2017.03.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 99 |
Krahn N, Spearman M, Meier M, Dorion-thibaudeau J, Mcdougall M, Patel TR, De Crescenzo G, Durocher Y, Stetefeld J, Butler M. Inhibition of glycosylation on a camelid antibody uniquely affects its FcγRI binding activity. European Journal of Pharmaceutical Sciences 2017;96:428-39. [DOI: 10.1016/j.ejps.2016.09.040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 100 |
Klapproth JA, Lichtenstein GR. Biologic Therapy for Crohn’s Disease: Infliximab. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_34] [Reference Citation Analysis]
|
| 101 |
Hernandez-gordillo V, Koppes AN, Griffith LG, Breault DT, Carrier RL. Engineering the Niche for Intestinal Regeneration. Biology and Engineering of Stem Cell Niches 2017. [DOI: 10.1016/b978-0-12-802734-9.00037-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 102 |
Johnsen KM, Goll R, Hansen V, Olsen T, Rismo R, Heitmann R, Gundersen MD, Kvamme JM, Paulssen EJ, Kileng H, Johnsen K, Florholmen J. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm. Eur J Gastroenterol Hepatol 2017;29:98-104. [PMID: 27749779 DOI: 10.1097/MEG.0000000000000753] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 103 |
Dave M, Jaiswal P, Cominelli F. Mesenchymal stem/stromal cell therapy for inflammatory bowel disease: an updated review with maintenance of remission. Curr Opin Gastroenterol 2017;33:59-68. [PMID: 28134690 DOI: 10.1097/MOG.0000000000000327] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 104 |
Kesselheim AS, Tan YT, Avorn J. The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs. Health Aff (Millwood) 2015;34:286-93. [PMID: 25646109 DOI: 10.1377/hlthaff.2014.1038] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 105 |
Zhang J, Lu Y, Wei J, Li L, Han L. Protective effect of carboxytmethylpachymaran on TNF-α-induced damage in Caco-2 cell monolayers. International Journal of Biological Macromolecules 2016;93:506-11. [DOI: 10.1016/j.ijbiomac.2016.07.095] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 106 |
Park J, Kang CK, Kim HB. Reduction of TNFα expression by Chungkookjang extracts in human breast cancer MDA-MB-231 cells. The Korean Journal of Microbiology 2016;52:380-382. [DOI: 10.7845/kjm.2016.6036] [Reference Citation Analysis]
|
| 107 |
Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opin Biol Ther. 2016;16:1277-1290. [PMID: 27329436 DOI: 10.1080/14712598.2016.1203897] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 108 |
Park SH, Hwang SW, Kwak MS, Kim WS, Lee JM, Lee HS, Yang DH, Kim KJ, Ye BD, Byeon JS, Myung SJ, Yoon YS, Yu CS, Kim JH, Yang SK. Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn's Disease: A Hospital-Based Cohort Study. Dig Dis Sci 2016;61:2060-7. [PMID: 26971089 DOI: 10.1007/s10620-016-4105-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 109 |
Shapiro JM, Hagin SE, Shah SA, Bright R, Law M, Moniz H, Giacalone J, Jackvony T, Taleban S, Samad Z, Merrick M, Sands BE, LeLeiko NS. Corticosteroid Use in a Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients. Dig Dis Sci 2016;61:1635-40. [PMID: 26725063 DOI: 10.1007/s10620-015-4010-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 110 |
Furfaro F, Fiorino G, Allocca M, Gilardi D, Danese S. Emerging therapeutic targets and strategies in Crohn's disease. Expert Rev Gastroenterol Hepatol 2016;10:735-44. [PMID: 26766496 DOI: 10.1586/17474124.2016.1142372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 111 |
Minar P, Saeed SA, Afreen M, Kim MO, Denson LA. Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2016;62:715-22. [PMID: 26551317 DOI: 10.1097/MPG.0000000000001029] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 112 |
Petkau JM, Eksteen B. Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab. Biologics 2016;10:33-52. [PMID: 27022240 DOI: 10.2147/BTT.S71679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 113 |
Efimov GA, Kruglov AA, Khlopchatnikova ZV, Rozov FN, Mokhonov VV, Rose-John S, Scheller J, Gordon S, Stacey M, Drutskaya MS, Tillib SV, Nedospasov SA. Cell-type-restricted anti-cytokine therapy: TNF inhibition from one pathogenic source. Proc Natl Acad Sci U S A 2016;113:3006-11. [PMID: 26936954 DOI: 10.1073/pnas.1520175113] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 114 |
Kucharski M, Karczewski J, Mańkowska-Wierzbicka D, Karmelita-Katulska K, Kaczmarek E, Iwanik K, Rzymski P, Grzymisławski M, Linke K, Dobrowolska A. Usefulness of Endoscopic Indices in Determination of Disease Activity in Patients with Crohn's Disease. Gastroenterol Res Pract 2016;2016:7896478. [PMID: 26997952 DOI: 10.1155/2016/7896478] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 115 |
Wallach D. The cybernetics of TNF: Old views and newer ones. Seminars in Cell & Developmental Biology 2016;50:105-14. [DOI: 10.1016/j.semcdb.2015.10.014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 116 |
Berns M, Hommes DW. Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future. Expert Opinion on Investigational Drugs 2016;25:129-43. [DOI: 10.1517/13543784.2016.1126247] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 117 |
Okamoto R, Watanabe M. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol 2016;51:11-21. [PMID: 26138071 DOI: 10.1007/s00535-015-1098-4] [Cited by in Crossref: 132] [Cited by in F6Publishing: 134] [Article Influence: 18.9] [Reference Citation Analysis]
|
| 118 |
Reich KM, Fedorak RN, Madsen K, Kroeker KI. Role of Vitamin D in Infliximab-induced Remission in Adult Patients with Crohn's Disease. Inflamm Bowel Dis 2016;22:92-9. [PMID: 26355467 DOI: 10.1097/MIB.0000000000000588] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 119 |
Hoffman JM, Baritaki S, Ruiz JJ, Sideri A, Pothoulakis C. Corticotropin-Releasing Hormone Receptor 2 Signaling Promotes Mucosal Repair Responses after Colitis. Am J Pathol. 2016;186:134-144. [PMID: 26597886 DOI: 10.1016/j.ajpath.2015.09.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 120 |
Dave M, Mehta K, Luther J, Baruah A, Dietz AB, Faubion WA Jr. Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2015;21:2696-707. [PMID: 26230863 DOI: 10.1097/MIB.0000000000000543] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 121 |
Zhou Y, He H, Wang P, Zhang T, Lin M, Wang H, Nie Y, Chen Y. Infliximab for the treatment of Crohn's disease: efficacy and safety in a Chinese single-center retrospective study. Eur J Gastroenterol Hepatol 2015;27:1270-5. [PMID: 26275085 DOI: 10.1097/MEG.0000000000000447] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 122 |
Bootz F, Neri D. Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions. Drug Discov Today 2016;21:180-9. [PMID: 26526566 DOI: 10.1016/j.drudis.2015.10.012] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 123 |
Astrakhantseva IV, Efimov GA, Drutskaya MS, Kruglov AA, Nedospasov SA. Modern anti-cytokine therapy of autoimmune diseases. Biochemistry (Mosc) 2014;79:1308-21. [PMID: 25716724 DOI: 10.1134/S0006297914120049] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 124 |
Sung DI, Park J, Kang CK, Kim HB. Peptide H reduces Il-6 expression in human breast cancer MDA-MB-231 cells. The Korean Journal of Microbiology 2015;51:308-311. [DOI: 10.7845/kjm.2015.5028] [Reference Citation Analysis]
|
| 125 |
De Siqueira J, Abdul Zani I, Russell DA, Wheatcroft SB, Ponnambalam S, Homer-Vanniasinkam S. Clinical and Preclinical Use of LOX-1-Specific Antibodies in Diagnostics and Therapeutics. J Cardiovasc Transl Res 2015;8:458-65. [PMID: 26385009 DOI: 10.1007/s12265-015-9655-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 126 |
Wang Y, Wu M, Ai C, Wang Y. Insight into the Structural Determinants of Imidazole Scaffold-Based Derivatives as TNF-α Release Inhibitors by in Silico Explorations. Int J Mol Sci 2015;16:20118-38. [PMID: 26307982 DOI: 10.3390/ijms160920118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 127 |
de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. Mediators Inflamm. 2015;2015:493012. [PMID: 26339135 DOI: 10.1155/2015/493012] [Cited by in Crossref: 108] [Cited by in F6Publishing: 116] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 128 |
Van Hauwermeiren F, Vandenbroucke RE, Grine L, Lodens S, Van Wonterghem E, De Rycke R, De Geest N, Hassan B, Libert C. TNFR1-induced lethal inflammation is mediated by goblet and Paneth cell dysfunction. Mucosal Immunol 2015;8:828-40. [PMID: 25425265 DOI: 10.1038/mi.2014.112] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 129 |
de Vallière C, Wang Y, Eloranta JJ, Vidal S, Clay I, Spalinger MR, Tcymbarevich I, Terhalle A, Ludwig MG, Suply T, Fried M, Kullak-Ublick GA, Frey-Wagner I, Scharl M, Seuwen K, Wagner CA, Rogler G. G Protein-coupled pH-sensing Receptor OGR1 Is a Regulator of Intestinal Inflammation. Inflamm Bowel Dis 2015;21:1269-81. [PMID: 25856770 DOI: 10.1097/MIB.0000000000000375] [Cited by in Crossref: 27] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 130 |
Yang C, Singh P, Singh H, Le ML, El-Matary W. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2015;41:1079-93. [PMID: 25858208 DOI: 10.1111/apt.13181] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 131 |
Geem D, Harusato A, Flannigan K, Denning TL. Harnessing regulatory T cells for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1409-18. [PMID: 25793328 DOI: 10.1097/MIB.0000000000000343] [Cited by in Crossref: 12] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 132 |
Principi M, Day R, Marangi S, Burattini O, De Francesco V, Ingrosso M, Pisani A, Panella C, Forbes A, Di Leo A, Francavilla A, Ierardi E. Differential Immunohistochemical Expression of Syndecan-1 and Tumor Necrosis Factor Alpha in Colonic Mucosa of Patients with Crohn’s Disease. Immunopharmacology and Immunotoxicology 2015;28:185-95. [DOI: 10.1080/08923970600815048a] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 133 |
Li G, Ren J, Wang G, Wu Q, Gu G, Ren H, Liu S, Hong Z, Li R, Li Y, Guo K, Wu X, Li J. Prevalence and risk factors of acute lower gastrointestinal bleeding in Crohn disease. Medicine (Baltimore) 2015;94:e804. [PMID: 25984665 DOI: 10.1097/MD.0000000000000804] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 134 |
Bouguen G, Laharie D, Nancey S, Hebuterne X, Flourie B, Filippi J, Roblin X, Trang C, Bourreille A, Babouri A, Bretagne JF, Siproudhis L, Peyrin-Biroulet L. Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease. Inflamm Bowel Dis 2015;21:1047-53. [PMID: 25803504 DOI: 10.1097/MIB.0000000000000359] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 135 |
Randall CW, Vizuete JA, Martinez N, Alvarez JJ, Garapati KV, Malakouti M, Taboada CM. From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol 2015;8:143-59. [PMID: 25949527 DOI: 10.1177/1756283X15576462] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 136 |
Cavaillon J. Molecular Mediators: Cytokines. Reviews in Cell Biology and Molecular Medicine 2015. [DOI: 10.1002/3527600906.mcb.200400134.pub2] [Reference Citation Analysis]
|
| 137 |
Grimpen F, Pavli P. Inflammatory Bowel Disease in Older People. Journal of Pharmacy Practice and Research 2008;38:234-8. [DOI: 10.1002/j.2055-2335.2008.tb00847.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 138 |
Marth T. Systematic review: Whipple's disease (Tropheryma whipplei infection) and its unmasking by tumour necrosis factor inhibitors. Aliment Pharmacol Ther 2015;41:709-24. [PMID: 25693648 DOI: 10.1111/apt.13140] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 139 |
Sacco R, Tanaka T, Yamamoto T, Bresci G, Saniabadi AR. Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders. Expert Rev Gastroenterol Hepatol 2015;9:327-33. [PMID: 25160857 DOI: 10.1586/17474124.2014.953060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 140 |
Biancone L, Onali S, Petruzziello C, Calabrese E, Pallone F. Cancer and immunomodulators in inflammatory bowel diseases. Inflamm Bowel Dis 2015;21:674-98. [PMID: 25545375 DOI: 10.1097/MIB.0000000000000243] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 141 |
Peng X, Liu B, Li Y, Wang H, Chen X, Guo H, Guo Q, Xu J, Wang H, Zhang D, Dai J, Hou S, Guo Y. Development and Validation of LC–MS/MS Method for the Quantitation of Infliximab in Human Serum. Chromatographia 2015;78:521-31. [DOI: 10.1007/s10337-015-2866-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 142 |
Bornstein JE, Steinhagen RM. History of Crohn’s Disease. Crohn’s Disease 2015. [DOI: 10.1007/978-3-319-14181-7_1] [Reference Citation Analysis]
|
| 143 |
Feldmann M. Discovery and Development of Anti-TNF Therapy. Molecular Biology of B Cells 2015. [DOI: 10.1016/b978-0-12-397933-9.00029-1] [Reference Citation Analysis]
|
| 144 |
Florholmen J. Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease. Scand J Gastroenterol 2015;50:43-52. [PMID: 25523555 DOI: 10.3109/00365521.2014.977943] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 145 |
Pekow J, Cohen RD. Medical Therapy: The Future. Crohn’s Disease 2015. [DOI: 10.1007/978-3-319-14181-7_4] [Reference Citation Analysis]
|
| 146 |
Thagia I, Shaw EJ, Smith E, Else KJ, Rigby RJ. Intestinal epithelial suppressor of cytokine signaling 3 enhances microbial-induced inflammatory tumor necrosis factor-α, contributing to epithelial barrier dysfunction. Am J Physiol Gastrointest Liver Physiol 2015;308:G25-31. [PMID: 25377316 DOI: 10.1152/ajpgi.00214.2014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 147 |
Samaan MA, D’haens G. The Use of Endoscopy to Follow the Clinical Course of Crohn’s Disease. Endoscopy in Inflammatory Bowel Disease 2015. [DOI: 10.1007/978-3-319-11077-6_14] [Reference Citation Analysis]
|
| 148 |
Scott FI, Lichtenstein GR. The Evaluation, Diagnosis, and Treatment of Inflammatory Bowel Diseases over the Past 100 Years: A Brief Review. Endoscopy in Inflammatory Bowel Disease 2015. [DOI: 10.1007/978-3-319-11077-6_1] [Reference Citation Analysis]
|
| 149 |
Jang BI. Changing Paradigm in the Management of Inflammatory Bowel Disease. Korean J Gastroenterol 2015;65:268. [DOI: 10.4166/kjg.2015.65.5.268] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 150 |
Patel PN, Shah RY, Ferguson JF, Reilly MP. Human experimental endotoxemia in modeling the pathophysiology, genomics, and therapeutics of innate immunity in complex cardiometabolic diseases. Arterioscler Thromb Vasc Biol 2015;35:525-34. [PMID: 25550206 DOI: 10.1161/ATVBAHA.114.304455] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 151 |
Zhang H, Hu CA, Kovacs-nolan J, Mine Y. Bioactive dietary peptides and amino acids in inflammatory bowel disease. Amino Acids 2015;47:2127-41. [DOI: 10.1007/s00726-014-1886-9] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 152 |
Pagnini C, Arseneau KO, Cominelli F. Safety considerations when using anti-TNFα therapy to treat Crohn's disease. Expert Opin Drug Saf 2015;14:31-44. [PMID: 25400161 DOI: 10.1517/14740338.2015.976610] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 153 |
Hindryckx P, Baert F, Hart A, Armuzzi A, Panès J, Peyrin-Biroulet L; Clinical Trial Committee Clincom of the European Crohn's and Colitis Organisation (ECCO). Clinical trials in luminal Crohn's disease: a historical perspective. J Crohns Colitis 2014;8:1339-50. [PMID: 24841216 DOI: 10.1016/j.crohns.2014.04.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 154 |
Fan R, Zhong J, Wang ZT, Li SY, Zhou J, Tang YH. Evaluation of “top-down” treatment of early Crohn’s disease by double balloon enteroscopy. World J Gastroenterol 2014; 20(39): 14479-14487 [PMID: 25339835 DOI: 10.3748/wjg.v20.i39.14479] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 155 |
Hashiguchi K, Takeshima F, Akazawa Y, Matsushima K, Minami H, Yamaguchi N, Shiozawa K, Ohnita K, Ichikawa T, Isomoto H. Bamboo joint-like appearance of the stomach: a stable endoscopic landmark for Crohn’s disease regardless of anti-tumor necrosis factor alpha treatment. Med Sci Monit. 2014;20:1918-1924. [PMID: 25308423 DOI: 10.12659/msm.891060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 156 |
Kerami Z, Duijvis NW, Vogels EW, van Dooren FH, Moerland PD, Te Velde AA. Effect of interleukin-17 on gene expression profile of fibroblasts from Crohn's disease patients. J Crohns Colitis 2014;8:1208-16. [PMID: 24637010 DOI: 10.1016/j.crohns.2014.02.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 157 |
Herfarth HH. Anti-tumor necrosis factor therapy to prevent Crohn's disease recurrence after surgery. Clin Gastroenterol Hepatol 2014;12:1503-6. [PMID: 24534549 DOI: 10.1016/j.cgh.2014.02.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 158 |
Vega VL, Crotty Alexander LE, Charles W, Hwang JH, Nizet V, De Maio A. Activation of the stress response in macrophages alters the M1/M2 balance by enhancing bacterial killing and IL-10 expression. J Mol Med (Berl) 2014;92:1305-17. [PMID: 25163764 DOI: 10.1007/s00109-014-1201-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 159 |
Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 160 |
Rahman K, Sasaki M, Nusrat A, Klapproth JM. Crohn's disease-associated Escherichia coli survive in macrophages by suppressing NFκB signaling. Inflamm Bowel Dis 2014;20:1419-25. [PMID: 24918323 DOI: 10.1097/MIB.0000000000000096] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 161 |
Urbano PC, Soccol VT, Azevedo VF. Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists. Biologics 2014;8:211-20. [PMID: 25114503 DOI: 10.2147/BTT.S57253] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 162 |
Jensen JS, Petersen NB, Biagini M, Bollen P, Qvist N. Infliximab treatment reduces tensile strength in intestinal anastomosis. J Surg Res 2015;193:145-52. [PMID: 25156230 DOI: 10.1016/j.jss.2014.07.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 163 |
Taxonera C, Olivares D, Mendoza JL, Díaz-Rubio M, Rey E. Need for infliximab dose intensification in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2014; 20(27): 9170-9177 [PMID: 25083091 DOI: 10.3748/wjg.v20.i27.9170] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
|
| 164 |
Turvill J. Mapping of Crohn's disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy. Frontline Gastroenterol 2014;5:167-75. [PMID: 28839766 DOI: 10.1136/flgastro-2014-100441] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 165 |
Antunes O, Filippi J, Hébuterne X, Peyrin-Biroulet L. Treatment algorithms in Crohn's - up, down or something else? Best Pract Res Clin Gastroenterol 2014;28:473-83. [PMID: 24913386 DOI: 10.1016/j.bpg.2014.05.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 166 |
Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014;14:329-42. [PMID: 24751956 DOI: 10.1038/nri3661] [Cited by in Crossref: 1545] [Cited by in F6Publishing: 1481] [Article Influence: 171.7] [Reference Citation Analysis]
|
| 167 |
Frostberg E, Ström P, Gerke O, Qvist N. Infliximab's influence on anastomotic strength and degree of inflammation in intestinal surgery in a rabbit model. BMC Surg 2014;14:23. [PMID: 24762063 DOI: 10.1186/1471-2482-14-23] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 168 |
de Boer NKh, Löwenberg M, Hoentjen F. Management of Crohn's disease in poor responders to adalimumab. Clin Exp Gastroenterol 2014;7:83-92. [PMID: 24748811 DOI: 10.2147/CEG.S47627] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 169 |
Weinstock JV. Crohn's Disease. Granulomatous Infections and Inflammations 2014. [DOI: 10.1128/9781555817879.ch11] [Reference Citation Analysis]
|
| 170 |
St-Pierre J, Chadee K. How the discovery of TNF-α has advanced gastrointestinal diseases and treatment regimes. Dig Dis Sci 2014;59:712-5. [PMID: 24504593 DOI: 10.1007/s10620-014-3042-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 171 |
Zenlea T, Peppercorn MA. Immunosuppressive therapies for inflammatory bowel disease. World J Gastroenterol 2014; 20(12): 3146-3152 [PMID: 24696600 DOI: 10.3748/wjg.v20.i12.3146] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 72] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 172 |
Clark IA, Vissel B. Inflammation-sleep interface in brain disease: TNF, insulin, orexin. J Neuroinflammation. 2014;11:51. [PMID: 24655719 DOI: 10.1186/1742-2094-11-51] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 173 |
Levy-clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert Panel Recommendations for the Use of Anti–Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders. Ophthalmology 2014;121:785-796.e3. [DOI: 10.1016/j.ophtha.2013.09.048] [Cited by in Crossref: 304] [Cited by in F6Publishing: 325] [Article Influence: 33.8] [Reference Citation Analysis]
|
| 174 |
Zielińska M, Święćkowski G, Hozyasz KK. Celiakia w polskojęzycznych publikacjach 1990–2012 – analiza bibliometryczna. Pediatria Polska 2014;89:106-111. [DOI: 10.1016/j.pepo.2014.01.002] [Reference Citation Analysis]
|
| 175 |
Abe M, Yuki Y, Kurokawa S, Mejima M, Kuroda M, Park EJ, Scheller J, Nakanishi U, Kiyono H. A rice-based soluble form of a murine TNF-specific llama variable domain of heavy-chain antibody suppresses collagen-induced arthritis in mice. J Biotechnol 2014;175:45-52. [PMID: 24548461 DOI: 10.1016/j.jbiotec.2014.02.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 176 |
Ji R, Wu HG, Shi Y. Regulatory effect of zinc finger protein A20 on inflammation and apoptosis: Implications for inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2014; 22(4): 508-514 [DOI: 10.11569/wcjd.v22.i4.508] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 177 |
Wright AJ, Steiner T, Bilawich AM, English JC, Ryan CF. Pulmonary mucormycosis in a patient with Crohn disease on immunosuppressive medications including infliximab. Can J Infect Dis Med Microbiol 2013;24:67-8. [PMID: 24421803 DOI: 10.1155/2013/363250] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 178 |
Chou C. The clinical application of etanercept in Chinese patients with rheumatic diseases. Modern Rheumatology 2014;16:206-13. [DOI: 10.3109/s10165-006-0486-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 179 |
Chatenoud L. Treatment of Autoimmune Disease. The Autoimmune Diseases 2014. [DOI: 10.1016/b978-0-12-384929-8.00081-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 180 |
Hunter CJ, De Plaen IG. Inflammatory signaling in NEC: Role of NF-κB, cytokines and other inflammatory mediators. Pathophysiology 2014;21:55-65. [PMID: 24388163 DOI: 10.1016/j.pathophys.2013.11.010] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 181 |
Papi C, Fascì-Spurio F, Rogai F, Settesoldi A, Margagnoni G, Annese V. Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors. Dig Liver Dis 2013;45:978-85. [PMID: 24018244 DOI: 10.1016/j.dld.2013.07.006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 182 |
Valatas V, Vakas M, Kolios G. The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol 2013;305:G763-85. [PMID: 23989010 DOI: 10.1152/ajpgi.00004.2013] [Cited by in Crossref: 74] [Cited by in F6Publishing: 76] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 183 |
Alvarenga V Jr, Pacheco RG, Esposito CC, Buongusto F, Castelo-Branco MT, Madi K, Belmiro CR, Pavão MS, de Souza HS, Schanaider A. Ascidian (chordate-tunicate) and mammalian heparin enemas attenuate experimental diversion colitis. Surgery 2014;155:217-27. [PMID: 24287143 DOI: 10.1016/j.surg.2013.06.057] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 184 |
Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. Aliment Pharmacol Ther 2013;38:1188-97. [PMID: 24118102 DOI: 10.1111/apt.12507] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 185 |
Bakirtzi K, Hoffman JM, Pothoulakis C. Silence Please!: siRNA approaches to tighten the intestinal barrier in vivo. Am J Pathol 2013;183:1700-2. [PMID: 24183845 DOI: 10.1016/j.ajpath.2013.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 186 |
van Heesch F, Prins J, Korte-bouws GA, Westphal KG, Lemstra S, Olivier B, Kraneveld AD, Korte SM. Systemic tumor necrosis factor-alpha decreases brain stimulation reward and increases metabolites of serotonin and dopamine in the nucleus accumbens of mice. Behavioural Brain Research 2013;253:191-5. [DOI: 10.1016/j.bbr.2013.07.038] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 187 |
Asgharpour A, Cheng J, Bickston SJ. Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial. Clin Exp Gastroenterol 2013;6:153-60. [PMID: 24039442 DOI: 10.2147/CEG.S35163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 188 |
Clark IA, Vissel B. Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease. Biochem Pharmacol 2013;86:862-71. [PMID: 23939185 DOI: 10.1016/j.bcp.2013.07.030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 189 |
Collins CB, Aherne CM, Ehrentraut SF, Gerich ME, McNamee EN, McManus MC, Lebsack MD, Jedlicka P, Azam T, de Zoeten EF, Dinarello CA, Rivera-Nieves J. Alpha-1-antitrypsin therapy ameliorates acute colitis and chronic murine ileitis. Inflamm Bowel Dis 2013;19:1964-73. [PMID: 23835442 DOI: 10.1097/MIB.0b013e31829292aa] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 190 |
Hatnapure GD, Keche AP, Rodge AH, Tale RH, Birajdar SS, Pawar MJ, Kamble VM. Synthesis and biological evaluation of novel 2′,4′,5′-trimethoxyflavonol derivatives as anti-inflammatory and antimicrobial agents. Med Chem Res 2014;23:461-70. [DOI: 10.1007/s00044-013-0651-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 191 |
Bell C, English L, Boulais J, Chemali M, Caron-Lizotte O, Desjardins M, Thibault P. Quantitative proteomics reveals the induction of mitophagy in tumor necrosis factor-α-activated (TNFα) macrophages. Mol Cell Proteomics 2013;12:2394-407. [PMID: 23674617 DOI: 10.1074/mcp.M112.025775] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 192 |
Scaldaferri F, Petito V, Lopetuso L, Bruno G, Gerardi V, Ianiro G, Sgambato A, Gasbarrini A, Cammarota G. Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives. Mediators Inflamm 2013;2013:391473. [PMID: 23737647 DOI: 10.1155/2013/391473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 193 |
Choi EY, Cho KK, Choi IS. Inflammatory Bowel Disease and Cytokine. Journal of Life Science 2013;23:448-461. [DOI: 10.5352/jls.2013.23.3.448] [Reference Citation Analysis]
|
| 194 |
To SQ, Knower KC, Clyne CD. Origins and actions of tumor necrosis factor α in postmenopausal breast cancer. J Interferon Cytokine Res 2013;33:335-45. [PMID: 23472660 DOI: 10.1089/jir.2012.0155] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 195 |
Condino G, Calabrese E, Zorzi F, Onali S, Lolli E, De Biasio F, Ascolani M, Pallone F, Biancone L. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study. Dig Liver Dis 2013;45:258-62. [PMID: 23195667 DOI: 10.1016/j.dld.2012.10.009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 196 |
Hisamatsu T, Kanai T, Mikami Y, Yoneno K, Matsuoka K, Hibi T. Immune aspects of the pathogenesis of inflammatory bowel disease. Pharmacology & Therapeutics 2013;137:283-297. [DOI: 10.1016/j.pharmthera.2012.10.008] [Cited by in Crossref: 63] [Cited by in F6Publishing: 69] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 197 |
De Plaen IG. Inflammatory signaling in necrotizing enterocolitis. Clin Perinatol 2013;40:109-24. [PMID: 23415267 DOI: 10.1016/j.clp.2012.12.008] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 198 |
Morrow T, Felcone LH. Defining the difference: What Makes Biologics Unique. Biotechnol Healthc. 2004;1:24-29. [PMID: 23393437 DOI: 10.1177/2050640615590302] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 199 |
De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis 2013;19:429-44. [PMID: 22539420 DOI: 10.1002/ibd.22977] [Cited by in Crossref: 111] [Cited by in F6Publishing: 88] [Article Influence: 11.1] [Reference Citation Analysis]
|
| 200 |
Hébuterne X, Lémann M, Bouhnik Y, Dewit O, Dupas JL, Mross M, D'Haens G, Mitchev K, Ernault É, Vermeire S, Brixi-Benmansour H, Moreels TG, Mary JY, Marteau P, Colombel JF. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013;62:201-8. [PMID: 22525883 DOI: 10.1136/gutjnl-2012-302262] [Cited by in Crossref: 133] [Cited by in F6Publishing: 135] [Article Influence: 13.3] [Reference Citation Analysis]
|
| 201 |
Laddha NC, Dwivedi M, Begum R. Increased Tumor Necrosis Factor (TNF)-α and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo. PLoS One 2012;7:e52298. [PMID: 23284977 DOI: 10.1371/journal.pone.0052298] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 202 |
Park JH, Lee MY, Kang MJ, Kim G, Kim D. Pharmaceutical perspectives for the delivery of TNF-α in cancer therapy. Journal of Pharmaceutical Investigation 2012;42:293-307. [DOI: 10.1007/s40005-012-0044-1] [Reference Citation Analysis]
|
| 203 |
Bendtzen K. Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine. Immunotherapy 2012;4:1167-79. [DOI: 10.2217/imt.12.114] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 204 |
Römkens TE, Kampschreur MT, Drenth JP, van Oijen MG, de Jong DJ. High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials. Inflamm Bowel Dis 2012;18:2190-8. [PMID: 22419617 DOI: 10.1002/ibd.22939] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 205 |
Vaiopoulou A, Gazouli M, Theodoropoulos G, Zografos G. Current advantages in the application of proteomics in inflammatory bowel disease. Dig Dis Sci 2012;57:2755-64. [PMID: 22740064 DOI: 10.1007/s10620-012-2291-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 206 |
Hatnapure GD, Keche AP, Rodge AH, Birajdar SS, Tale RH, Kamble VM. Synthesis and biological evaluation of novel piperazine derivatives of flavone as potent anti-inflammatory and antimicrobial agent. Bioorganic & Medicinal Chemistry Letters 2012;22:6385-90. [DOI: 10.1016/j.bmcl.2012.08.071] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 207 |
Seven G, Assaad A, Biehl T, Kozarek RA. Use of anti tumor necrosis factor-alpha monoclonal antibody for ulcerative jejunoileitis. World J Gastroenterol 2012; 18(36): 5135-5137 [PMID: 23049226 DOI: 10.3748/wjg.v18.i36.5135] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 208 |
Beck PL, Wallace JL. Cytokines in inflammatory bowel disease. Mediat of Inflammat. 1997;6:95-103. [PMID: 18472842 DOI: 10.1080/09629359791785] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 209 |
Bao CH, Wu LY, Wu HG, Shi Y, Liu HR, Zhang R, Yu LQ, Wang JH. Moxibustion inhibits apoptosis and tumor necrosis factor-alpha/tumor necrosis factor receptor 1 in the colonic epithelium of Crohn's disease model rats. Dig Dis Sci 2012;57:2286-95. [PMID: 22531889 DOI: 10.1007/s10620-012-2161-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 210 |
Waldner MJ, Neurath MF. Potential avenues for immunotherapy of colitis-associated neoplasia. Immunotherapy 2012;4:397-405. [PMID: 22512634 DOI: 10.2217/imt.12.15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 211 |
de Buck van Overstraeten A, Wolthuis A, D’Hoore A. Surgery for Crohn’s disease in the era of biologicals: A reduced need or delayed verdict? World J Gastroenterol 2012; 18(29): 3828-3832 [PMID: 22876034 DOI: 10.3748/wjg.v18.i29.3828] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 212 |
Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease. Inflamm Bowel Dis 2012;18:1480-7. [PMID: 21987418 DOI: 10.1002/ibd.21886] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 213 |
Pariente B, Pineton de Chambrun G, Krzysiek R, Desroches M, Louis G, De Cassan C, Baudry C, Gornet JM, Desreumaux P, Emilie D, Colombel JF, Allez M. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:1199-206. [PMID: 22127789 DOI: 10.1002/ibd.21839] [Cited by in Crossref: 90] [Cited by in F6Publishing: 66] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 214 |
Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012;107:1051-63. [PMID: 22613901 DOI: 10.1038/ajg.2012.89] [Cited by in Crossref: 154] [Cited by in F6Publishing: 148] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 215 |
Caprilli R, Latella G, Frieri G. Treatment of inflammatory bowel diseases: to heal the wound or to heal the sick? J Crohns Colitis 2012;6:621-5. [PMID: 22425510 DOI: 10.1016/j.crohns.2012.02.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 216 |
Biancone L, Zuzzi S, Ranieri M, Petruzziello C, Calabrese E, Onali S, Ascolani M, Zorzi F, Condino G, Iacobelli S, Pallone F. Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study. J Crohns Colitis 2012;6:578-87. [PMID: 22398047 DOI: 10.1016/j.crohns.2011.11.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 217 |
Singh UP, Singh NP, Busbee B, Guan H, Singh B, Price RL, Taub DD, Mishra MK, Nagarkatti M, Nagarkatti PS. Alternative medicines as emerging therapies for inflammatory bowel diseases. Int Rev Immunol. 2012;31:66-84. [PMID: 22251008 DOI: 10.3109/08830185.2011.642909] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 218 |
Schoepfer AM, Vavricka S, Zahnd-Straumann N, Straumann A, Beglinger C. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J Crohns Colitis 2012;6:412-8. [PMID: 22398068 DOI: 10.1016/j.crohns.2011.09.008] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 219 |
Riccioni ME, Urgesi R, Cianci R, Bizzotto A, Spada C, Costamagna G. Colon capsule endoscopy: Advantages, limitations and expectations. Which novelties? World J Gastrointest Endosc 2012; 4(4): 99-107 [PMID: 22523610 DOI: 10.4253/wjge.v4.i4.99] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 220 |
Marques S, Garcia-gonzalo J, Botequim B, Ricardo A, Borges J, Tome M, Oliveira M. Assessing wildfire occurrence probability in Pinus pinaster Ait. stands in Portugal. Forest Syst 2012;21:111. [DOI: 10.5424/fs/2112211-11374] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 221 |
Ul-Haq Z, Khan W, Zia SR, Iqbal S. Structure-based 3D-QSAR models and dynamics analysis of novel N-benzyl pyridinone as p38α MAP kinase inhibitors for anticytokine activity. J Mol Graph Model 2012;36:48-61. [PMID: 22534481 DOI: 10.1016/j.jmgm.2012.02.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 222 |
Tai EK, Wu WK, Wang XJ, Wong HP, Yu L, Li ZJ, Lee CW, Wong CC, Yu J, Sung JJ. Intrarectal administration of mCRAMP-encoding plasmid reverses exacerbated colitis in Cnlp(-/-) mice. Gene Ther. 2013;20:187-193. [PMID: 22378344 DOI: 10.1038/gt.2012.22] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 223 |
Aringer M, Smolen JS. Therapeutic blockade of TNF in patients with SLE—Promising or crazy? Autoimmunity Reviews 2012;11:321-5. [DOI: 10.1016/j.autrev.2011.05.001] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 224 |
Vos AC, Wildenberg ME, Arijs I, Duijvestein M, Verhaar AP, de Hertogh G, Vermeire S, Rutgeerts P, van den Brink GR, Hommes DW. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm Bowel Dis 2012;18:401-8. [PMID: 21936028 DOI: 10.1002/ibd.21818] [Cited by in Crossref: 121] [Cited by in F6Publishing: 108] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 225 |
Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 2012;1253:170-80. [PMID: 22288459 DOI: 10.1111/j.1749-6632.2011.06305.x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 142] [Article Influence: 12.7] [Reference Citation Analysis]
|
| 226 |
Hoentjen F, Sakuraba A, Hanauer S. Biologic Therapy of Crohn’s Disease: Infliximab. Crohn's Disease and Ulcerative Colitis 2012. [DOI: 10.1007/978-1-4614-0998-4_33] [Reference Citation Analysis]
|
| 227 |
Yoshimura N, Tadami T, Kawaguchi T, Sako M, Yoshimoto H, Yamaka T, Takazoe M. Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes. J Gastroenterol 2012;47:49-55. [PMID: 21915624 DOI: 10.1007/s00535-011-0464-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 228 |
Leite MR, Santos SS, Lyra AC, Mota J, Santana GO. Thalidomide induces mucosal healing in Crohn's disease: Case report. World J Gastroenterol 2011; 17(45): 5028-5031 [PMID: 22174554 DOI: 10.3748/wjg.v17.i45.5028] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 229 |
Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, Hildner K, Hoffman A, Kiesslich R, Rink AD, Rau TT, Rose-John S, Kessler H, Schmidt J, Neurath MF. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages. Gastroenterology 2011;141:2026-38. [PMID: 21875498 DOI: 10.1053/j.gastro.2011.08.032] [Cited by in Crossref: 165] [Cited by in F6Publishing: 173] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 230 |
Cottone M, Criscuoli V. Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol 2011;4:227-38. [PMID: 22016584 DOI: 10.2147/CEG.S6440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 231 |
Abdelsadik A, Trad A. Toll-like receptors on the fork roads between innate and adaptive immunity. Hum Immunol 2011;72:1188-93. [PMID: 21920397 DOI: 10.1016/j.humimm.2011.08.015] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 232 |
Pham M, Chow CC, Badawi D, Tu EY. Use of infliximab in the treatment of peripheral ulcerative keratitis in Crohn disease. Am J Ophthalmol 2011;152:183-188.e2. [PMID: 21652024 DOI: 10.1016/j.ajo.2011.01.059] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 233 |
van Rappard DC, Leenarts MF, Meijerink-van 't Oost L, Mekkes JR. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J Dermatolog Treat. 2012;23:284-289. [PMID: 21756155 DOI: 10.3109/09546634.2011.571657] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 234 |
Na SJ, So SH, Lee KO, Choi YC. Elevated serum level of interleukin-32α in the patients with myasthenia gravis. J Neurol 2011;258:1865-70. [PMID: 21487807 DOI: 10.1007/s00415-011-6036-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 235 |
Spada C, Hassan C, Sturniolo GC, Marmo R, Riccioni ME, de Franchis R, Van Gossum A, Costamagna G. Literature review and recommendations for clinical application of Colon Capsule Endoscopy. Dig Liver Dis 2011;43:251-8. [PMID: 21067981 DOI: 10.1016/j.dld.2010.10.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 236 |
Zheng JJ, Zhi P, Wang YM, Zhu F, Gu W, Xing YC, Zhou CL, Shen BW. Short-term study of infliximab treatment for Crohn's disease in China. J Dig Dis 2011;12:105-9. [PMID: 21401895 DOI: 10.1111/j.1751-2980.2011.00485.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 237 |
Zheng CF, Xu JH, Huang Y, Leung YK. Treatment of pediatric refractory Crohn’s disease with thalidomide. World J Gastroenterol 2011; 17(10): 1286-1291 [PMID: 21455327 DOI: 10.3748/wjg.v17.i10.1286] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 238 |
Machado J, Moncada JC, Pineda R. Perfil de utilización de los anti-factor de necrosis tumoral en pacientes de Colombia. biomedica 2011;31:250. [DOI: 10.7705/biomedica.v31i2.319] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 239 |
Conrad U, Plagmann I, Malchow S, Sack M, Floss DM, Kruglov AA, Nedospasov SA, Rose-John S, Scheller J. ELPylated anti-human TNF therapeutic single-domain antibodies for prevention of lethal septic shock. Plant Biotechnol J 2011;9:22-31. [PMID: 20444206 DOI: 10.1111/j.1467-7652.2010.00523.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 240 |
Biancone L, Petruzziello C, Orlando A, Kohn A, Ardizzone S, Daperno M, Angelucci E, Castiglione F, D'Incà R, Zorzi F, Papi C, Meucci G, Riegler G, Sica G, Rizzello F, Mocciaro F, Onali S, Calabrese E, Cottone M, Pallone F. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis 2011;17:758-66. [PMID: 20684009 DOI: 10.1002/ibd.21416] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 241 |
Shi Y, Zhou EH, Wu HG, Zhou CL, Wang QY, Qi L. Moxibustion treatment restoring the intestinal epithelium barrier in rats with Crohn’s disease by down-regulating tumor necrosis factor alpha, tumor necrosis factor receptor 1, and tumor necrosis factor receptor 2. Chin J Integr Med. 2011;17:212-217. [PMID: 21359923 DOI: 10.1007/s11655-011-0669-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 242 |
Parray FQ, Wani ML, Bijli AH, Thakur N, Irshad I; Nayeem-ul-Hassan. Crohn's disease: a surgeon's perspective. Saudi J Gastroenterol 2011;17:6-15. [PMID: 21196646 DOI: 10.4103/1319-3767.74430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 243 |
Cho MS, Song SM, Oh SH, Lee YJ, Jang JY, Kim KM. Tumor Necrosis Factor-α Gene Polymorphisms in Korean Children with Inflammatory Bowel Disease. Korean J Pediatr Gastroenterol Nutr 2011;14:269. [DOI: 10.5223/kjpgn.2011.14.3.269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 244 |
Kirsner JB. The Influence of Twentieth-Century Biomedical Thought on the Origins of Inflammatory Bowel Disease Therapy. Inflammatory Bowel Disease 2011. [DOI: 10.1007/978-1-60327-433-3_1] [Reference Citation Analysis]
|
| 245 |
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163:50-58. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 246 |
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011;163:50-8. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 247 |
Ohkawara T, Koyama Y, Onodera S, Takeda H, Kato M, Asaka M, Nishihira J. DNA vaccination targeting macrophage migration inhibitory factor prevents murine experimental colitis. Clin Exp Immunol 2011;163:113-22. [PMID: 21062270 DOI: 10.1111/j.1365-2249.2010.04277.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 248 |
Eshuis EJ, Magnin KM, Stokkers PC, Bemelman WA, Bartelsman J. Suicide attempt in ulcerative colitis patient after 4 months of infliximab therapy--a case report. J Crohns Colitis 2010;4:591-3. [PMID: 21122565 DOI: 10.1016/j.crohns.2010.04.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 249 |
Tanaka T, Okanobu H, Kuga Y, Yoshifuku Y, Fujino H, Miwata T, Moriya T, Nishida T, Oya T. Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol Clin Biol. 2010;34:687-695. [PMID: 20934287 DOI: 10.1016/j.gcb.2010.08.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 250 |
Maltby S, Wohlfarth C, Gold M, Zbytnuik L, Hughes MR, McNagny KM. CD34 is required for infiltration of eosinophils into the colon and pathology associated with DSS-induced ulcerative colitis. Am J Pathol. 2010;177:1244-1254. [PMID: 20696776 DOI: 10.2353/ajpath.2010.100191] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 251 |
Bultman E, Kuipers EJ, van der Woude CJ. Systematic review: steroid withdrawal in anti-TNF-treated patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010;32:313-23. [PMID: 20497138 DOI: 10.1111/j.1365-2036.2010.04373.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 252 |
Slattery E, Keegan D, O'Donoghue D. Anorectal stenosis after treatment with tumor necrosis factor alpha antibodies: a case series. J Med Case Rep 2010;4:226. [PMID: 20659338 DOI: 10.1186/1752-1947-4-226] [Reference Citation Analysis]
|
| 253 |
Freeman HJ, Perry T, Webber DL, Chang SD, Loh MY. Mucinous carcinoma in Crohn’s disease originating in a fistulous tract. World J Gastrointest Oncol 2010; 2(7): 307-310 [PMID: 21160662 DOI: 10.4251/wjgo.v2.i7.307] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 254 |
Chalaris A, Adam N, Sina C, Rosenstiel P, Lehmann-Koch J, Schirmacher P, Hartmann D, Cichy J, Gavrilova O, Schreiber S, Jostock T, Matthews V, Häsler R, Becker C, Neurath MF, Reiss K, Saftig P, Scheller J, Rose-John S. Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med 2010;207:1617-24. [PMID: 20603312 DOI: 10.1084/jem.20092366] [Cited by in Crossref: 220] [Cited by in F6Publishing: 231] [Article Influence: 16.9] [Reference Citation Analysis]
|
| 255 |
Giersberg M, Floss DM, Kipriyanov S, Conrad U, Scheller J. Covalent dimerization of camelidae anti-human TNF-alpha single domain antibodies by the constant kappa light chain domain improves neutralizing activity. Biotechnol Bioeng 2010;106:161-6. [PMID: 20047190 DOI: 10.1002/bit.22653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 256 |
Tiemi J, Komati S, Sdepanian VL. Effectiveness of infliximab in Brazilian children and adolescents with Crohn disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use. J Pediatr Gastroenterol Nutr 2010;50:628-33. [PMID: 20386321 DOI: 10.1097/MPG.0b013e3181bbf481] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 257 |
Singh UP, Singh NP, Singh B, Mishra MK, Nagarkatti M, Nagarkatti PS, Singh SR. Stem cells as potential therapeutic targets for inflammatory bowel disease. Front Biosci (Schol Ed). 2010;2:993-1008. [PMID: 20515838 DOI: 10.2741/s115] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 258 |
Keshaw H, Foong KS, Forbes A, Day RM. Perianal fistulae in Crohn's Disease: current and future approaches to treatment. Inflamm Bowel Dis 2010;16:870-80. [PMID: 19834976 DOI: 10.1002/ibd.21137] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 259 |
Chevaux JB, Bigard MA, Bensenane M, Oussalah A, Jarlot S, Belle A, Nani A, Bronowicki JP, Peyrin-Biroulet L. Inflammatory bowel disease and hepatitis B and C. Gastroenterol Clin Biol. 2009;33:1082-1093. [PMID: 19896313 DOI: 10.1016/j.gcb.2009.03.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 260 |
Vardanyan M, Parkin EC, Rodriguez Rilo HL. Infliximab/Anti‐TNF. Immunotherapy in Transplantation 2010. [DOI: 10.1002/9781444355628.ch26] [Reference Citation Analysis]
|
| 261 |
Bellizzi A, Barucca V, Fioriti D, Colosimo MT, Mischitelli M, Anzivino E, Chiarini F, Pietropaolo V. Early years of biological agents therapy in Crohn's disease and risk of the human polyomavirus JC reactivation. J Cell Physiol 2010;224:316-26. [DOI: 10.1002/jcp.22146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 262 |
Jacob N, Stohl W. Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity 2010;43:84-97. [PMID: 20014977 DOI: 10.3109/08916930903374600] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 263 |
Amasheh M, Grotjohann I, Amasheh S, Fromm A, Söderholm JD, Zeitz M, Fromm M, Schulzke JD. Regulation of mucosal structure and barrier function in rat colon exposed to tumor necrosis factor alpha and interferon gamma in vitro: a novel model for studying the pathomechanisms of inflammatory bowel disease cytokines. Scand J Gastroenterol 2009;44:1226-35. [PMID: 19658020 DOI: 10.1080/00365520903131973] [Cited by in Crossref: 88] [Cited by in F6Publishing: 95] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 264 |
Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OØ, Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009;44:774-81. [PMID: 19140087 DOI: 10.1080/00365520802699278] [Cited by in Crossref: 115] [Cited by in F6Publishing: 115] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 265 |
Weber CR, Raleigh DR, Su L, Shen L, Sullivan EA, Wang Y, Turner JR. Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J Biol Chem. 2010;285:12037-12046. [PMID: 20177070 DOI: 10.1074/jbc.m109.064808] [Cited by in Crossref: 198] [Cited by in F6Publishing: 207] [Article Influence: 15.2] [Reference Citation Analysis]
|
| 266 |
Ghosh N, Chaki R, Mandal V, Lin GD, Mandal SC. Mechanisms and Efficacy of Immunobiologic Therapies for Inflammatory Bowel Diseases. International Reviews of Immunology 2010;29:4-37. [DOI: 10.3109/08830180903437212] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 267 |
Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, Van Huysse J, Demetter P, Steidler L, Remaut E, Cuvelier C, Rottiers P. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 2010;3:49-56. [PMID: 19794409 DOI: 10.1038/mi.2009.116] [Cited by in Crossref: 187] [Cited by in F6Publishing: 191] [Article Influence: 14.4] [Reference Citation Analysis]
|
| 268 |
Hibi T. 3) Antibody Therapy for Inflammatory Bowel Disease. J Jpn Soc Intern Med 2010;99:2172-2176. [DOI: 10.2169/naika.99.2172] [Reference Citation Analysis]
|
| 269 |
Sands BE, Siegel CA. Crohn's Disease. Sleisenger and Fordtran's Gastrointestinal and Liver Disease 2010. [DOI: 10.1016/b978-1-4160-6189-2.00111-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 270 |
Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7:15-29. [PMID: 19949430 DOI: 10.1038/nrgastro.2009.203] [Cited by in Crossref: 328] [Cited by in F6Publishing: 271] [Article Influence: 25.2] [Reference Citation Analysis]
|
| 271 |
Jacob N, Jacob CO. On Anti-Tumor Necrosis Factor-induced Systemic Lupus Erythematosus. J Rheumatol 2009;37:3-5. [DOI: 10.3899/jrheum.091071] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 272 |
Krebs S, Omer TN, Omer B. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn’s disease - A controlled clinical trial. Phytomedicine. 2010;17:305-309. [PMID: 19962291 DOI: 10.1016/j.phymed.2009.10.013] [Cited by in Crossref: 73] [Cited by in F6Publishing: 54] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 273 |
Hitraya E, Schaible T. Anti – Tumor Necrosis Factor Therapies In Crohn’s Disease And Rheumatoid Arthritis. In: Ciliberto G, Savino R, editors. Cytokine Inhibitors. CRC Press; 2000. [DOI: 10.1201/9780203904244.ch4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 274 |
Chevaux J, Bigard M, Bensenane M, Oussalah A, Jarlot S, Belle A, Nani A, Bronowicki J, Peyrin-biroulet L. Maladies inflammatoires chroniques intestinales et hépatites B et C. Gastroentérologie Clinique et Biologique 2009;33:e1-e14. [DOI: 10.1016/j.gcb.2009.09.001] [Reference Citation Analysis]
|
| 275 |
Habib SF, Hasan MZ, Salam I. Infliximab therapy for HIV positive Crohn's disease: A case report. J Crohns Colitis 2009;3:302-4. [PMID: 21172291 DOI: 10.1016/j.crohns.2009.06.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 276 |
Michetti P, Stelle M, Juillerat P, Gassull M, Heil FJ, Stange E, Mottet C, Gonvers JJ, Pittet V, Vader JP, Froehlich F, Felley C; EPACT II Study Group. Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel-EPACT II. J Crohns Colitis 2009;3:232-40. [PMID: 21172281 DOI: 10.1016/j.crohns.2009.05.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 277 |
Dideberg V, Théâtre E, Farnir F, Vermeire S, Rutgeerts P, De Vos M, Belaiche J, Franchimont D, Van Gossum A, Louis E, Bours V. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet Genomics 2006;16:727-34. [PMID: 17001292 DOI: 10.1097/01.fpc.0000230117.26581.a4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 278 |
Cornillie F. Ten years of infliximab (Remicade®) in clinical practice: The story from bench to bedside. European Journal of Pharmacology 2009;623:S1-4. [DOI: 10.1016/j.ejphar.2009.10.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 279 |
Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, Chao J, Mulani PM. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease. Pharmacoeconomics. 2009;27:609-621. [PMID: 19663531 DOI: 10.2165/11312710-000000000-00000] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 280 |
Stillie R, Stadnyk AW. Role of TNF receptors, TNFR1 and TNFR2, in dextran sodium sulfate-induced colitis. Inflamm Bowel Dis 2009;15:1515-25. [PMID: 19479745 DOI: 10.1002/ibd.20951] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 281 |
Snoeks L, Weber CR, Wasland K, Turner JR, Vainder C, Qi W, Savkovic SD. Tumor suppressor FOXO3 participates in the regulation of intestinal inflammation. Lab Invest 2009;89:1053-62. [PMID: 19636295 DOI: 10.1038/labinvest.2009.66] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 282 |
Cosnes J, Seksik P. Maladies inflammatoires chroniques de l’intestin : de la sulfasalazine aux biothérapies. Gastroentérologie Clinique et Biologique 2009;33:692-701. [DOI: 10.1016/j.gcb.2009.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 283 |
Chowdhury M, Kudara N, Chiba T, Endo M, Akasaka R, Tomita K, Fujiwara S, Mizutani T, Sugai T, Takikawa Y, Suzuki K. Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn's Disease Using Double-Balloon Endoscopy. Case Rep Gastroenterol 2009;3:193-7. [PMID: 21103274 DOI: 10.1159/000224712] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 284 |
Pang Z, Shen BW, Zheng JJ. Intra-abdominal abscess develops during infliximab treatment of refractory Crohn's disease: a report of one case. Shijie Huaren Xiaohua Zazhi 2009; 17(21): 2221-2222 [DOI: 10.11569/wcjd.v17.i21.2221] [Reference Citation Analysis]
|
| 285 |
Gomollón F, Gisbert JP. [Must immunomodulators be added to biological treatment in inflammatory bowel disease?]. Gastroenterol Hepatol 2010;33:43-53. [PMID: 19616870 DOI: 10.1016/j.gastrohep.2009.03.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 286 |
Kokura S, Yoshida N, Okuda T, Nakabe N, Sakamoto N, Isozaki Y, Hattori T, Handa O, Takagi T, Naito Y, Yoshikawa T. Hyperthermia ameliorates 2,4,6-trinitrobenzene sulphonic acid-induced colitis in rats: The role of heat shock proteins. International Journal of Hyperthermia 2009;23:17-28. [DOI: 10.1080/02656730601090223] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 287 |
Salomonsson S, Lundberg IE. Cytokines in idiopathic inflammatory myopathies: REVIEW. Autoimmunity 2009;39:177-90. [DOI: 10.1080/08916930600622256] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 288 |
Tran S, Hooker RS, Cipher DJ, Reimold A. Patterns of Biologic Agent Use in Older Males with Inflammatory Diseases: An Institution-Focused, Observational Post-Marketing Study. Drugs & Aging 2009;26:607-15. [DOI: 10.2165/11316350-000000000-00000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 289 |
Jansen van Rensburg CE, Naude PJ. Potassium Humate Inhibits Complement Activation and the Production of Inflammatory Cytokines In Vitro. Inflammation 2009;32:270-6. [DOI: 10.1007/s10753-009-9130-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 290 |
Eshuis EJ, Bemelman WA, Stokkers PC. Infliximab for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol 2009;3:219-29. [PMID: 19485804 DOI: 10.1586/egh.09.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 291 |
Malheiros APR, Teixeira MG, Scanavini Neto A, Silva Filho EV, Rodrigues LCDO, Thierry R, Nahas S, Cecconello I. Tratamento da doença de Crohn com infliximabe: primeira opção? ABCD, arq bras cir dig 2009;22:101-104. [DOI: 10.1590/s0102-67202009000200007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 292 |
Koenecke C, Förster R. CCR9 and inflammatory bowel disease. Expert Opinion on Therapeutic Targets 2009;13:297-306. [DOI: 10.1517/14728220902762928] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 293 |
Pimentel-Nunes P, Dinis-Ribeiro M, Magro F. Systematic review on drug and diet-induced endoscopic remission in Crohn's disease. Eur J Gastroenterol Hepatol 2009;21:491-503. [PMID: 19293722 DOI: 10.1097/MEG.0b013e3283196b03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 294 |
Plagmann I, Chalaris A, Kruglov AA, Nedospasov S, Rosenstiel P, Rose-John S, Scheller J. Transglutaminase-catalyzed covalent multimerization of Camelidae anti-human TNF single domain antibodies improves neutralizing activity. J Biotechnol 2009;142:170-8. [PMID: 19439388 DOI: 10.1016/j.jbiotec.2009.04.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 295 |
Farhi D, Dupin N. [Biologic therapies in the treatment of psoriasis]. Presse Med 2009;38:832-43. [PMID: 19282134 DOI: 10.1016/j.lpm.2008.07.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 296 |
Jacob N, Yang H, Pricop L, Liu Y, Gao X, Zheng SG, Wang J, Gao HX, Putterman C, Koss MN, Stohl W, Jacob CO. Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol 2009;182:2532-41. [PMID: 19201910 DOI: 10.4049/jimmunol.0802948] [Cited by in Crossref: 83] [Cited by in F6Publishing: 86] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 297 |
Belmiro CL, Castelo-Branco MT, Melim LM, Schanaider A, Elia C, Madi K, Pavão MS, de Souza HS. Unfractionated heparin and new heparin analogues from ascidians (chordate-tunicate) ameliorate colitis in rats. J Biol Chem 2009;284:11267-78. [PMID: 19258310 DOI: 10.1074/jbc.M807211200] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 298 |
Drews BH, Barth TF, Hänle MM, Akinli AS, Mason RA, Muche R, Thiel R, Pauls S, Klaus J, von Boyen G. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn’s disease. Eur Radiol. 2009;19:1379-1386. [PMID: 19184036 DOI: 10.1007/s00330-008-1290-5] [Cited by in Crossref: 83] [Cited by in F6Publishing: 67] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 299 |
Nielsen OH, Rogler G, Hahnloser D, Thomsen OØ. Diagnosis and management of fistulizing Crohn’s disease. Nat Clin Pract Gastroenterol Hepatol. 2009;6:92-106. [PMID: 19153563 DOI: 10.1038/ncpgasthep1340] [Cited by in Crossref: 74] [Cited by in F6Publishing: 85] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 300 |
Hisamatsu T, Hibi T. Biologics in Current Therapy for Inflammatory Bowel Disease. Jpn J Clin Immunol 2009;32:168-179. [DOI: 10.2177/jsci.32.168] [Reference Citation Analysis]
|
| 301 |
Claudepierre P, Wendling D. Espondiloartritis anquilosante. EMC - Aparato Locomotor 2009;42:1-18. [DOI: 10.1016/s1286-935x(09)70896-2] [Reference Citation Analysis]
|
| 302 |
Claudepierre P, Wendling D. Spondylarthrite ankylosante. EMC - Appareil locomoteur 2009;4:1-18. [DOI: 10.1016/s0246-0521(09)48913-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 303 |
Alós R, Hinojosa J. Timing of surgery in Crohn’s disease: A key issue in the management. World J Gastroenterol 2008; 14(36): 5532-5539 [PMID: 18810772 DOI: 10.3748/wjg.14.5532] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 46] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 304 |
Esposito E, Mazzon E, Riccardi L, Caminiti R, Meli R, Cuzzocrea S. Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis. J Pineal Res 2008;45:166-73. [PMID: 18429971 DOI: 10.1111/j.1600-079X.2008.00572.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 305 |
Edelblum KL, Goettel JA, Koyama T, McElroy SJ, Yan F, Polk DB. TNFR1 promotes tumor necrosis factor-mediated mouse colon epithelial cell survival through RAF activation of NF-kappaB. J Biol Chem 2008;283:29485-94. [PMID: 18713739 DOI: 10.1074/jbc.M801269200] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 306 |
Laclotte C, Oussalah A, Rey P, Bensenane M, Pluvinage N, Chevaux JB, Trouilloud I, Serre AA, Boucekkine T, Bigard MA, Peyrin-Biroulet L. [Helminths and inflammatory bowel diseases]. Gastroenterol Clin Biol 2008;32:1064-74. [PMID: 18619749 DOI: 10.1016/j.gcb.2008.04.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 307 |
Sorrentino D, Terrosu G, Avellini C. Infliximab in Crohn's disease: a look at the (not so distant) future. Dig Liver Dis 2008;40 Suppl 2:S229-35. [PMID: 18598994 DOI: 10.1016/S1590-8658(08)60531-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 308 |
Sorrentino D. Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far? Digestion 2008;77:38-47. [PMID: 18285676 DOI: 10.1159/000117306] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 309 |
Krueger JG, Ochs HD, Patel P, Gilkerson E, Guttman-Yassky E, Dummer W. Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. J Invest Dermatol 2008;128:2615-24. [PMID: 18496564 DOI: 10.1038/jid.2008.98] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 310 |
Wu EQ, Mulani PM, Yu AP, Tang J, Pollack PF. Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective. Value Health. 2008;11:820-829. [PMID: 18489509 DOI: 10.1111/j.1524-4733.2008.00335.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 311 |
Hanai H, Iida T, Takeuchi K, Watanabe F, Yamada M, Kikuyama M, Maruyama Y, Iwaoka Y, Hirayama K, Nagata S, Takai K. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol 2008;103:1210-6. [PMID: 18177452 DOI: 10.1111/j.1572-0241.2007.01714.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 312 |
Islam MS, Murata T, Fujisawa M, Nagasaka R, Ushio H, Bari AM, Hori M, Ozaki H. Anti-inflammatory effects of phytosteryl ferulates in colitis induced by dextran sulphate sodium in mice. Br J Pharmacol 2008;154:812-24. [PMID: 18536734 DOI: 10.1038/bjp.2008.137] [Cited by in Crossref: 154] [Cited by in F6Publishing: 158] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 313 |
Rudolph SJ, Weinberg DI, McCabe RP. Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci 2008;53:1033-41. [PMID: 17934827 DOI: 10.1007/s10620-007-9969-z] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 314 |
Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK. Alterations in the function of circulating mononuclear cells derived from patients with Crohn’s disease treated with mastic. World J Gastroenterol. 2007;13:6031-6036. [PMID: 18023095 DOI: 10.3748/wjg.13.6031] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 315 |
Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK. Alterations in the function of circulating mononuclear cells derived from patients with Crohn's disease treated with mastic. World J Gastroenterol 2007;13:6031-6. [PMID: 18023095 DOI: 10.3748/wjg.v13.45.6031] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 17] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 316 |
Sopwith M. Therapeutic Applications of Monoclonal Antibodies: A Clinical Overview. Biotechnology 2008. [DOI: 10.1002/9783527620869.ch12] [Reference Citation Analysis]
|
| 317 |
Ye D, Ma TY. Cellular and molecular mechanisms that mediate basal and tumour necrosis factor-alpha-induced regulation of myosin light chain kinase gene activity. J Cell Mol Med. 2008;12:1331-1346. [PMID: 18363837 DOI: 10.1111/j.1582-4934.2008.00302.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 86] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 318 |
Phelan JD, Orekov T, Finkelman FD. Cutting edge: mechanism of enhancement of in vivo cytokine effects by anti-cytokine monoclonal antibodies. J Immunol 2008;180:44-8. [PMID: 18097002 DOI: 10.4049/jimmunol.180.1.44] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 319 |
Michetti P, Mottet C, Juillerat P, Pittet V, Felley C, Vader JP, Gonvers JJ, Froehlich F. Severe and steroid-resistant Crohn's disease. Digestion 2007;76:99-108. [PMID: 18239400 DOI: 10.1159/000111023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 320 |
Hendel J, Brynskov J, Særmark T, Bendtzen K. Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Experimental cytokine modulation therapy of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Expert Opinion on Investigational Drugs 2008;5:843-50. [DOI: 10.1517/13543784.5.7.843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 321 |
de Ridder L, Rings EH, Damen GM, Kneepkens CM, Schweizer JJ, Kokke FT, Benninga MA, Norbruis OF, Hoekstra JH, Gijsbers CF, Escher JC. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis 2008;14:353-8. [PMID: 18069674 DOI: 10.1002/ibd.20329] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 322 |
Ogata T, Yamashita K, Horiuchi H, Okuda K, Todo S. A novel tumor necrosis factor-alpha suppressant, ONO-SM362, prevents liver failure and promotes liver regeneration after extensive hepatectomy. Surgery. 2008;143:545-555. [PMID: 18374053 DOI: 10.1016/j.surg.2007.11.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 323 |
Shirota Y, Illei GG, Nikolov NP. Biologic treatments for systemic rheumatic diseases. Oral Dis 2008;14:206-16. [PMID: 18282173 DOI: 10.1111/j.1601-0825.2008.01440.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 324 |
Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;CD006893. [PMID: 18254120 DOI: 10.1002/14651858.cd006893] [Cited by in Crossref: 71] [Cited by in F6Publishing: 122] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 325 |
Din S, Cochrane CJ, Noble CL, Satsangi J, Arnott ID. Combination therapy of infliximab and azathioprine reduces disease progression in Crohn's disease. Inflamm Bowel Dis 2008;14:143-5. [PMID: 17932978 DOI: 10.1002/ibd.20260] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 326 |
Marteau P. La maladie de Crohn. De Barrett à Zollinger-Ellison Quelques cas historiques en gastroentérologie 2008. [DOI: 10.1007/978-2-287-77052-4_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 327 |
Shealy DJ, Visvanathan S. Anti-TNF antibodies: lessons from the past, roadmap for the future. Handb Exp Pharmacol 2008;:101-29. [PMID: 18071943 DOI: 10.1007/978-3-540-73259-4_5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 328 |
Atreya R, Neurath MF. Future Trends in Confocal Laser Endomicroscopy: Improved Imaging Quality and Immunoendoscopy. Atlas of Endomicroscopy. [DOI: 10.1007/978-3-540-35115-3_15] [Reference Citation Analysis]
|
| 329 |
Weersma RK, van Dullemen HM, van der Steege G, Nolte IM, Kleibeuker JH, Dijkstra G. Review article: Inflammatory bowel disease and genetics. Aliment Pharmacol Ther 2007;26 Suppl 2:57-65. [PMID: 18081650 DOI: 10.1111/j.1365-2036.2007.03476.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 330 |
Minderhoud IM, Samsom M, Oldenburg B. What predicts mucosal inflammation in Crohn's disease patients? Inflamm Bowel Dis 2007;13:1567-72. [PMID: 17663422 DOI: 10.1002/ibd.20233] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 331 |
Saniabadi AR, Hanai H, Fukunaga K, Sawada K, Shima C, Bjarnason I, Lofberg R. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci. 2007;37:191-200. [PMID: 17974479 DOI: 10.1016/j.transci.2007.08.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 332 |
Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gjertson D, Singh RR. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126:13-30. [PMID: 17916445 DOI: 10.1016/j.clim.2007.08.012] [Cited by in Crossref: 172] [Cited by in F6Publishing: 186] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 333 |
Fischetti G, Di Crosta G. Enterovesical Fistulas Secondary to Crohn's Disease: Medical versus Surgical Therapies. Urologia 2007;74:228-232. [DOI: 10.1177/039156030707400406] [Reference Citation Analysis]
|
| 334 |
Tran CN, Lundy SK, White PT, Endres JL, Motyl CD, Gupta R, Wilke CM, Shelden EA, Chung KC, Urquhart AG, Fox DA. Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-alpha on cytokine-activated T cells. Am J Pathol 2007;171:1588-98. [PMID: 17823284 DOI: 10.2353/ajpath.2007.070004] [Cited by in Crossref: 46] [Cited by in F6Publishing: 54] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 335 |
Murphy MS. New drugs: kids come first; con: first adults, then children. Inflamm Bowel Dis 2007;13:1170-5; discussion 1176-7. [PMID: 17538986 DOI: 10.1002/ibd.20179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 336 |
Ruocco E, Cuomo A, Salerno R, Ruocco V, Romano M, Baroni A. Crohn’s disease and its mucocutaneous involvement. Skinmed. 2007;6:179-185. [PMID: 17618178 DOI: 10.1111/j.1540-9740.2007.05907.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 337 |
Vielhauer V, Mayadas TN. Functions of TNF and its receptors in renal disease: distinct roles in inflammatory tissue injury and immune regulation. Semin Nephrol. 2007;27:286-308. [PMID: 17533007 DOI: 10.1016/j.semnephrol.2007.02.004] [Cited by in Crossref: 85] [Cited by in F6Publishing: 85] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 338 |
Salar A, Bessa X, Muñiz E, Monfort D, Besses C, Andreu M. Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease. Gut 2007;56:1169-70. [PMID: 17344276 DOI: 10.1136/gut.2007.123547] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 339 |
Bhatia JK, Korelitz BI, Panagopoulos G, Lobel E, Mirsky F, Sultan K, DiSanti W, Chun A, Keenan G, Mamun K. A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone. J Clin Gastroenterol 2007;41:677-81. [PMID: 17667052 DOI: 10.1097/MCG.0b013e31802c2a23] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 340 |
Srivastava AS, Feng Z, Mishra R, Malhotra R, Kim HS, Carrier E. Embryonic stem cells ameliorate piroxicam-induced colitis in IL10-/- KO mice. Biochem Biophys Res Commun 2007;361:953-9. [PMID: 17692287 DOI: 10.1016/j.bbrc.2007.07.139] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 341 |
de Ridder L, Benninga MA, Taminiau JA, Hommes DW, van Deventer SJ. Infliximab use in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;45:3-14. [PMID: 17592358 DOI: 10.1097/MPG.0b013e31803e171c] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 342 |
White ES, Lynch Iii JP. Current and emerging strategies for the management of sarcoidosis. Expert Opinion on Pharmacotherapy 2007;8:1293-311. [DOI: 10.1517/14656566.8.9.1293] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 343 |
Gilmore JL, King BW, Asakawa N, Harrison K, Tebben A, Sheppeck JE 2nd, Liu RQ, Covington M, Duan JJ. Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett 2007;17:4678-82. [PMID: 17576061 DOI: 10.1016/j.bmcl.2007.05.100] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 344 |
Rogler G. Multi-site therapeutic modalities for inflammatory bowel diseases — mechanisms of action. Inflammatory Bowel Disease: From Bench to Bedside. [DOI: 10.1007/0-387-25808-6_26] [Reference Citation Analysis]
|
| 345 |
Hanauer SB, Dassopoulos T. Medical therapy for Crohn’s disease. Inflammatory Bowel Disease: From Bench to Bedside. [DOI: 10.1007/0-387-25808-6_33] [Reference Citation Analysis]
|
| 346 |
Tamagawa H, Hiroi T, Mizushima T, Ito T, Matsuda H, Kiyono H. Therapeutic effects of roxithromycin in interleukin-10-deficient colitis. Inflamm Bowel Dis 2007;13:547-56. [PMID: 17245768 DOI: 10.1002/ibd.20093] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 347 |
Clancy R, Ren Z, Turton J, Pang G, Wettstein A. Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease correlates with enhanced TNF-alpha secretion. Dig Liver Dis 2007;39:445-51. [PMID: 17317344 DOI: 10.1016/j.dld.2006.12.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 348 |
Grover P, Kamat D. Management of inflammatory bowel disease. Clin Pediatr (Phila) 2007;46:359-64. [PMID: 17475997 DOI: 10.1177/0009922806289837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 349 |
Carvalho AT, Souza H, Carneiro AJ, Castelo-Branco M, Madi K, Schanaider A, Silva F, Pereira Jứnior FA, Pereira MG, Tortori C, Dines I, Carvalho J, Rocha E, Elia C. Therapeutic and prophylactic thalidomide in TNBS-induced colitis: Synergistic effects on TNF-α, IL-12 and VEGF production. World J Gastroenterol 2007; 13(15): 2166-2173 [PMID: 17465495 DOI: 10.3748/wjg.v13.i15.2166] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 350 |
Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999;5:119-33. [DOI: 10.1002/ibd.3780050209] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 351 |
Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn's disease. Aliment Pharmacol Ther 2007;25:861-70. [PMID: 17402989 DOI: 10.1111/j.1365-2036.2007.03276.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 64] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 352 |
Eivindson M, Grønbaek H, Skogstrand K, Thorsen P, Frystyk J, Flyvbjerg A, Dahlerup JF. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease. Scand J Gastroenterol 2007;42:464-70. [PMID: 17454856 DOI: 10.1080/00365520601010115] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 353 |
Van den Brande JM, Koehler TC, Zelinkova Z, Bennink RJ, te Velde AA, ten Cate FJ, van Deventer SJ, Peppelenbosch MP, Hommes DW. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 2007;56:509-17. [PMID: 17082252 DOI: 10.1136/gut.2006.105379] [Cited by in Crossref: 129] [Cited by in F6Publishing: 135] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 354 |
Solomon A, Akabayov B, Frenkel A, Milla ME, Sagi I. Key feature of the catalytic cycle of TNF-alpha converting enzyme involves communication between distal protein sites and the enzyme catalytic core. Proc Natl Acad Sci U S A 2007;104:4931-6. [PMID: 17360351 DOI: 10.1073/pnas.0700066104] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 355 |
Frulloni L, Bernardoni L, Scattolini C, Vantini I. Biological Approach in the Treatment of Crohn’s Disease. Inflammatory Bowel Disease and Familial Adenomatous Polyposis. [DOI: 10.1007/88-470-0434-9_16] [Reference Citation Analysis]
|
| 356 |
Dinarello CA. Established and novel methods for treating inflammatory diseases by inhibition of cytokines. Falk Symposium. [DOI: 10.1007/1-4020-4144-6_28] [Reference Citation Analysis]
|
| 357 |
Tilg H. Role of cytokines and their receptors in inflammatory bowel diseases. Falk Symposium. [DOI: 10.1007/1-4020-2912-8_9] [Reference Citation Analysis]
|
| 358 |
Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007;25:247-55. [PMID: 17217454 DOI: 10.1111/j.1365-2036.2006.03184.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 81] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 359 |
Biancone L, Calabrese E, Petruzziello C, Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Rev Gastroenterol Hepatol 2007;4:78-91. [DOI: 10.1038/ncpgasthep0695] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 360 |
Taylor SR, McCluskey P, Lightman S. The ocular manifestations of inflammatory bowel disease. Curr Opin Ophthalmol. 2006;17:538-544. [PMID: 17065922 DOI: 10.1097/icu.0b013e3280109461] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 361 |
Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007;42:16-25. [PMID: 17322989 DOI: 10.1007/s00535-006-1995-7] [Cited by in Crossref: 168] [Cited by in F6Publishing: 177] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 362 |
Connors JM. Crohn's Disease of the Stomach and Duodenum. xPharm: The Comprehensive Pharmacology Reference 2007. [DOI: 10.1016/b978-008055232-3.60714-7] [Reference Citation Analysis]
|
| 363 |
Elliott MJ. VALIDATION OF TNF AS A DRUG TARGET IN INFLAMMATORY BOWEL DISEASE. Target Validation in Drug Discovery 2007. [DOI: 10.1016/b978-012369393-8/50006-7] [Reference Citation Analysis]
|
| 364 |
Remick DG, Ward PA. Evaluation of endotoxin models for the study of sepsis. Shock. 2005;24 Suppl 1:7-11. [PMID: 16374366 DOI: 10.1097/01.shk.0000191384.34066.85] [Cited by in Crossref: 133] [Cited by in F6Publishing: 141] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 365 |
White ES, Lynch JP. Pharmacological therapy for Wegener's granulomatosis. Drugs 2006;66:1209-28. [PMID: 16827598 DOI: 10.2165/00003495-200666090-00004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 366 |
Le Buanec H, Delavallée L, Bessis N, Paturance S, Bizzini B, Gallo R, Zagury D, Boissier MC. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci U S A 2006;103:19442-7. [PMID: 17158801 DOI: 10.1073/pnas.0604827103] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 367 |
Rahimi R, Nikfar S, Abdollahi M. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn’s disease? A systematic meta-analysis of controlled clinical trials. Biomed Pharmacother. 2007;61:75-80. [PMID: 17184965 DOI: 10.1016/j.biopha.2006.06.022] [Cited by in Crossref: 47] [Cited by in F6Publishing: 57] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 368 |
Richter JA, Bickston SJ. Infliximab use in luminal Crohn's disease. Gastroenterol Clin North Am 2006;35:775-93. [PMID: 17129813 DOI: 10.1016/j.gtc.2006.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 369 |
Atreya R, Atreya I, Neurath MF. Novel signal transduction pathways: analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease. Ann N Y Acad Sci. 2006;1072:98-113. [PMID: 17057193 DOI: 10.1196/annals.1326.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 370 |
White ES. Infliximab in sarcoidosis: more answers or more questions? Am J Respir Crit Care Med 2006;174:732-3. [PMID: 16988163 DOI: 10.1164/rccm.200606-858ED] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 371 |
Beltrán B, Nos P, Bastida G, Iborra M, Hoyos M, Ponce J. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease. Gut 2006;55:1670-1. [PMID: 17047119 DOI: 10.1136/gut.2006.101386] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 372 |
Mazzon E, Esposito E, Crisafulli C, Riccardi L, Muià C, Di Bella P, Meli R, Cuzzocrea S. Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J Pineal Res 2006;41:363-73. [PMID: 17014694 DOI: 10.1111/j.1600-079X.2006.00378.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 373 |
Sands BE. New therapies for the treatment of inflammatory bowel disease. Surg Clin North Am. 2006;86:1045-1064. [PMID: 16905423 DOI: 10.1016/j.suc.2006.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 374 |
Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin JM, Watier H, Goupille P, Paintaud G. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit. 2006;28:169-174. [PMID: 16628126 DOI: 10.1097/01.ftd.0000189901.08684.4b] [Cited by in Crossref: 86] [Cited by in F6Publishing: 87] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 375 |
Tamaki H, Nakamura H, Nishio A, Nakase H, Ueno S, Uza N, Kido M, Inoue S, Mikami S, Asada M, Kiriya K, Kitamura H, Ohashi S, Fukui T, Kawasaki K, Matsuura M, Ishii Y, Okazaki K, Yodoi J, Chiba T. Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology 2006;131:1110-21. [PMID: 17030181 DOI: 10.1053/j.gastro.2006.08.023] [Cited by in Crossref: 91] [Cited by in F6Publishing: 97] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 376 |
Ancowitz B, Shah SA. Infusion services in the gastroenterology practice. Gastrointest Endosc Clin N Am 2006;16:727-42. [PMID: 17098619 DOI: 10.1016/j.giec.2006.08.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 377 |
Cavaillon J. Molecular Mediators: Cytokines. Encyclopedia of Molecular Cell Biology and Molecular Medicine 2006. [DOI: 10.1002/3527600906.mcb.200400134] [Reference Citation Analysis]
|
| 378 |
Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, Ost A, Hittel N, Saniabadi A, Löfberg R. Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis 2006;21:493-504. [PMID: 16538495 DOI: 10.1007/s00384-005-0069-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 379 |
de Ridder L, Benninga MA, Taminiau JA, Hommes DW. Infliximab as first-line therapy in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2006;43:388-90. [PMID: 16954965 DOI: 10.1097/01.mpg.0000226369.31956.bf] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 380 |
Kostyk AG, Dahl KM, Wynes MW, Whittaker LA, Weiss DJ, Loi R, Riches DW. Regulation of chemokine expression by NaCl occurs independently of cystic fibrosis transmembrane conductance regulator in macrophages. Am J Pathol 2006;169:12-20. [PMID: 16816357 DOI: 10.2353/ajpath.2006.051042] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 381 |
Hsia EC, Ruley KM, Rahman MU. Infliximab (RemicadeR): from bench to clinical practice. A paradigm shift in rheumatology practice. APLAR J Rheumatol 2006;9:107-18. [DOI: 10.1111/j.1479-8077.2006.00185.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 382 |
Dideberg V, Louis E, Farnir F, Bertoli S, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Bours V. Lymphotoxin alpha gene in Crohn’s disease patients: absence of implication in the response to infliximab in a large cohort study. Pharmacogenet Genomics. 2006;16:369-373. [PMID: 16609369 DOI: 10.1097/01.fpc.0000204993.91806.b1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 383 |
Schmidt C, Wittig BM, Moser C, Zeitz M, Stallmach A. Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn's disease. Aliment Pharmacol Ther 2006;24:343-50. [PMID: 16842461 DOI: 10.1111/j.1365-2036.2006.02988.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 384 |
Kanai T, Uraushihara K, Totsuka T, Nemoto Y, Fujii R, Kawamura T, Makita S, Sawada D, Yagita H, Okumura K, Watanabe M. Ameliorating effect of saporin-conjugated anti-CD11b monoclonal antibody in a murine T-cell-mediated chronic colitis. J Gastroenterol Hepatol 2006;21:1136-42. [PMID: 16824065 DOI: 10.1111/j.1440-1746.2006.04391.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 385 |
Cao Q, Zhu Q, Wu M, Hu W, Gao M, Si J. Genetic susceptibility to ulcerative colitis in the Chinese Han ethnic population: association with TNF polymorphisms: . Chinese Medical Journal 2006;119:1198-203. [DOI: 10.1097/00029330-200607020-00011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 386 |
Suárez Pedreira I, Santos Juanes J, Caminal Montero L, Trapiella L. Infliximab: una alternativa en la eritrodermia psoriásica refractaria. Piel 2006;21:317-8. [DOI: 10.1016/s0213-9251(06)72498-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 387 |
Dalmasso G, Loubat A, Dahan S, Calle G, Rampal P, Czerucka D. Saccharomyces boulardii prevents TNF-α-induced apoptosis in EHEC-infected T84 cells. Research in Microbiology 2006;157:456-65. [DOI: 10.1016/j.resmic.2005.11.007] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 388 |
Kruis W, Dignass A, Steinhagen-Thiessen E, Morgenstern J, Mössner J, Schreiber S, Vecchi M, Malesci A, Reinshagen M, Löfberg R. Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol 2005;11:7001-6. [PMID: 16437606 DOI: 10.3748/wjg.v11.i44.7001] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 389 |
Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu R, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP, Duan JJ. Synthesis and structure–activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors. Bioorganic & Medicinal Chemistry Letters 2006;16:2699-704. [DOI: 10.1016/j.bmcl.2006.02.015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 390 |
Feldmann M, Pusey CD. Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. J Am Soc Nephrol. 2006;17:1243-1252. [PMID: 16624928 DOI: 10.1681/asn.2005121359] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 391 |
Sorrentino D, Avellini C, Beltrami CA, Pasqual E, Zearo E. Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease. Int J Colorectal Dis 2006;21:276-81. [PMID: 15951989 DOI: 10.1007/s00384-005-0739-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 392 |
Romano C, Cucchiara S, Barabino A, Annese V, Sferlazzas C. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World J Gastroenterol 2005;11:7118-21. [PMID: 16437657 DOI: 10.3748/wjg.v11.i45.7118] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 70] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 393 |
Baqir M, Usman MH, Adenwalla HN, Aziz S, Noor F, ul- Islam T, Ahmed M, Hotiana M. Takayasu's arteritis with skin manifestations in a patient with inflammatory bowel disease: coincidence or concurrence? Clin Rheumatol 2007;26:996-8. [PMID: 16555017 DOI: 10.1007/s10067-006-0233-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 394 |
Bratcher JM, Korelitz BI. Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin Drug Saf 2006;5:9-16. [PMID: 16370952 DOI: 10.1517/14740338.5.1.9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 395 |
Baeten D. Infliximab: a chimeric anti-TNF- monoclonal antibody for the treatment of ankylosing spondylitis and other spondyloarthritides. Therapy 2006;3:191-200. [DOI: 10.1586/14750708.3.2.191] [Reference Citation Analysis]
|
| 396 |
Baeten D. Infliximab: a chimeric anti-TNF-α monoclonal antibody for the treatment of ankylosing spondylitis and other spondyloarthritides. Therapy 2006;3:191-200. [DOI: 10.2217/14750708.3.2.191] [Reference Citation Analysis]
|
| 397 |
Biancone L, Cretella M, Tosti C, Palmieri G, Petruzziello C, Geremia A, Calabrese E, Pallone F. Local injection of infliximab in the postoperative recurrence of Crohn's disease. Gastrointest Endosc 2006;63:486-92. [PMID: 16500402 DOI: 10.1016/j.gie.2005.08.047] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 398 |
Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-42; quiz 464. [PMID: 16500392 DOI: 10.1016/j.gie.2005.08.011] [Cited by in Crossref: 409] [Cited by in F6Publishing: 426] [Article Influence: 24.1] [Reference Citation Analysis]
|
| 399 |
Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-87. [PMID: 16530532 DOI: 10.1053/j.gastro.2006.01.048] [Cited by in Crossref: 338] [Cited by in F6Publishing: 354] [Article Influence: 19.9] [Reference Citation Analysis]
|
| 400 |
Stio M, Martinesi M, Bruni S, Treves C, d'Albasio G, Bagnoli S, Bonanomi AG. Interaction among vitamin D(3) analogue KH 1060, TNF-alpha, and vitamin D receptor protein in peripheral blood mononuclear cells of inflammatory bowel disease patients. Int Immunopharmacol. 2006;6:1083-1092. [PMID: 16714211 DOI: 10.1016/j.intimp.2006.01.018] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 401 |
Augustsson J, Jonsdottir T, Klareskog L, van Vollenhoven RF. Infliximab in the treatment of rheumatoid arthritis. Aging Health 2006;2:19-33. [DOI: 10.2217/1745509x.2.1.19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 402 |
Poupardin C, Lémann M, Gendre J, Sabaté J, Marteau P, Chaussade S, Delchier J, Bouhnik Y, Chaput J, Poupon R, Soulé J, Benhamou Y, Grangé J, Coffin B. Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. Gastroentérologie Clinique et Biologique 2006;30:247-52. [DOI: 10.1016/s0399-8320(06)73161-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 403 |
Sou S, Matsui T, Yao T, Yorioka M, Tsuda S, Kikuchi Y, Wada Y, Nagahama T, Yao K. CLINICAL AND ENDOSCOPIC HEALING AFTER INFLIXIMAB TREATMENT IN PATIENTS WITH CROHN's DISEASE. Dig Endosc 2006;18:29-33. [DOI: 10.1111/j.1443-1661.2006.00566.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 404 |
Remaut E, Braat H, Vandenbroucke K, Rotteiers P, Steidler L. Clinical Potential of <i>Lactococcus lactis</i> Mediated Delivery of Human Interleukin-10 and Trefoil Factors. Bioscience Microflora 2006;25:81-97. [DOI: 10.12938/bifidus.25.81] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 405 |
Wagner H. Endogenous TLR ligands and autoimmunity. Adv Immunol 2006;91:159-73. [PMID: 16938540 DOI: 10.1016/S0065-2776(06)91004-9] [Cited by in Crossref: 85] [Cited by in F6Publishing: 93] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 406 |
Saha RN, Pahan K. TNF-α in CNS: Physiologic and Pathologic Roles. Handbook of Neurochemistry and Molecular Neurobiology 2006. [DOI: 10.1007/978-0-387-30381-9_9] [Reference Citation Analysis]
|
| 407 |
Chatenoud L. Emerging Therapies for Autoimmune Diseases. The Autoimmune Diseases 2006. [DOI: 10.1016/b978-012595961-2/50079-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 408 |
Nieuwenhuis EES, Blumberg RS. The Role of the Epithelial Barrier in Inflammatory Bowel Disease. Immune Mechanisms in Inflammatory Bowel Disease 2006. [DOI: 10.1007/0-387-33778-4_7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 409 |
Beutler B. Microbial Pathogenesis and the Discovery of Toll-Like Receptor Function. Vaccine Adjuvants 2006. [DOI: 10.1007/978-1-59259-970-7_1] [Reference Citation Analysis]
|
| 410 |
Schröder O, Blumenstein I, Stein J. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. Eur J Gastroenterol Hepatol 2006;18:11-6. [PMID: 16357613 DOI: 10.1097/00042737-200601000-00003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 411 |
Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005;25:1181-92. [PMID: 16164393 DOI: 10.1592/phco.2005.25.9.1181] [Cited by in Crossref: 95] [Cited by in F6Publishing: 102] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 412 |
Armstrong AM, Gardiner KR, Kirk SJ, Halliday MI, Rowlands BJ. Tumour necrosis factor and inflammatory bowel disease: TUMOUR NECROSIS FACTOR AND INFLAMMATORY BOWEL DISEASE. Br J Surg 1997;84:1051-8. [DOI: 10.1046/j.1365-2168.1997.02860.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 413 |
Matsumoto T, Iida M, Kohgo Y, Imamura A, Kusugami K, Nakano H, Fujiyama Y, Matsu T, Hibi T. Therapeutic efficacy of infliximab on active Crohn's disease under nutritional therapy. Scand J Gastroenterol 2005;40:1423-30. [PMID: 16316890 DOI: 10.1080/00365520510023639] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 414 |
Bodger K. Economic implications of biological therapies for Crohn's disease: review of infliximab. Pharmacoeconomics 2005;23:875-88. [PMID: 16153132 DOI: 10.2165/00019053-200523090-00002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 415 |
Kirchner S, Holler E, Haffner S, Andreesen R, Eissner G. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine. 2004;28:67-74. [PMID: 15381183 DOI: 10.1016/j.cyto.2004.06.008] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 416 |
Ohkawara T, Takeda H, Nishihira J, Miyashita K, Nihiwaki M, Ishiguro Y, Takeda K, Akira S, Iwanaga T, Sugiyama T. Macrophage migration inhibitory factor contributes to the development of acute dextran sulphate sodium-induced colitis in Toll-like receptor 4 knockout mice. Clin Exp Immunol. 2005;141:412-421. [PMID: 16045730 DOI: 10.1111/j.1365-2249.2005.02877.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 417 |
Ohkawara T, Nishihira J, Takeda H, Miyashita K, Kato K, Kato M, Sugiyama T, Asaka M. Geranylgeranylacetone protects mice from dextran sulfate sodium-induced colitis. Scand J Gastroenterol 2005;40:1049-57. [PMID: 16211708 DOI: 10.1080/00365520510023161] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 418 |
Davidson NJ. The therapeutic potential of anti-cytokine antibodies in the treatment of chronic inflammatory disease. Expert Opin Investig Drugs 1998;7:1115-20. [PMID: 15992019 DOI: 10.1517/13543784.7.7.1115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 419 |
Trepicchio WL, Dorner AJ. The therapeutic utility of Interleukin-11 in the treatment of inflammatory disease. Expert Opin Investig Drugs. 1998;7:1501-1504. [PMID: 15992047 DOI: 10.1517/13543784.7.9.1501] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 420 |
Sekut L, Connolly K. AntiTNF-alpha agents in the treatment of inflammation. Expert Opin Investig Drugs 1998;7:1825-39. [PMID: 15991932 DOI: 10.1517/13543784.7.11.1825] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 421 |
Chauveau E, Terrier F, Casassus-Buihle D, Moncoucy X, Oddes B. [Macrophage activation syndrome after treatment with infliximab for fistulated Crohn's disease]. Presse Med 2005;34:583-4. [PMID: 15962497 DOI: 10.1016/s0755-4982(05)83984-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 422 |
Díaz F. Infliximab en el tratamiento de las espondiloartropatías. Reumatología Clínica 2005;1:S41-S45. [DOI: 10.1016/s1699-258x(05)72762-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 423 |
Limdi JK, Shaffer JL. How "NICE" were we with infliximab? Inflamm Bowel Dis 2005;11:705-6. [PMID: 15973126 DOI: 10.1097/01.mib.0000169733.88645.da] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 424 |
Gratacós J. Estrategias terapéuticas en las manifestaciones extraarticulares de la espondiloartritis anquilosante. Reumatología Clínica 2005;1:S54-S60. [DOI: 10.1016/s1699-258x(05)72765-0] [Reference Citation Analysis]
|
| 425 |
Suenaert P, Bulteel V, Vermeire S, Noman M, Van Assche G, Rutgeerts P. Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent. Inflamm Bowel Dis 2005;11:667-73. [PMID: 15973122 DOI: 10.1097/01.mib.0000168371.87283.4b] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 426 |
Michetti P, Mottet C, Juillerat P, Felley C, Vader JP, Burnand B, Gonvers JJ, Froehlich F. Severe and steroid-resistant Crohn's disease. Digestion 2005;71:19-25. [PMID: 15711044 DOI: 10.1159/000083867] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 427 |
Ikenoue Y, Tagami T, Murata M. Development and validation of a novel IL-10 deficient cell transfer model for colitis. International Immunopharmacology 2005;5:993-1006. [DOI: 10.1016/j.intimp.2005.01.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 428 |
Mielants H, De Keyser F, Baeten D, Van den Bosch F. Gut inflammation in the spondyloarthropathies. Curr Rheumatol Rep 2005;7:188-94. [PMID: 15918994 DOI: 10.1007/s11926-996-0038-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 429 |
Ohkawara T, Miyashita K, Nishihira J, Mitsuyama K, Takeda H, Kato M, Kondo N, Yamasaki Y, Sata M, Yoshiki T. Transgenic over-expression of macrophage migration inhibitory factor renders mice markedly more susceptible to experimental colitis. Clin Exp Immunol. 2005;140:241-248. [PMID: 15807847 DOI: 10.1111/j.1365-2249.2005.02771.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 430 |
Farrar M, Whitehead T, Lan J, Dilger P, Thorpe R, Holland K, Carding S. Engineering of the gut commensal bacterium Bacteroides ovatus to produce and secrete biologically active murine interleukin-2 in response to xylan. J Appl Microbiol 2005;98:1191-7. [DOI: 10.1111/j.1365-2672.2005.02565.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 431 |
Mahgoub A, El-medany A, Mustafa A, Arafah M, Moursi M. Azithromycin and erythromycin ameliorate the extent of colonic damage induced by acetic acid in rats. Toxicology and Applied Pharmacology 2005;205:43-52. [DOI: 10.1016/j.taap.2004.09.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 432 |
Bewtra M, Lichtenstein GR. Infliximab use in Crohn’s disease. Expert Opinion on Biological Therapy 2005;5:589-99. [DOI: 10.1517/14712598.5.4.589] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 433 |
High WA, Muldrow ME, Fitzpatrick JE. Cutaneous lupus erythematosus induced by infliximab. Journal of the American Academy of Dermatology 2005;52:E7-8. [DOI: 10.1016/s0190-9622(03)00869-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 434 |
Casellas i Jordà F. [TNF-alpha inhibitors in inflammatory bowel disease]. Med Clin (Barc) 2004;123:627-34. [PMID: 15546523 DOI: 10.1016/s0025-7753(04)74622-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 435 |
Balding J, Livingstone WJ, Conroy J, Mynett-Johnson L, Weir DG, Mahmud N, Smith OP. Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms. Mediators Inflamm. 2004;13:181-187. [PMID: 15223609 DOI: 10.1080/09511920410001713529] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 436 |
Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005;22:131-142. [PMID: 15664165 DOI: 10.1016/j.immuni.2004.12.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 244] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 437 |
Cuzzocrea S. Emerging biotherapies for inflammatory bowel disease. Expert Opinion on Emerging Drugs 2005;8:339-47. [DOI: 10.1517/14728214.8.2.339] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 438 |
Srinivasan R, Lichtenstein GR. Recent developments in the pharmacological treatment of Crohn’s disease. Expert Opinion on Investigational Drugs 2005;13:373-91. [DOI: 10.1517/13543784.13.4.373] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 439 |
Murthy S, Flanigan A. Recent developments in inflammatory bowel disease therapy. Expert Opinion on Therapeutic Patents 2005;7:695-715. [DOI: 10.1517/13543776.7.7.695] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 440 |
Lowe C. Tumour necrosis factor-α antagonists and their therapeutic applications. Expert Opinion on Therapeutic Patents 2005;8:1309-22. [DOI: 10.1517/13543776.8.10.1309] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 441 |
Chantry D. Tumour necrosis factor antagonists. Emerging Drugs 2005;4:5-13. [DOI: 10.1517/14728214.4.1.5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 442 |
Mckaig B, Stack W. Novel approaches to inflammatory bowel disease. Expert Opinion on Investigational Drugs 2005;7:1099-113. [DOI: 10.1517/13543784.7.7.1099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 443 |
Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther 2005;21:373-84. [PMID: 15709987 DOI: 10.1111/j.1365-2036.2005.02336.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 444 |
Weidler C, Struharova S, Schmidt M, Ugele B, Schölmerich J, Straub RH. Tumor necrosis factor inhibits conversion of dehydroepiandrosterone sulfate (DHEAS) to DHEA in rheumatoid arthritis synovial cells: A prerequisite for local androgen deficiency. Arthritis Rheum 2005;52:1721-9. [DOI: 10.1002/art.21112] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 445 |
Ardizzone S, Bianchi Porro G. Biologic Therapy for Inflammatory Bowel Disease: . Drugs 2005;65:2253-86. [DOI: 10.2165/00003495-200565160-00002] [Cited by in Crossref: 191] [Cited by in F6Publishing: 206] [Article Influence: 10.6] [Reference Citation Analysis]
|
| 446 |
van Westerloo D, Giebelen I, van der Poll T. The Central and Autonomic Nervous Systems: Essential Regulators of the Immune Response. Yearbook of Intensive Care and Emergency Medicine 2005 2005. [DOI: 10.1007/0-387-26272-5_37] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 447 |
Holtmann MH, Neurath MF. Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis 2005;20:1-8. [PMID: 15459771 DOI: 10.1007/s00384-004-0634-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 448 |
Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004;64:1767-1777. [PMID: 15301561 DOI: 10.2165/00003495-200464160-00004] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 449 |
Murata Y, Onda A, Rydevik B, Takahashi K, Olmarker K. Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced histologic changes in the dorsal root ganglion. Spine (Phila Pa 1976) 2004;29:2477-84. [PMID: 15543058 DOI: 10.1097/01.brs.0000144406.17512.ea] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 450 |
Shiraki M, Aihara H, Kinouchi Y, Takahashi S, Oki M, Noguchi M, Takahashi K, Miyazaki J, Shimosegawa T. IL-12 p40 prevents the development of chronic enterocolitis in IL-10-deficient mice. Lab Invest 2004;84:1491-500. [PMID: 15448706 DOI: 10.1038/labinvest.3700175] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 451 |
Ochsenkühn T, Sackmann M, Göke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004;16:1167-71. [PMID: 15489577 DOI: 10.1097/00042737-200411000-00014] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 452 |
van Assche G, Ferrante M, Vermeire S, Rutgeerts P. The role and importance of endoscopic mucosal healing in Crohn’s disease. Techniques in Gastrointestinal Endoscopy 2004;6:138-43. [DOI: 10.1016/j.tgie.2004.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 453 |
Corazza N, Brunner T, Buri C, Rihs S, Imboden MA, Seibold I, Mueller C. Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form. Gastroenterology 2004;127:816-25. [PMID: 15362037 DOI: 10.1053/j.gastro.2004.06.036] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 454 |
Poritz LS, Gagliano GA, McLeod RS, MacRae H, Cohen Z. Surgical management of entero and colocutaneous fistulae in Crohn's disease: 17 year's experience. Int J Colorectal Dis 2004;19:481-5; discussion 486. [PMID: 15168043 DOI: 10.1007/s00384-004-0580-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 455 |
Zeissig S, Bojarski C, Buergel N, Mankertz J, Zeitz M, Fromm M, Schulzke JD. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut 2004;53:1295-302. [PMID: 15306588 DOI: 10.1136/gut.2003.036632] [Cited by in Crossref: 225] [Cited by in F6Publishing: 243] [Article Influence: 11.8] [Reference Citation Analysis]
|
| 456 |
Goedkoop AY, Kraan MC, Teunissen MB, Picavet DI, de Rie MA, Bos JD, Tak PP. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004;63:769-73. [PMID: 15194570 DOI: 10.1136/ard.2003.018085] [Cited by in Crossref: 70] [Cited by in F6Publishing: 87] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 457 |
Wenzl HH, Reinisch W, Jahnel J, Stockenhuber F, Tilg H, Kirchgatterer A, Petritsch W. Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up. Eur J Gastroenterol Hepatol 2004;16:767-73. [PMID: 15256978 DOI: 10.1097/01.meg.0000108355.41221.77] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 458 |
Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsushita I, Iwaoka Y, Saniabadi A. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol 2004;99:1532-8. [PMID: 15307873 DOI: 10.1111/j.1572-0241.2004.30432.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 459 |
Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 2004;430:257-263. [PMID: 15241424 DOI: 10.1038/nature02761] [Cited by in Crossref: 1111] [Cited by in F6Publishing: 1154] [Article Influence: 58.5] [Reference Citation Analysis]
|
| 460 |
de Ridder L, Escher JC, Bouquet J, Schweizer JJ, Rings EH, Tolboom JJ, Houwen RH, Norbruis OF, Derkx BH, Taminiau JA. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr 2004;39:46-52. [PMID: 15187780 DOI: 10.1097/00005176-200407000-00010] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 461 |
Kormeili T, Lowe N, Yamauchi P. Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences. Br J Dermatol 2004;151:3-15. [DOI: 10.1111/j.1365-2133.2004.06009.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 462 |
Youdim A, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC, Lechago J, Paavola J, Loane J, Lee SK, Gaiennie J, Smith K, Do J, Abreu MT. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004;10:333-8. [PMID: 15475739 DOI: 10.1097/00054725-200407000-00002] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 463 |
Comerford LW, Bickston SJ. Treatment of luminal and fistulizing Crohn's disease with infliximab. Gastroenterol Clin North Am 2004;33:387-406, xi. [PMID: 15177545 DOI: 10.1016/j.gtc.2004.02.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 464 |
Sperandio da Silva GM, Sant'anna CM, Barreiro EJ. A novel 3D-QSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors. Bioorganic & Medicinal Chemistry 2004;12:3159-66. [DOI: 10.1016/j.bmc.2004.04.004] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 465 |
Chang JC, Cohen RD. Medical management of severe ulcerative colitis. Gastroenterol Clin North Am 2004;33:235-50, viii. [PMID: 15177536 DOI: 10.1016/j.gtc.2004.02.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 466 |
Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci 2004;49:1036-9. [PMID: 15309897 DOI: 10.1023/b:ddas.0000034568.69407.47] [Cited by in Crossref: 65] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 467 |
Vilcek J, Feldmann M. Historical review: Cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci 2004;25:201-9. [PMID: 15063084 DOI: 10.1016/j.tips.2004.02.011] [Cited by in Crossref: 120] [Cited by in F6Publishing: 126] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 468 |
Premehand P, Takeuchi K, Bjarnason I. Selective bloodletting for severe ulcerative colitis. Scand J Gastroenterol 2004;39:416-7. [PMID: 15180176 DOI: 10.1080/00365520410008854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 469 |
Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593-610. [PMID: 15168370 DOI: 10.1053/j.gastro.2004.02.070] [Cited by in Crossref: 304] [Cited by in F6Publishing: 307] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 470 |
Liu Y, Zhang W, Yu X, Zhang H, Zhao R, Shangguan D, Li Y, Shen B, Liu G. Quartz crystal biosensor for real-time kinetic analysis of interaction between human TNF-α and monoclonal antibodies. Sensors and Actuators B: Chemical 2004;99:416-24. [DOI: 10.1016/j.snb.2003.12.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 471 |
Dolnik O, Volchkova V, Garten W, Carbonnelle C, Becker S, Kahnt J, Ströher U, Klenk HD, Volchkov V. Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J 2004;23:2175-84. [PMID: 15103332 DOI: 10.1038/sj.emboj.7600219] [Cited by in Crossref: 125] [Cited by in F6Publishing: 130] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 472 |
Alzoghaibi MA, Walsh SW, Willey A, Yager DR, Fowler AA 3rd, Graham MF. Linoleic acid induces interleukin-8 production by Crohn's human intestinal smooth muscle cells via arachidonic acid metabolites. Am J Physiol Gastrointest Liver Physiol 2004;286:G528-37. [PMID: 14656710 DOI: 10.1152/ajpgi.00189.2003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 473 |
Zanditenas D, Hagège H, Rosa I, Cattan P, Ratel-saby S, Lons T, Chousterman M. Colite inflammatoire et granulomatose septique, à propos d’un cas de cortico-dépendance. Gastroentérologie Clinique et Biologique 2004;28:398-401. [DOI: 10.1016/s0399-8320(04)94942-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 474 |
Fuss IJ. Treatment of ulcerative colitis with infliximab: are we there yet? J Pediatr Gastroenterol Nutr 2004;38:247-9. [PMID: 15076622 DOI: 10.1097/00005176-200403000-00005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 475 |
Waetzig GH, Schreiber S. Mechanisms of infliximab: the reverse side of a drug effect. Inflamm Bowel Dis 2004;10 Suppl 1:S38-43. [PMID: 15168830 DOI: 10.1097/00054725-200402001-00009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 476 |
Stio M, Treves C, Martinesi M, d'Albasio G, Bagnoli S, Bonanomi AG. Effect of anti-TNF therapy and vitamin D derivatives on the proliferation of peripheral blood mononuclear cells in Crohn's disease. Dig Dis Sci 2004;49:328-35. [PMID: 15104379 DOI: 10.1023/b:ddas.0000017460.90887.11] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 477 |
Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 2003;9:1245-1250. [PMID: 14520364 DOI: 10.1038/nm939] [Cited by in Crossref: 421] [Cited by in F6Publishing: 446] [Article Influence: 22.2] [Reference Citation Analysis]
|
| 478 |
Ghanchi FD, Rembacken BJ. Inflammatory bowel disease and the eye. Surv Ophthalmol. 2003;48:663-676. [PMID: 14609712 DOI: 10.1016/j.survophthal.2003.08.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 479 |
Man HW, Corral LG, Stirling DI, Muller GW. Alpha-fluoro-substituted thalidomide analogues. Bioorg Med Chem Lett 2003;13:3415-7. [PMID: 14505639 DOI: 10.1016/s0960-894x(03)00778-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 480 |
Veljača M. Pharmacotherapy of inflammatory bowel disease: Novel therapeutic approaches. Pharmacotherapy of Gastrointestinal Inflammation 2004. [DOI: 10.1007/978-3-0348-7930-9_2] [Reference Citation Analysis]
|
| 481 |
Miehsler W, Reinisch W, Kazemi-Shirazi L, Dejaco C, Novacek G, Ferenci P, Herbst F, Karner J, Téleky B, Schober E, Vogelsang H. Infliximab: lack of efficacy on perforating complications in Crohn's disease. Inflamm Bowel Dis 2004;10:36-40. [PMID: 15058525 DOI: 10.1097/00054725-200401000-00006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 482 |
Lin TS, Byrd JC. Monoclonal Antibody Therapy in Lymphoid Leukemias. Treatment of Leukemia and Lymphoma. Elsevier; 2004. pp. 127-67. [DOI: 10.1016/s1054-3589(04)51006-2] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 483 |
Hibi T, Yoshizawa S. Anti Tumor Necrosis Factor-α Antibody : Biological Significance and Therapeutic Target for Crohn’s disease. Jpn J Clin Immunol 2004;27:16-21. [DOI: 10.2177/jsci.27.16] [Reference Citation Analysis]
|
| 484 |
Lin TS, Lucas MS, Byrd JC. Monoclonal Antibody Therapy in Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia 2004. [DOI: 10.1007/978-1-59259-412-2_15] [Reference Citation Analysis]
|
| 485 |
Xue C, He X, Roderick J, Corbett RL, Duan JJ, Liu R, Covington MB, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP. Rational design, synthesis and structure–Activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 1: lead identification. Bioorganic & Medicinal Chemistry Letters 2003;13:4293-7. [DOI: 10.1016/j.bmcl.2003.09.056] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 486 |
Xue C, He X, Roderick J, Corbett RL, Duan JJ, Liu R, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Christ DD, Newton RC, Trzaskos JM, Magolda RL, Wexler RR, Decicco CP. Rational design, synthesis and structure–activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 2: lead optimization. Bioorganic & Medicinal Chemistry Letters 2003;13:4299-304. [DOI: 10.1016/j.bmcl.2003.09.057] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 487 |
Chin R, Wang J, Fu YX. Lymphoid microenvironment in the gut for immunoglobulin A and inflammation. Immunol Rev 2003;195:190-201. [PMID: 12969319 DOI: 10.1034/j.1600-065x.2003.00066.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 488 |
de Beaufort AJ, Bakker AC, van Tol MJ, Poorthuis BJ, Schrama AJ, Berger HM. Meconium is a source of pro-inflammatory substances and can induce cytokine production in cultured A549 epithelial cells. Pediatr Res 2003;54:491-5. [PMID: 12840156 DOI: 10.1203/01.PDR.0000082017.97479.39] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 489 |
Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, De Keyser F, Veys EM. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829-34. [PMID: 12922954 DOI: 10.1136/ard.62.9.829] [Cited by in Crossref: 115] [Cited by in F6Publishing: 131] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 490 |
Ishikura T, Kanai T, Uraushihara K, Iiyama R, Makita S, Totsuka T, Yamazaki M, Sawada T, Nakamura T, Miyata T, Kitahora T, Hibi T, Hoshino T, Watanabe M. Interleukin-18 overproduction exacerbates the development of colitis with markedly infiltrated macrophages in interleukin-18 transgenic mice. J Gastroenterol Hepatol 2003;18:960-9. [PMID: 12859727 DOI: 10.1046/j.1440-1746.2003.03097.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 491 |
Scheinin T, Butler DM, Salway F, Scallon B, Feldmann M. Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis. Clin Exp Immunol 2003;133:38-43. [PMID: 12823276 DOI: 10.1046/j.1365-2249.2003.02193.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 492 |
Hommes DW, van Deventer SJ. Targeting tumor necrosis factor-alpha in inflammatory bowel disease: why, how, and when? Curr Opin Gastroenterol 2003;19:350-7. [PMID: 15703576 DOI: 10.1097/00001574-200307000-00005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 493 |
Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85. [PMID: 12806611 DOI: 10.1016/s0016-5085(03)00382-2] [Cited by in Crossref: 545] [Cited by in F6Publishing: 572] [Article Influence: 27.3] [Reference Citation Analysis]
|
| 494 |
Scribano M, Prantera C. Review article: medical treatment of moderate to severe Crohn's disease. Aliment Pharmacol Ther 2003;17 Suppl 2:23-30. [PMID: 12786609 DOI: 10.1046/j.1365-2036.17.s2.23.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 495 |
Straub RH, Pongratz G, Schölmerich J, Kees F, Schaible TF, Antoni C, Kalden JR, Lorenz HM. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion. Arthritis Rheum 2003;48:1504-12. [PMID: 12794817 DOI: 10.1002/art.11036] [Cited by in Crossref: 34] [Cited by in F6Publishing: 43] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 496 |
Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A, Pallone F. Review article: maintenance treatment of Crohn's disease. Aliment Pharmacol Ther 2003;17 Suppl 2:31-7. [PMID: 12786610 DOI: 10.1046/j.1365-2036.17.s2.20.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 497 |
Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 2003;9:176-8. [PMID: 12792223 DOI: 10.1097/00054725-200305000-00005] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 498 |
McIlwain L, Carter JD, Bin-Sagheer S, Vasey FB, Nord J. Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol 2003;36:411-3. [PMID: 12702983 DOI: 10.1097/00004836-200305000-00010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 499 |
Loher F, Schmall K, Freytag P, Landauer N, Hallwachs R, Bauer C, Siegmund B, Rieder F, Lehr HA, Dauer M, Kapp JF, Endres S, Eigler A. The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. J Pharmacol Exp Ther 2003;305:549-56. [PMID: 12606674 DOI: 10.1124/jpet.102.039529] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 500 |
Yoo J, Nichols A, Song JC, Mammen J, Calvo I, Worrell RT, Cuppoletti J, Matlin K, Matthews JB. Bryostatin-1 attenuates TNF-induced epithelial barrier dysfunction: role of novel PKC isozymes. Am J Physiol Gastrointest Liver Physiol 2003;284:G703-12. [PMID: 12505880 DOI: 10.1152/ajpgi.00214.2002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 501 |
Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8. [PMID: 12738464 DOI: 10.1111/j.1572-0241.2003.07343.x] [Cited by in Crossref: 138] [Cited by in F6Publishing: 142] [Article Influence: 6.9] [Reference Citation Analysis]
|
| 502 |
Totsuka T, Kanai T, Uraushihara K, Iiyama R, Yamazaki M, Akiba H, Yagita H, Okumura K, Watanabe M. Therapeutic effect of anti-OX40L and anti-TNF-alpha MAbs in a murine model of chronic colitis. Am J Physiol Gastrointest Liver Physiol 2003;284:G595-603. [PMID: 12631559 DOI: 10.1152/ajpgi.00450.2002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 503 |
Papi C, Gili L, Tarquini M, Antonelli G, Capurso L. Infliximab for severe recurrent Crohn's disease presenting with massive gastrointestinal hemorrhage. J Clin Gastroenterol 2003;36:238-41. [PMID: 12590236 DOI: 10.1097/00004836-200303000-00011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 504 |
Kinney T, Rawlins M, Kozarek R, France R, Patterson D. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol 2003;98:608-12. [PMID: 12650795 DOI: 10.1111/j.1572-0241.2003.07286.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 505 |
Stallmach A, Wittig BM, Moser C, Fischinger J, Duchmann R, Zeitz M. Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut 2003;52:377-82. [PMID: 12584219 DOI: 10.1136/gut.52.3.377] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 506 |
van Deventer SJ. New biological therapies in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2003;17:119-30. [PMID: 12617887 DOI: 10.1053/bega.2003.0360] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 507 |
Braun J, Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin Biol Ther 2003;3:141-68. [PMID: 12718738 DOI: 10.1517/14712598.3.1.141] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 508 |
Van Assche G, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, D'Hoore A, Penninckx F, Marchal G, Cornillie F, Rutgeerts P. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003;98:332-9. [PMID: 12591051 DOI: 10.1111/j.1572-0241.2003.07241.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 114] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 509 |
Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 2003;98:504-5. [PMID: 12591081 DOI: 10.1111/j.1572-0241.2003.07245.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 510 |
Hanauer SB, Dassopoulos T. Medical therapy for Crohn’s disease. Inflammatory Bowel Disease: From Bench to Bedside 2003. [DOI: 10.1007/978-1-4020-3477-0_33] [Reference Citation Analysis]
|
| 511 |
Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003;17:75-84. [PMID: 12492735 DOI: 10.1046/j.1365-2036.2003.01411.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 95] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 512 |
van Deventer SJH. Targeted therapies for inflammatory bowel disease. Inflammatory Bowel Disease: From Bench to Bedside 2003. [DOI: 10.1007/978-1-4020-3477-0_27] [Reference Citation Analysis]
|
| 513 |
Agyekum S, Church A, Sohail M, Krausz T, Van Noorden S, Polak J, Cohen J. Expression of lymphotoxin-beta (LT-beta) in chronic inflammatory conditions. J Pathol 2003;199:115-21. [PMID: 12474234 DOI: 10.1002/path.1249] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 514 |
van Deventer SJH. Targeted therapies for inflammatory bowel disease. Inflammatory Bowel Disease: From Bench to Bedside 2003. [DOI: 10.1007/0-387-25808-6_27] [Reference Citation Analysis]
|
| 515 |
Rogler G. Multi-site therapeutic modalities for inflammatory bowel diseases — mechanisms of action. Inflammatory Bowel Disease: From Bench to Bedside 2003. [DOI: 10.1007/978-1-4020-3477-0_26] [Reference Citation Analysis]
|
| 516 |
Ziegenhagen MW, Müller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med 2003;253:18-30. [PMID: 12588535 DOI: 10.1046/j.1365-2796.2003.01074.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 104] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 517 |
Rogler G. Was bringen neue Zytokine und Antizytokine bei chronisch entzündlichen Darmerkrankungen? Chronisch entzündliche Darmerkrankungen 2003. [DOI: 10.1007/978-3-642-19025-4_15] [Reference Citation Analysis]
|
| 518 |
Kim HJ. Diagnosis and Treatment of Inflammatory Bowel Disease. J Korean Med Assoc 2003;46:605. [DOI: 10.5124/jkma.2003.46.7.605] [Reference Citation Analysis]
|
| 519 |
Arnott ID, Watts D, Satsangi J. Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacol Res 2003;47:1-10. [PMID: 12526855 DOI: 10.1016/s1043-6618(02)00264-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 520 |
Musch MW, Clarke LL, Mamah D, Gawenis LR, Zhang Z, Ellsworth W, Shalowitz D, Mittal N, Efthimiou P, Alnadjim Z, Hurst SD, Chang EB, Barrett TA. T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+/K+-ATPase. J Clin Invest 2002;110:1739-47. [DOI: 10.1172/jci0215695] [Cited by in Crossref: 130] [Cited by in F6Publishing: 126] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 521 |
De Keyser F, Baeten D, Van den Bosch F, De Vos M, Cuvelier C, Mielants H, Veys E. Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep 2002;4:525-32. [PMID: 12427369 DOI: 10.1007/s11926-002-0061-6] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 522 |
Belaiche J, Louis E. Severe lower gastrointestinal bleeding in Crohn's disease: successful control with infliximab. Am J Gastroenterol 2002;97:3210-1. [PMID: 12492221 DOI: 10.1111/j.1572-0241.2002.07143.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 523 |
Ardizzone S, Bianchi Porro G. Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med 2002;252:475-96. [PMID: 12472908 DOI: 10.1046/j.1365-2796.2002.01067.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 130] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 524 |
Ruemmele FM, Beaulieu JF, Dionne S, Levy E, Seidman EG, Cerf-Bensussan N, Lentze MJ. Lipopolysaccharide modulation of normal enterocyte turnover by toll-like receptors is mediated by endogenously produced tumour necrosis factor alpha. Gut 2002;51:842-8. [PMID: 12427787 DOI: 10.1136/gut.51.6.842] [Cited by in Crossref: 75] [Cited by in F6Publishing: 78] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 525 |
Musch MW, Clarke LL, Mamah D, Gawenis LR, Zhang Z, Ellsworth W, Shalowitz D, Mittal N, Efthimiou P, Alnadjim Z, Hurst SD, Chang EB, Barrett TA. T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+/K+-ATPase. J Clin Invest 2002;110:1739-47. [PMID: 12464679 DOI: 10.1172/JCI15695] [Cited by in Crossref: 3] [Cited by in F6Publishing: 69] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 526 |
Williams DW, Leigh J, Ramirez-Amador V, Kaonga K, Russo D, Schiødt M. Host pathogen interaction and the development of oral lesions. Oral Dis 2002;8 Suppl 2:120-5. [PMID: 12164645 DOI: 10.1034/j.1601-0825.8.s2.2.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 527 |
Van Den Brande JM, Peppelenbosch MP, Van Deventer SJ. Treating Crohn's disease by inducing T lymphocyte apoptosis. Ann N Y Acad Sci 2002;973:166-80. [PMID: 12485856 DOI: 10.1111/j.1749-6632.2002.tb04628.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 528 |
Van Den Blink B, Ten Hove T, Van Den Brink GR, Peppelenbosch MP, Van Deventer SJ. From extracellular to intracellular targets, inhibiting MAP kinases in treatment of Crohn's disease. Ann N Y Acad Sci 2002;973:349-58. [PMID: 12485892 DOI: 10.1111/j.1749-6632.2002.tb04664.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 529 |
Boismenu R, Chen Y, Chou K, El-Sheikh A, Buelow R. Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis. Ann Rheum Dis 2002;61 Suppl 2:ii19-24. [PMID: 12379615 DOI: 10.1136/ard.61.suppl_2.ii19] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 530 |
Kanai T, Totsuka T, Tezuka K, Watanabe M. ICOS costimulation in inflammatory bowel disease. J Gastroenterol 2002;37 Suppl 14:78-81. [PMID: 12572871 DOI: 10.1007/BF03326419] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 531 |
Su C, Lichtenstein GR. Recent developments in inflammatory bowel disease. Med Clin North Am 2002;86:1497-523. [PMID: 12510462 DOI: 10.1016/s0025-7125(02)00085-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 532 |
Nakajima A, Wada K, Katayama K, Saubermann L, Osawa E, Nagase H, Ueno N, Matsuhashi N, Aburatani H. Gene expression profile after peroxisome proliferator activator receptor-gamma ligand administration in dextran sodium sulfate mice. J Gastroenterol 2002;37 Suppl 14:62-6. [PMID: 12572868 DOI: 10.1007/BF03326416] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 533 |
Bodger K. Cost of illness of Crohn's disease. Pharmacoeconomics 2002;20:639-52. [PMID: 12162753 DOI: 10.2165/00019053-200220100-00001] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 534 |
Tilg H, Kaser A. Antitumour necrosis factor therapy in Crohn's disease. Expert Opin Biol Ther 2002;2:715-21. [PMID: 12387670 DOI: 10.1517/14712598.2.7.715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 535 |
Mascheretti S, Hampe J, Croucher PJ, Nikolaus S, Andus T, Schubert S, Olson A, Bao W, Fölsch UR, Schreiber S. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 2002;12:509-15. [PMID: 12360101 DOI: 10.1097/00008571-200210000-00002] [Cited by in Crossref: 111] [Cited by in F6Publishing: 115] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 536 |
Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 2002;16:111-48. [PMID: 11985485 DOI: 10.2165/00063030-200216020-00005] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 537 |
Biancone L, Monteleone I, Del Vecchio Blanco G, Vavassori P, Pallone F. Resident bacterial flora and immune system. Dig Liver Dis 2002;34 Suppl 2:S37-43. [PMID: 12408438 DOI: 10.1016/s1590-8658(02)80162-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 538 |
Baeten D, De Keyser F, Mielants H, Veys EM. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2002;16:537-49. [PMID: 12406426 DOI: 10.1053/berh.2002.0249] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 539 |
Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002;97:2357-63. [PMID: 12358256 DOI: 10.1111/j.1572-0241.2002.05991.x] [Cited by in Crossref: 160] [Cited by in F6Publishing: 169] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 540 |
Schreiber S. Molecular therapies in Crohn's disease: coming of age. Int J Colorectal Dis 2002;17:285-6. [PMID: 12420727 DOI: 10.1007/s00384-002-0422-7] [Reference Citation Analysis]
|
| 541 |
Lombardi DA, Feller ER, Shah SA. Medical management of inflammatory bowel disease in the new millennium. Compr Ther 2002;28:39-49. [PMID: 11894442 DOI: 10.1007/s12019-002-0041-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 542 |
Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, Geboes K, Ceuppens JL, Rutgeerts P. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002;97:2000-4. [PMID: 12190167 DOI: 10.1111/j.1572-0241.2002.05914.x] [Cited by in Crossref: 278] [Cited by in F6Publishing: 302] [Article Influence: 13.2] [Reference Citation Analysis]
|
| 543 |
Andreakos ET, Foxwell BM, Brennan FM, Maini RN, Feldmann M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev 2002;13:299-313. [PMID: 12220545 DOI: 10.1016/s1359-6101(02)00018-7] [Cited by in Crossref: 124] [Cited by in F6Publishing: 129] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 544 |
Ohkawara T, Nishihira J, Takeda H, Hige S, Kato M, Sugiyama T, Iwanaga T, Nakamura H, Mizue Y, Asaka M. Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology 2002;123:256-70. [PMID: 12105854 DOI: 10.1053/gast.2002.34236] [Cited by in Crossref: 121] [Cited by in F6Publishing: 127] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 545 |
Baeten D, De Keyser F, Mielants H, Veys EM. Immune linkages between inflammatory bowel disease and spondyloarthropathies. Curr Opin Rheumatol 2002;14:342-7. [PMID: 12118165 DOI: 10.1097/00002281-200207000-00002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 546 |
Bremner AR, Beattie RM. Therapy of Crohn's disease in childhood. Expert Opin Pharmacother 2002;3:809-25. [PMID: 12083982 DOI: 10.1517/14656566.3.7.809] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 547 |
Rizzello F, Gionchetti P, Venturi A, Morselli C, Campieri M. Review article: the management of refractory Crohn's disease. Aliment Pharmacol Ther 2002;16 Suppl 4:40-7. [PMID: 12047259 DOI: 10.1046/j.1365-2036.16.s4.6.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 548 |
Seegers D, Bouma G, Peña AS. Review article: a critical approach to new forms of treatment of Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2002;16 Suppl 4:53-8. [PMID: 12047261 DOI: 10.1046/j.1365-2036.16.s4.8.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 549 |
van Balkom BP, Schoon EJ, Stockbrügger RW, Wolters FL, van Hogezand RA, van Deventer SJ, Oldenburg B, van Dullemen HM, Russel MG. Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn's disease. Aliment Pharmacol Ther 2002;16:1101-7. [PMID: 12030951 DOI: 10.1046/j.1365-2036.2002.01268.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 550 |
Kashiwagi N, Sugimura K, Koiwai H, Yamamoto H, Yoshikawa T, Saniabadi AR, Adachi M, Shimoyama T. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 2002;47:1334-41. [PMID: 12064810 DOI: 10.1023/a:1015330816364] [Cited by in Crossref: 127] [Cited by in F6Publishing: 130] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 551 |
D'Hauteville H, Khan S, Maskell DJ, Kussak A, Weintraub A, Mathison J, Ulevitch RJ, Wuscher N, Parsot C, Sansonetti PJ. Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium. J Immunol 2002;168:5240-51. [PMID: 11994481 DOI: 10.4049/jimmunol.168.10.5240] [Cited by in Crossref: 110] [Cited by in F6Publishing: 112] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 552 |
Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002;122:1592-608. [PMID: 12016425 DOI: 10.1053/gast.2002.33426] [Cited by in Crossref: 228] [Cited by in F6Publishing: 235] [Article Influence: 10.9] [Reference Citation Analysis]
|
| 553 |
Schooltink H, Rose-John S. Cytokines as therapeutic drugs. J Interferon Cytokine Res 2002;22:505-16. [PMID: 12060489 DOI: 10.1089/10799900252981981] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 554 |
Batres LA, Mamula P, Baldassano RN. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr 2002;34:558-60. [PMID: 12050585 DOI: 10.1097/00005176-200205000-00016] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 555 |
Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002;2:364-71. [PMID: 12033742 DOI: 10.1038/nri802] [Cited by in Crossref: 504] [Cited by in F6Publishing: 526] [Article Influence: 24.0] [Reference Citation Analysis]
|
| 556 |
Kitano E, Kitamura H. Synthesis of factor D by gastric cancer-derived cell lines. Int Immunopharmacol 2002;2:843-8. [PMID: 12095175 DOI: 10.1016/s1567-5769(02)00028-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 557 |
Wan MX, Riaz AA, Schramm R, Wang Y, Vestweber D, Menger MD, Thorlacius H. Leukocyte rolling is exclusively mediated by P-selectinin colonic venules. Br J Pharmacol 2002;135:1749-56. [PMID: 11934816 DOI: 10.1038/sj.bjp.0704638] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 558 |
Cunliffe RN, Scott BB. Review article: monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:647-62. [PMID: 11929382 DOI: 10.1046/j.1365-2036.2002.01216.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 559 |
Hommes DW, van de Heisteeg BH, van der Spek M, Bartelsman JF, van Deventer SJ. Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital. Inflamm Bowel Dis 2002;8:81-6. [PMID: 11854604 DOI: 10.1097/00054725-200203000-00002] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 560 |
Gillett HR, Arnott ID, McIntyre M, Campbell S, Dahele A, Priest M, Jackson R, Ghosh S. Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology 2002;122:800-5. [PMID: 11875014 DOI: 10.1053/gast.2002.31874] [Cited by in Crossref: 95] [Cited by in F6Publishing: 102] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 561 |
Harrison J, Hanauer SB. Medical treatment of Crohn's disease. Gastroenterol Clin North Am 2002;31:167-84, x. [PMID: 12122730 DOI: 10.1016/s0889-8553(01)00011-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 562 |
Ruemmele FM, Seidman EG, Lentze MJ. Regulation of intestinal epithelial cell apoptosis and the pathogenesis of inflammatory bowel disorders. J Pediatr Gastroenterol Nutr 2002;34:254-60. [PMID: 11964947 DOI: 10.1097/00005176-200203000-00005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 563 |
Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, Veys EM. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;46:755-65. [PMID: 11920412 DOI: 10.1002/art.511] [Cited by in Crossref: 224] [Cited by in F6Publishing: 265] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 564 |
Bariol C, Meagher AP, Vickers CR, Byrnes DJ, Edwards PD, Hing M, Wettstein AR, Field A. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. Journal of Gastroenterology and Hepatology 2002;17:135-139. [DOI: 10.1046/j.1440-1746.2002.02564.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 565 |
Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002;50:196-200. [PMID: 11788559 DOI: 10.1136/gut.50.2.196] [Cited by in Crossref: 91] [Cited by in F6Publishing: 108] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 566 |
ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11. [PMID: 11788561 DOI: 10.1136/gut.50.2.206] [Cited by in Crossref: 383] [Cited by in F6Publishing: 428] [Article Influence: 18.2] [Reference Citation Analysis]
|
| 567 |
Mamula P, Mascarenhas MR, Baldassano RN. Biological and novel therapies for inflammatory bowel disease in children. Pediatr Clin North Am 2002;49:1-25. [PMID: 11826800 DOI: 10.1016/s0031-3955(03)00106-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 568 |
Das UN. Is insulin an antiinflammatory molecule? Nutrition. 2001;17:409-413. [PMID: 11377135 DOI: 10.1016/s0899-9007(01)00518-4] [Cited by in Crossref: 106] [Cited by in F6Publishing: 117] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 569 |
Cavaillon J, Adib-conquy M. The Pro-Inflammatory Cytokine Cascade. Immune Response in the Critically Ill 2002. [DOI: 10.1007/978-3-642-57210-4_4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 570 |
Kono M, Oshitani N, Sawa Y, Higuchi K, Matsumoto T, Arakawa T. Successful treatment with topical mesalazine for a patient with intractable crohn’s colitis. Digestive Endoscopy 2002;14:16-19. [DOI: 10.1046/j.1443-1661.2002.00157.x] [Reference Citation Analysis]
|
| 571 |
Imai E, Isaka Y. Targeting growth factors to the kidney: myth or reality? Curr Opin Nephrol Hypertens 2002;11:49-57. [PMID: 11753087 DOI: 10.1097/00041552-200201000-00008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 572 |
Kanai T, Watanabe M, Hibi T. Cytokine networks in the development of intestinal inflammation in Crohn's disease. Folia Pharmacol Jpn 2002;120:39-45. [DOI: 10.1254/fpj.120.39] [Reference Citation Analysis]
|
| 573 |
Chadwick N, Jewell DP. The Immunology of Inflammatory Bowel Disease. Immunology for Surgeons 2002. [DOI: 10.1007/978-1-4471-0201-4_25] [Reference Citation Analysis]
|
| 574 |
Mueller C. Tumour necrosis factor in mouse models of chronic intestinal inflammation. Immunology 2002;105:1-8. [PMID: 11849309 DOI: 10.1046/j.1365-2567.2002.01329.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 575 |
Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, Tytgat G, Peppelenbosch M, Van Deventer S. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002;122:7-14. [PMID: 11781274 DOI: 10.1053/gast.2002.30770] [Cited by in Crossref: 278] [Cited by in F6Publishing: 284] [Article Influence: 13.2] [Reference Citation Analysis]
|
| 576 |
Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001;167:6821-6. [PMID: 11739498 DOI: 10.4049/jimmunol.167.12.6821] [Cited by in Crossref: 120] [Cited by in F6Publishing: 130] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 577 |
Kojima Y, Kinouchi Y, Takahashi S, Negoro K, Hiwatashi N, Shimosegawa T. Inflammatory bowel disease is associated with a novel promoter polymorphism of natural resistance-associated macrophage protein 1 (NRAMP1) gene. Tissue Antigens 2001;58:379-84. [PMID: 11929588 DOI: 10.1034/j.1399-0039.2001.580606.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 578 |
Meng X, Ao L, Shames BD, Harken AH. Inhibition of cyclic-3',5'-nucleotide phosphodiesterase abrogates the synergism of hypoxia with lipopolysaccharide in the induction of macrophage TNF-alpha production. J Surg Res 2001;101:210-5. [PMID: 11735278 DOI: 10.1006/jsre.2001.6290] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 579 |
Wallace JL, Ma L. Inflammatory mediators in gastrointestinal defense and injury. Exp Biol Med (Maywood) 2001;226:1003-15. [PMID: 11743136 DOI: 10.1177/153537020122601107] [Cited by in Crossref: 74] [Cited by in F6Publishing: 79] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 580 |
Singh B, Powrie F, Mortensen NJ. Immune therapy in inflammatory bowel disease and models of colitis. Br J Surg 2001;88:1558-69. [PMID: 11736965 DOI: 10.1046/j.0007-1323.2001.01909.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 581 |
Cuzzocrea S, Mazzon E, Dugo L, Caputi AP, Riley DP, Salvemini D. Protective effects of M40403, a superoxide dismutase mimetic, in a rodent model of colitis. Eur J Pharmacol 2001;432:79-89. [PMID: 11734191 DOI: 10.1016/s0014-2999(01)01427-3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 582 |
Gonçalves NS, Ghaem-Maghami M, Monteleone G, Frankel G, Dougan G, Lewis DJ, Simmons CP, MacDonald TT. Critical role for tumor necrosis factor alpha in controlling the number of lumenal pathogenic bacteria and immunopathology in infectious colitis. Infect Immun 2001;69:6651-9. [PMID: 11598034 DOI: 10.1128/IAI.69.11.6651-6659.2001] [Cited by in Crossref: 83] [Cited by in F6Publishing: 85] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 583 |
Probert L, Akassoglou K. Glial expression of tumor necrosis factor in transgenic animals: how do these models reflect the "normal situation"? Glia 2001;36:212-9. [PMID: 11596129 DOI: 10.1002/glia.1110] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 584 |
Ritz MA, Jost R. Severe pneumococcal pneumonia following treatment with infliximab for Crohn's disease. Inflamm Bowel Dis 2001;7:327. [PMID: 11720324 DOI: 10.1097/00054725-200111000-00009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 585 |
Baldassano RN. Anti-TNF therapies have eliminated the need for steroids in pediatric Crohn's disease: pro. Why use steroids if safer therapies are available? Inflamm Bowel Dis 2001;7:338-41; discussion 345-6. [PMID: 11720326 DOI: 10.1097/00054725-200111000-00011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 586 |
Isogai E, Isogai H, Hirose K, Kubota T, Kimura K, Fujii N, Hayashi S, Takeshi K, Oguma K. Therapeutic effect of anti-TNF-alpha antibody and levofloxacin (LVFX) in a mouse model of enterohemorrhagic Escherichia coli O157 infection. Comp Immunol Microbiol Infect Dis 2001;24:217-31. [PMID: 11561957 DOI: 10.1016/s0147-9571(01)00009-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 587 |
LaDuca JR, Gaspari AA. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin 2001;19:617-35. [PMID: 11705350 DOI: 10.1016/s0733-8635(05)70304-1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 588 |
Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther 2001;15:1639-46. [PMID: 11564005 DOI: 10.1046/j.1365-2036.2001.01092.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 589 |
Dohi T, Rennert PD, Fujihashi K, Kiyono H, Shirai Y, Kawamura YI, Browning JL, McGhee JR. Elimination of colonic patches with lymphotoxin beta receptor-Ig prevents Th2 cell-type colitis. J Immunol 2001;167:2781-90. [PMID: 11509623 DOI: 10.4049/jimmunol.167.5.2781] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 590 |
Prehn JL, Landers C, Muller GW, Man HW, Stirling DI, Targan SR. Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues. J Clin Immunol 2001;21:357-64. [PMID: 11720008 DOI: 10.1023/a:1012292703871] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 591 |
Agnholt J, Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 2001;15:212-22. [PMID: 11563881 DOI: 10.1006/cyto.2001.0919] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 592 |
Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP. Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem 2001;44:2636-60. [PMID: 11472217 DOI: 10.1021/jm010127e] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 593 |
Chey WY, Hussain A, Ryan C, Potter GD, Shah A. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001;96:2373-81. [PMID: 11513177 DOI: 10.1111/j.1572-0241.2001.04039.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 100] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 594 |
Lawrance IC, Maxwell L, Doe W. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm Bowel Dis 2001;7:226-36. [PMID: 11515849 DOI: 10.1097/00054725-200108000-00008] [Cited by in Crossref: 92] [Cited by in F6Publishing: 102] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 595 |
Shames BD, McIntyre RC Jr, Bensard DD, Pulido EJ, Selzman CH, Reznikov LL, Harken AH, Meng X. Suppression of tumor necrosis factor alpha production by cAMP in human monocytes: dissociation with mRNA level and independent of interleukin-10. J Surg Res 2001;99:187-93. [PMID: 11469886 DOI: 10.1006/jsre.2001.6178] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 596 |
Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, Asakura H, Tanaka T, Kasukawa R, Kimura K, Suzuki Y, Nagamachi Y, Muto T, Nagawa H, Iizuka B, Baba S, Nasu M, Kataoka T, Kashiwagi N, Saniabadi AR. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 2001;16:1-9. [PMID: 11309823 DOI: 10.1002/jca.1000] [Cited by in Crossref: 200] [Cited by in F6Publishing: 207] [Article Influence: 9.1] [Reference Citation Analysis]
|
| 597 |
Blam ME, Stein RB, Lichtenstein GR. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol 2001;96:1977-97. [PMID: 11467623 DOI: 10.1111/j.1572-0241.2001.03931.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 34] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 598 |
Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN Jr, Mannick EE. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001;35:823-8. [PMID: 11485127 DOI: 10.1345/aph.10395] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 599 |
Asakura H, Yao T, Matsui T, Koganei K, Fukushima T, Takazoe M, Hobara R, Nakano H, Okamura S, Matsueda K, Kashida H, Makiyama K, Hiwatashi N, Kashiwagi K, Hibi T. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings. J Gastroenterol Hepatol 2001;16:763-9. [PMID: 11446884 DOI: 10.1046/j.1440-1746.2001.02507.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 600 |
Beutler B. Autoimmunity and apoptosis: the Crohn's connection. Immunity 2001;15:5-14. [PMID: 11485733 DOI: 10.1016/s1074-7613(01)00176-5] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 601 |
Tervahartiala T, Koski H, Xu JW, Häyrinen-Immonen R, Hietanen J, Sorsa T, Konttinen YT. Tumor necrosis factor-alpha and its receptors, p55 and p75, in gingiva of adult periodontitis. J Dent Res 2001;80:1535-9. [PMID: 11499508 DOI: 10.1177/00220345010800061101] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 602 |
Sopwith M. Therapeutic Applications of Monoclonal Antibodies: A Clinical Overview. Biotechnology Set 2001. [DOI: 10.1002/9783527620999.ch12d] [Reference Citation Analysis]
|
| 603 |
Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7:83-8. [PMID: 11383595 DOI: 10.1097/00054725-200105000-00001] [Cited by in Crossref: 296] [Cited by in F6Publishing: 310] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 604 |
Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 2: the newer drugs and drug strategies. Am J Ther 2001;8:163-79. [PMID: 11344384 DOI: 10.1097/00045391-200105000-00005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 605 |
Chang Q, Tepperman BL. The role of protein kinase C isozymes in TNF-alpha-induced cytotoxicity to a rat intestinal epithelial cell line. Am J Physiol Gastrointest Liver Physiol 2001;280:G572-83. [PMID: 11254483 DOI: 10.1152/ajpgi.2001.280.4.G572] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 606 |
Spiekermann GM, Walker WA. Oral tolerance and its role in clinical disease. J Pediatr Gastroenterol Nutr 2001;32:237-55. [PMID: 11345170 DOI: 10.1097/00005176-200103000-00003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 607 |
Zareie M, Singh PK, Irvine EJ, Sherman PM, McKay DM, Perdue MH. Monocyte/macrophage activation by normal bacteria and bacterial products: implications for altered epithelial function in Crohn's disease. Am J Pathol 2001;158:1101-9. [PMID: 11238058 DOI: 10.1016/S0002-9440(10)64057-6] [Cited by in Crossref: 71] [Cited by in F6Publishing: 75] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 608 |
Karkar AM, Smith J, Pusey CD. Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha. Nephrol Dial Transplant 2001;16:518-24. [PMID: 11239025 DOI: 10.1093/ndt/16.3.518] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 609 |
Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001;96:722-9. [PMID: 11280541 DOI: 10.1111/j.1572-0241.2001.03612.x] [Cited by in Crossref: 210] [Cited by in F6Publishing: 223] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 610 |
Farrell RJ, Banerjee S, Peppercorn MA. Recent advances in inflammatory bowel disease. Crit Rev Clin Lab Sci 2001;38:33-108. [PMID: 11256517 DOI: 10.1080/20014091084173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 611 |
Capini CJ, Richardson MW, Hendel H, Sverstiuk A, Mirchandani J, Régulier EG, Khalili K, Zagury JF, Rappaport J. Autoantibodies to TNFalpha in HIV-1 infection: prospects for anti-cytokine vaccine therapy. Biomed Pharmacother 2001;55:23-31. [PMID: 11237281 DOI: 10.1016/s0753-3322(00)00018-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 612 |
Stein RB, Lichtenstein GR. Medical therapy for Crohn's disease: the state of the art. Surg Clin North Am 2001;81:71-101, viii. [PMID: 11218170 DOI: 10.1016/s0039-6109(05)70274-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 613 |
Armstrong AM, Foulkes R, Jennings G, Gannon C, Kirk SJ, Gardiner KR. Tumour necrosis factor inhibitors reduce the acute-phase response in hapten-induced colitis. Br J Surg 2001;88:235-40. [PMID: 11167873 DOI: 10.1046/j.1365-2168.2001.01646.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 614 |
Schreiber S. Immunopathophysiology of inflammatory bowel disease. Immunological Aspects of Gastroenterology 2001. [DOI: 10.1007/978-94-010-0790-0_9] [Reference Citation Analysis]
|
| 615 |
Folwaczny C. Gerinnungssystem und chronisch entzündliche Darmerkrankungen. Chronisch entzündliche Darmerkrankungen 2001. [DOI: 10.1007/978-3-642-59556-1_11] [Reference Citation Analysis]
|
| 616 |
Emmrich J, Liebe S. Monoklonale Antikörper und Antisense-Oligonukleotide. Chronisch entzündliche Darmerkrankungen 2001. [DOI: 10.1007/978-3-642-59556-1_13] [Reference Citation Analysis]
|
| 617 |
Chatenoud L. Polyclonal and Monoclonal Antibodies. Therapeutic Immunosuppression 2001. [DOI: 10.1007/978-94-010-0765-8_3] [Reference Citation Analysis]
|
| 618 |
Maiuri L, Ciacci C, Vacca L, Ricciardelli I, Auricchio S, Quaratino S, Londei M. IL-15 drives the specific migration of CD94+ and TCR-gammadelta+ intraepithelial lymphocytes in organ cultures of treated celiac patients. Am J Gastroenterol 2001;96:150-6. [PMID: 11197245 DOI: 10.1111/j.1572-0241.2001.03437.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 619 |
Regueiro MD. Update in medical treatment of Crohn's disease. J Clin Gastroenterol 2000;31:282-91. [PMID: 11129268 DOI: 10.1097/00004836-200012000-00004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 620 |
Barabino A, Castellano E, Gandullia P, Biscaldi E. A girl with severe fistulizing Crohn's disease. Dig Liver Dis 2000;32:792-4. [PMID: 11215560 DOI: 10.1016/s1590-8658(00)80357-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 621 |
Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000;95:3469-77. [PMID: 11151879 DOI: 10.1111/j.1572-0241.2000.03363.x] [Cited by in Crossref: 163] [Cited by in F6Publishing: 173] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 622 |
Illei GG, Lipsky PE. Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases. Curr Opin Immunol 2000;12:712-8. [PMID: 11102777 DOI: 10.1016/s0952-7915(00)00167-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 623 |
Sopwith M. Therapeutic Applications of Monoclonal Antibodies: A Clinical Overview. Novel Therapeutic Proteins 2000. [DOI: 10.1002/9783527613021.ch12] [Reference Citation Analysis]
|
| 624 |
Sopwith M, Stephens S. An Engineered Human Antibody for Chronic Therapy: CDP571. Novel Therapeutic Proteins 2000. [DOI: 10.1002/9783527613021.ch14] [Reference Citation Analysis]
|
| 625 |
Monteleone G, MacDonald TT. Manipulation of cytokines in the management of patients with inflammatory bowel disease. Ann Med 2000;32:552-60. [PMID: 11127933 DOI: 10.3109/07853890008998835] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 626 |
Kast RE. Tumor necrosis factor has positive and negative self regulatory feed back cycles centered around cAMP. Int J Immunopharmacol 2000;22:1001-6. [PMID: 11090708 DOI: 10.1016/s0192-0561(00)00046-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 627 |
Heuschkel RB. New immunologic treatments for inflammatory bowel disease. Curr Opin Gastroenterol 2000;16:565-70. [PMID: 17031139 DOI: 10.1097/00001574-200011000-00018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 628 |
Nikolaus S, Raedler A, Kühbacker T, Sfikas N, Fölsch UR, Schreiber S. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000;356:1475-9. [PMID: 11081530 DOI: 10.1016/s0140-6736(00)02871-3] [Cited by in Crossref: 97] [Cited by in F6Publishing: 98] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 629 |
Hawkins J, Zheng S, Frantz B, LoGrasso P. p38 map kinase substrate specificity differs greatly for protein and peptide substrates. Arch Biochem Biophys 2000;382:310-3. [PMID: 11068883 DOI: 10.1006/abbi.2000.2005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 630 |
Suvannavejh GC, Lee HO, Padilla J, Dal Canto MC, Barrett TA, Miller SD. Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis. Cell Immunol 2000;205:24-33. [PMID: 11078604 DOI: 10.1006/cimm.2000.1706] [Cited by in Crossref: 115] [Cited by in F6Publishing: 121] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 631 |
Marano CW, Garulacan LA, Laughlin KV, Igidbashian L, Trace C, Goldman SM, Sutter FP, Reichard GA Jr, Mullin JM. Plasma concentrations of soluble tumor necrosis factor receptor I and tumor necrosis factor during cardiopulmonary bypass. Ann Thorac Surg 2000;70:1313-8. [PMID: 11081891 DOI: 10.1016/s0003-4975(00)01932-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 632 |
Fautrel B, Cherin P. [Value of anti-TNF-alpha molecules in inflammatory and infectious diseases]. Rev Med Interne 2000;21:872-88. [PMID: 11075396 DOI: 10.1016/s0248-8663(00)00238-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 633 |
Vasiliauskas E. Pediatric Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2000;3:403-24. [PMID: 11096601 DOI: 10.1007/s11938-000-0055-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 634 |
Kerschner JE, Beste DJ, Lynch JB, Fox MC, Kehl KS. Interleukin-1 receptor antagonist as an adjunct in the treatment of Haemophilus influenzae otitis media in the chinchilla. Laryngoscope 2000;110:1457-61. [PMID: 10983942 DOI: 10.1097/00005537-200009000-00009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 635 |
Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000;95:2338-42. [PMID: 11007239 DOI: 10.1111/j.1572-0241.2000.02324.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 72] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 636 |
Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech 2000;50:229-35. [PMID: 10891888 DOI: 10.1002/1097-0029(20000801)50:3<229::AID-JEMT6>3.0.CO;2-H] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 637 |
Monteleone G, Biancone L, Wedel S, Pallone F. IL-4 hyporesponsiveness of Crohn's disease mucosal T lymphocytes: a response of polarised Th1 cells? Dig Liver Dis 2000;32:495-7. [PMID: 11057924 DOI: 10.1016/s1590-8658(00)80006-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 638 |
Gerson LB, Triadafilopoulos G. Palliative care in inflammatory bowel disease: an evidence-based approach. Inflamm Bowel Dis 2000;6:228-43. [PMID: 10961595 DOI: 10.1097/00054725-200008000-00009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 639 |
Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000;137:192-6. [PMID: 10931411 DOI: 10.1067/mpd.2000.107161] [Cited by in Crossref: 102] [Cited by in F6Publishing: 111] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 640 |
Fujiwara N, Fujita H, Iwai K, Kurimoto A, Murata S, Kawakami H. Synthesis and bioactivities of novel piperidylpyrimidine derivatives: inhibitors of tumor necrosis factor-alpha production. Bioorg Med Chem Lett 2000;10:1317-20. [PMID: 10890155 DOI: 10.1016/s0960-894x(00)00227-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 641 |
Alavi K, Schwartz MZ, Palazzo JP, Prasad R. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg 2000;35:847-51. [PMID: 10873024 DOI: 10.1053/jpsu.2000.6861] [Cited by in Crossref: 78] [Cited by in F6Publishing: 79] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 642 |
Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-33. [PMID: 10834859 DOI: 10.1136/ard.59.6.428] [Cited by in Crossref: 193] [Cited by in F6Publishing: 226] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 643 |
Simpson SJ, de Jong YP, Comiskey M, Terhorst C. Pathways of T cell pathology in models of chronic intestinal inflammation. Int Rev Immunol 2000;19:1-37. [PMID: 10723675 DOI: 10.3109/08830180009048387] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 644 |
Hommes DW, van Deventer SJ. Anti- and proinflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease. Curr Opin Clin Nutr Metab Care 2000;3:191-5. [PMID: 10871234 DOI: 10.1097/00075197-200005000-00005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 645 |
Bell SJ, Kamm MA. Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease. Aliment Pharmacol Ther 2000;14:501-14. [PMID: 10792111 DOI: 10.1046/j.1365-2036.2000.00777.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 646 |
Beattie RM. Therapy of Crohn's disease in childhood. Paediatr Drugs 2000;2:193-203. [PMID: 10937470 DOI: 10.2165/00128072-200002030-00004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 647 |
Hill DB, Barve S, Joshi-Barve S, McClain C. Increased monocyte nuclear factor-kappaB activation and tumor necrosis factor production in alcoholic hepatitis. J Lab Clin Med 2000;135:387-95. [PMID: 10811053 DOI: 10.1067/mlc.2000.106451] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 648 |
Rutgeerts P. Infliximab is the drug we have been waiting for in Crohn's disease. Inflamm Bowel Dis 2000;6:132-6. [PMID: 10833073 DOI: 10.1097/00054725-200005000-00010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 649 |
Hanano T, Adachi K, Aoki Y, Morimoto H, Naka Y, Hisadome M, Fukuda T, Sumichika H. Novel phenylpiperazine derivatives as dual cytokine regulators with TNF-alpha suppressing and IL-10 augmenting activity. Bioorg Med Chem Lett 2000;10:875-9. [PMID: 10853650 DOI: 10.1016/s0960-894x(00)00128-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 650 |
Caulin C, Ware CF, Magin TM, Oshima RG. Keratin-dependent, epithelial resistance to tumor necrosis factor-induced apoptosis. J Cell Biol 2000;149:17-22. [PMID: 10747083 DOI: 10.1083/jcb.149.1.17] [Cited by in Crossref: 220] [Cited by in F6Publishing: 226] [Article Influence: 9.6] [Reference Citation Analysis]
|
| 651 |
Strand V. Recent advances in the treatment of rheumatoid arthritis. Clin Cornerstone 1999;2:38-50. [PMID: 10689543 DOI: 10.1016/s1098-3597(99)90013-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 652 |
Morelli J, Wilson FA. Does administration of infliximab increase susceptibility to listeriosis? Am J Gastroenterol 2000;95:841-2. [PMID: 10710107 DOI: 10.1111/j.1572-0241.2000.01872.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 653 |
Croxford JL, Triantaphyllopoulos KA, Neve RM, Feldmann M, Chernajovsky Y, Baker D. Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor. J Immunol 2000;164:2776-81. [PMID: 10679120 DOI: 10.4049/jimmunol.164.5.2776] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 654 |
Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000;95:359-67. [PMID: 10685736 DOI: 10.1111/j.1572-0241.2000.t01-1-01790.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 42] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 655 |
Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000;118:S68-82. [PMID: 10868899 DOI: 10.1016/s0016-5085(00)70007-2] [Cited by in Crossref: 167] [Cited by in F6Publishing: 172] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 656 |
Suitters A, Foulkes R. Cytokine-neutralizing therapeutic antibodies. Novel Cytokine Inhibitors 2000. [DOI: 10.1007/978-3-0348-8450-1_6] [Reference Citation Analysis]
|
| 657 |
Narula S, Smith S, Grint P. Interleukin 10. New Cytokines as Potential Drugs 2000. [DOI: 10.1007/978-3-0348-8456-3_2] [Reference Citation Analysis]
|
| 658 |
Karp LC, Targan SR. Antibodies to proinflammatory cytokines. Trends in Inflammatory Bowel Disease Therapy 1999 2000. [DOI: 10.1007/978-94-011-4002-7_22] [Reference Citation Analysis]
|
| 659 |
Taylor PC. Antibodies for inflammatory disease : cytokines. Methods Mol Med 2000;40:115-39. [PMID: 21337087 DOI: 10.1385/1-59259-076-4:115] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 660 |
Proujansky R. Therapeutic Approaches to Gastrointestinal Viral Infection of the Pediatric Bone Marrow Transplant Patient. Pediatric Pathology & Molecular Medicine 2000;19:179-185. [DOI: 10.1080/15513810009168632] [Reference Citation Analysis]
|
| 661 |
Meager A. Blockade of cytokine activity by soluble cytokine receptors. Novel Cytokine Inhibitors 2000. [DOI: 10.1007/978-3-0348-8450-1_8] [Reference Citation Analysis]
|
| 662 |
Van Assche G, Rutgeerts P. Anti-TNF agents in Crohn's disease. Expert Opin Investig Drugs 2000;9:103-11. [PMID: 11060664 DOI: 10.1517/13543784.9.1.103] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 663 |
Proujansky R. Fixing the intestinal mucosa in the bone marrow transplant patient: lessons from other intestinal immunodeficiencies and inflammatory disorders. Pediatr Transplant 1999;3 Suppl 1:9-13. [PMID: 10587965 DOI: 10.1034/j.1399-3046.1999.00071.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 664 |
Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999;117:1278-87. [PMID: 10579968 DOI: 10.1016/s0016-5085(99)70277-5] [Cited by in Crossref: 215] [Cited by in F6Publishing: 217] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 665 |
Sands BE. New biologic agents: a critical appraisal. Curr Gastroenterol Rep 1999;1:470-5. [PMID: 10980988 DOI: 10.1007/s11894-999-0005-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 666 |
Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999;117:1271-7. [PMID: 10579967 DOI: 10.1016/s0016-5085(99)70276-3] [Cited by in Crossref: 230] [Cited by in F6Publishing: 235] [Article Influence: 9.6] [Reference Citation Analysis]
|
| 667 |
Hanauer SB. Evolutionary biologic therapy for inflammatory bowel disease. Curr Gastroenterol Rep 1999;1:467-9. [PMID: 10980987 DOI: 10.1007/s11894-999-0004-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 668 |
Corazza N, Eichenberger S, Eugster HP, Mueller C. Nonlymphocyte-derived tumor necrosis factor is required for induction of colitis in recombination activating gene (RAG)2(-/-) mice upon transfer of CD4(+)CD45RB(hi) T cells. J Exp Med 1999;190:1479-92. [PMID: 10562322 DOI: 10.1084/jem.190.10.1479] [Cited by in Crossref: 103] [Cited by in F6Publishing: 109] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 669 |
D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999;50:667-71. [PMID: 10536324 DOI: 10.1016/s0016-5107(99)80017-0] [Cited by in Crossref: 155] [Cited by in F6Publishing: 168] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 670 |
Heller T, James SP, Drachenberg C, Hernandez C, Darwin PE. Treatment of severe esophageal Crohn's disease with infliximab. Inflamm Bowel Dis 1999;5:279-82. [PMID: 10579121 DOI: 10.1097/00054725-199911000-00006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 671 |
Cario E, Becker A, Sturm A, Goebell H, Dignass AU. Peripheral blood mononuclear cells promote intestinal epithelial restitution in vitro through an interleukin-2/interferon-gamma-dependent pathway. Scand J Gastroenterol 1999;34:1132-8. [PMID: 10582765 DOI: 10.1080/003655299750024940] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 672 |
van Deventer SJ. Anti-TNF antibody treatment of Crohn's disease. Ann Rheum Dis 1999;58 Suppl 1:I114-20. [PMID: 10577987 DOI: 10.1136/ard.58.2008.i114] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 673 |
Bregenholt S, Brimnes J, Nissen MH, Claesson MH. In vitro activated CD4+ T cells from interferon-gamma (IFN-gamma)-deficient mice induce intestinal inflammation in immunodeficient hosts. Clin Exp Immunol 1999;118:228-34. [PMID: 10540183 DOI: 10.1046/j.1365-2249.1999.01058.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 674 |
Negoro K, Kinouchi Y, Hiwatashi N, Takahashi S, Takagi S, Satoh J, Shimosegawa T, Toyota T. Crohn's disease is associated with novel polymorphisms in the 5'-flanking region of the tumor necrosis factor gene. Gastroenterology 1999;117:1062-8. [PMID: 10535868 DOI: 10.1016/s0016-5085(99)70390-2] [Cited by in Crossref: 134] [Cited by in F6Publishing: 138] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 675 |
Prehn JL, Landers CJ, Targan SR. A Soluble Factor Produced by Lamina Propria Mononuclear Cells Is Required for TNF-α Enhancement of IFN-γ Production by T Cells. The Journal of Immunology 1999;163:4277-4283. [DOI: 10.4049/jimmunol.163.8.4277] [Reference Citation Analysis]
|
| 676 |
Wall GC, Heyneman C, Pfanner TP. Medical options for treating Crohn's disease in adults: focus on antitumor necrosis factor-alpha chimeric monoclonal antibody. Pharmacotherapy 1999;19:1138-52. [PMID: 10512063 DOI: 10.1592/phco.19.15.1138.30574] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 677 |
Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9. [PMID: 10500056 DOI: 10.1016/s0016-5085(99)70332-x] [Cited by in Crossref: 769] [Cited by in F6Publishing: 786] [Article Influence: 32.0] [Reference Citation Analysis]
|
| 678 |
Hurd LB, Lichtenstein GR. Therapeutic potential of infliximab in inflammatory bowel disease. Gastroenterol Nurs 1999;22:199-208. [PMID: 10776108 DOI: 10.1097/00001610-199909000-00003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 679 |
Present DH. Review article: the efficacy of infliximab in Crohn's disease--healing of fistulae. Aliment Pharmacol Ther 1999;13 Suppl 4:23-8; discussion 38. [PMID: 10597336 DOI: 10.1046/j.1365-2036.1999.00026.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 680 |
Feagan BG. Review article: economic issues in Crohn's disease--assessing the effects of new treatments on health-related quality of life. Aliment Pharmacol Ther 1999;13 Suppl 4:29-37; discussion 38. [PMID: 10597337 DOI: 10.1046/j.1365-2036.1999.00028.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 681 |
McClane SJ, Rombeau JL. Cytokines and inflammatory bowel disease: a review. JPEN J Parenter Enteral Nutr 1999;23:S20-4. [PMID: 10483888 DOI: 10.1177/014860719902300506] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 682 |
van Deventer SJ. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab. Aliment Pharmacol Ther 1999;13 Suppl 4:3-8; discussion 38. [PMID: 10597333 DOI: 10.1046/j.1365-2036.1999.00024.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 64] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 683 |
Rutgeerts PJ. Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission. Aliment Pharmacol Ther 1999;13 Suppl 4:9-15; discussion 38. [PMID: 10597334 DOI: 10.1046/j.1365-2036.1999.00025.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 684 |
Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, Feldmann M, Maini RN. Regulation of Cytokines, Cytokine Inhibitors, and Acute-Phase Proteins Following Anti-TNF-α Therapy in Rheumatoid Arthritis. The Journal of Immunology 1999;163:1521-1528. [DOI: 10.4049/jimmunol.163.3.1521] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 685 |
Capristo E, De Gaetano A, Mingrone G, Addolorato G, Greco AV, Castagneto M, Gasbarrini G. Multivariate identification of metabolic features in inflammatory bowel disease. Metabolism 1999;48:952-6. [PMID: 10459556 DOI: 10.1016/s0026-0495(99)90188-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 686 |
Fish SM, Proujansky R, Reenstra WW. Synergistic effects of interferon gamma and tumour necrosis factor alpha on T84 cell function. Gut 1999;45:191-8. [PMID: 10403730 DOI: 10.1136/gut.45.2.191] [Cited by in Crossref: 124] [Cited by in F6Publishing: 129] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 687 |
Newton RC, Decicco CP. Therapeutic potential and strategies for inhibiting tumor necrosis factor-alpha. J Med Chem 1999;42:2295-314. [PMID: 10395470 DOI: 10.1021/jm980541n] [Cited by in Crossref: 160] [Cited by in F6Publishing: 164] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 688 |
Liverton NJ, Butcher JW, Claiborne CF, Claremon DA, Libby BE, Nguyen KT, Pitzenberger SM, Selnick HG, Smith GR, Tebben A, Vacca JP, Varga SL, Agarwal L, Dancheck K, Forsyth AJ, Fletcher DS, Frantz B, Hanlon WA, Harper CF, Hofsess SJ, Kostura M, Lin J, Luell S, O'Neill EA, O'Keefe SJ. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J Med Chem 1999;42:2180-90. [PMID: 10377223 DOI: 10.1021/jm9805236] [Cited by in Crossref: 174] [Cited by in F6Publishing: 174] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 689 |
Muller GW, Chen R, Huang SY, Corral LG, Wong LM, Patterson RT, Chen Y, Kaplan G, Stirling DI. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999;9:1625-30. [PMID: 10386948 DOI: 10.1016/s0960-894x(99)00250-4] [Cited by in Crossref: 277] [Cited by in F6Publishing: 282] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 690 |
Sands BE. Novel therapies for inflammatory bowel disease. Gastroenterol Clin North Am 1999;28:323-51. [PMID: 10372271 DOI: 10.1016/s0889-8553(05)70059-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 691 |
Wirtz S, Galle PR, Neurath MF. Efficient gene delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure. Gut 1999;44:800-7. [PMID: 10323880 DOI: 10.1136/gut.44.6.800] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 692 |
Williams AM, Whiting CV, Bonhagen K, Reimann J, Bregenholt S, Claesson MH, Bland PW. Tumour necrosis factor-alpha (TNF-alpha) transcription and translation in the CD4+ T cell-transplanted scid mouse model of colitis. Clin Exp Immunol 1999;116:415-24. [PMID: 10361228 DOI: 10.1046/j.1365-2249.1999.00915.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 693 |
Stein RB, Hanauer SB. Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am 1999;28:297-321. [PMID: 10372270 DOI: 10.1016/s0889-8553(05)70058-3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 694 |
Dinarello CA. Blocking IL-1 and TNF. Journal of Endotoxin Research 1999;5:174-176. [DOI: 10.1177/09680519990050030201] [Reference Citation Analysis]
|
| 695 |
Michetti P, Peppercorn MA. Medical therapy of specific clinical presentations. Gastroenterol Clin North Am 1999;28:353-70, viii. [PMID: 10372272 DOI: 10.1016/s0889-8553(05)70060-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 696 |
D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999;116:1029-34. [PMID: 10220494 DOI: 10.1016/s0016-5085(99)70005-3] [Cited by in Crossref: 519] [Cited by in F6Publishing: 548] [Article Influence: 21.6] [Reference Citation Analysis]
|
| 697 |
Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999;5:119-33. [PMID: 10338381 DOI: 10.1097/00054725-199905000-00008] [Cited by in Crossref: 276] [Cited by in F6Publishing: 286] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 698 |
Cada DJ, Baker DE. Etanercept. Hosp Pharm 1999;34:462-481. [DOI: 10.1177/001857879903400409] [Reference Citation Analysis]
|
| 699 |
Lavy A. Long-term cyclosporine for resistant Crohn's disease. J Clin Gastroenterol 1999;28:254-5. [PMID: 10192614 DOI: 10.1097/00004836-199904000-00014] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 700 |
Eysselein VE. Proteolytic release of membrane bound intercellular regulators. Gut 1999;44:454. [PMID: 10075948 DOI: 10.1136/gut.44.4.454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 701 |
Yang H, Plevy SE, Taylor K, Tyan D, Fischel-Ghodsian N, McElree C, Targan SR, Rotter JI. Linkage of Crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses. Gut 1999;44:519-26. [PMID: 10075959 DOI: 10.1136/gut.44.4.519] [Cited by in Crossref: 74] [Cited by in F6Publishing: 79] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 702 |
Gotteland M, Lopez M, Muñoz C, Saez R, Altshiller H, Llorens P, Brunser O. Local and systemic liberation of proinflammatory cytokines in ulcerative colitis. Dig Dis Sci 1999;44:830-5. [PMID: 10219845 DOI: 10.1023/a:1026690631693] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 703 |
Bondeson J, Browne KA, Brennan FM, Foxwell BMJ, Feldmann M. Selective Regulation of Cytokine Induction by Adenoviral Gene Transfer of IκBα into Human Macrophages: Lipopolysaccharide-Induced, But Not Zymosan-Induced, Proinflammatory Cytokines Are Inhibited, But IL-10 Is Nuclear Factor-κB Independent. The Journal of Immunology 1999;162:2939-2945. [DOI: 10.4049/jimmunol.162.5.2939] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 704 |
Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999;116:602-9. [PMID: 10029619 DOI: 10.1016/s0016-5085(99)70182-4] [Cited by in Crossref: 162] [Cited by in F6Publishing: 177] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 705 |
Brown GR, Lindberg G, Meddings J, Silva M, Beutler B, Thiele D. Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease. Gastroenterology 1999;116:593-601. [PMID: 10029618 DOI: 10.1016/s0016-5085(99)70181-2] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 706 |
Hodgson H. Prospects of new therapeutic approaches for Crohn's disease. Lancet 1999;353:425-6. [PMID: 9989709 DOI: 10.1016/S0140-6736(98)00304-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 707 |
Bouma G, Crusius JB, García-González MA, Meijer BU, Hellemans HP, Hakvoort RJ, Schreuder GM, Kostense PJ, Meuwissen SG, Peña AS. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol 1999;115:294-300. [PMID: 9933456 DOI: 10.1046/j.1365-2249.1999.00797.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 98] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 708 |
Murthy S, Cooper HS, Yoshitake H, Meyer C, Meyer CJ, Murthy NS. Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis. Aliment Pharmacol Ther 1999;13:251-60. [PMID: 10102957 DOI: 10.1046/j.1365-2036.1999.00457.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 709 |
Plitz T, Huffstadt U, Endres R, Schaller E, Mak TW, Wagner H, Pfeffer K. The resistance against Listeria monocytogenes and the formation of germinal centers depend on a functional death domain of the 55 kDa tumor necrosis factor receptor. Eur J Immunol 1999;29:581-91. [PMID: 10064074 DOI: 10.1002/(SICI)1521-4141(199902)29:02<581::AID-IMMU581>3.0.CO;2-A] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 710 |
Katz JA, Fiocchi C. Pathogenesis. Operative Strategies in Inflammatory Bowel Disease 1999. [DOI: 10.1007/978-1-4612-1396-3_3] [Reference Citation Analysis]
|
| 711 |
Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-8. [PMID: 9869598 DOI: 10.1016/s0016-5085(99)70224-6] [Cited by in Crossref: 338] [Cited by in F6Publishing: 351] [Article Influence: 14.1] [Reference Citation Analysis]
|
| 712 |
Pena LR, Hill DB, McClain CJ. Treatment with glutathione precursor decreases cytokine activity. JPEN J Parenter Enteral Nutr 1999;23:1-6. [PMID: 9888410 DOI: 10.1177/014860719902300101] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 713 |
Giacomelli R, Passacantando A, Frieri G, Parzanese I, D'Alò S, Vernia P, Pimpo MT, Petrucci C, Caprilli R, Cifone MG, Tonietti G. Circulating soluble factor-inhibiting natural killer (NK) activity of fresh peripheral blood mononuclear cells (PBMC) from inflammatory bowel disease (IBD) patients. Clin Exp Immunol 1999;115:72-7. [PMID: 9933422 DOI: 10.1046/j.1365-2249.1999.00741.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 714 |
Schmitz H, Fromm M, Bentzel C, Scholz P, Detjen K, Mankertz J, Bode H, Epple H, Riecken E, Schulzke J. Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. Journal of Cell Science 1999;112:137-46. [DOI: 10.1242/jcs.112.1.137] [Cited by in Crossref: 270] [Cited by in F6Publishing: 268] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 715 |
Hanauer SB, Stein RB. Medical Therapy. Operative Strategies in Inflammatory Bowel Disease 1999. [DOI: 10.1007/978-1-4612-1396-3_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 716 |
Perini P, Gallo P. Immunotherapies for Multiple Sclerosis. From Basic Immunology to Immune-Mediated Demyelination 1999. [DOI: 10.1007/978-88-470-2143-3_20] [Reference Citation Analysis]
|
| 717 |
Pathmakanthan S, Stack WA. Novel treatments in inflammatory bowel disease. Hosp Med 1999;60:19-23. [PMID: 10197093 DOI: 10.12968/hosp.1999.60.1.1019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 718 |
Conlong P, Nicholson DA, Shaffer JL, Jewell D. Crohn's Disease - Current views on Aetiology and its Impact on Management. Journal of the Royal College of Physicians of Edinburgh 1998;28:589-601. [DOI: 10.1177/147827159802800417] [Reference Citation Analysis]
|
| 719 |
Mackay F, Browning JL, Lawton P, Shah SA, Comiskey M, Bhan AK, Mizoguchi E, Terhorst C, Simpson SJ. Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. Gastroenterology 1998;115:1464-75. [PMID: 9834274 DOI: 10.1016/s0016-5085(98)70025-3] [Cited by in Crossref: 122] [Cited by in F6Publishing: 123] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 720 |
Stack WA, Jenkins D, Vivet P, Hawkey CJ. Lack of effectiveness of the platelet-activating factor antagonist SR27417A in patients with active ulcerative colitis: a randomized controlled trial. The Platelet Activating Factor Antagonist Study Group in Ulcerative Colitis. Gastroenterology 1998;115:1340-5. [PMID: 9834260 DOI: 10.1016/s0016-5085(98)70011-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 721 |
Neurath MF, Becker C, Barbulescu K. Role of NF-kappaB in immune and inflammatory responses in the gut. Gut 1998;43:856-60. [PMID: 9824616 DOI: 10.1136/gut.43.6.856] [Cited by in Crossref: 248] [Cited by in F6Publishing: 266] [Article Influence: 9.9] [Reference Citation Analysis]
|
| 722 |
Neurath MF, Fuss I, Schürmann G, Pettersson S, Arnold K, Müller-Lobeck H, Strober W, Herfarth C, Büschenfelde KH. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann N Y Acad Sci 1998;859:149-59. [PMID: 9928378 DOI: 10.1111/j.1749-6632.1998.tb11119.x] [Cited by in Crossref: 164] [Cited by in F6Publishing: 171] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 723 |
Camoglio L, Te Velde AA, Tigges AJ, Das PK, Van Deventer SJH. Altered Expression of Interferon-γ and Interleukin-4 in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 1998;4:285-90. [DOI: 10.1097/00054725-199811000-00005] [Cited by in Crossref: 78] [Cited by in F6Publishing: 79] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 724 |
Katsuyama K, Kojima R, Yokoyama S, Yanai M, Sueda N, Sugita M, Momose K, Yamada H. N2733, 1-[3-(3-pyridyl)-acryloyl]-2-pyrrolidinone hydrochloride inhibits LPS-induced TNF-alpha production and improves survival in endotoxemic mice. Biosci Biotechnol Biochem 1998;62:2177-81. [PMID: 9972238 DOI: 10.1271/bbb.62.2177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 725 |
Marriott JB, Westby M, Cookson S, Guckian M, Goodbourn S, Muller G, Shire MG, Stirling D, Dalgleish AG. CC-3052: A Water-Soluble Analog of Thalidomide and Potent Inhibitor of Activation-Induced TNF-α Production. The Journal of Immunology 1998;161:4236-4243. [DOI: 10.4049/jimmunol.161.8.4236] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 726 |
Muller GW, Shire MG, Wong LM, Corral LG, Patterson RT, Chen Y, Stirling DI. Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett 1998;8:2669-74. [PMID: 9873600 DOI: 10.1016/s0960-894x(98)00475-2] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 727 |
Simpson SJ, De Jong YP, Shah SA, Comiskey M, Wang B, Spielman JA, Podack ER, Mizoguchi E, Bhan AK, Terhorst C. Consequences of Fas-ligand and perforin expression by colon T cells in a mouse model of inflammatory bowel disease. Gastroenterology 1998;115:849-55. [PMID: 9753487 DOI: 10.1016/s0016-5085(98)70256-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 728 |
van Dullemen HM, Wolbink GJ, Wever PC, van der Poll T, Hack CE, Tytgat GN, van Deventer SJ. Reduction of circulating secretory phospholipase A2 levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn's disease. Relation between tumor necrosis factor and secretory phospholipase A2 in healthy humans and in active Crohn's disease. Scand J Gastroenterol 1998;33:1094-8. [PMID: 9829366 DOI: 10.1080/003655298750026813] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 729 |
Murch SH. Local and systemic effects of macrophage cytokines in intestinal inflammation. Nutrition 1998;14:780-3. [PMID: 9785361 DOI: 10.1016/s0899-9007(98)00083-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 730 |
Tillinger W, Gasche C, Reinisch W, Lichtenberger C, Bakos S, Dejaco C, Moser G, Vogelsang H, Gangl A, Lochs H. Influence of topically and systemically active steroids on circulating leukocytes in Crohn's disease. Am J Gastroenterol 1998;93:1848-53. [PMID: 9772043 DOI: 10.1111/j.1572-0241.1998.536_e.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 731 |
Clark MA, Plank LD, Connolly AB, Streat SJ, Hill AA, Gupta R, Monk DN, Shenkin A, Hill GL. Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis--a randomized, clinical trial. Crit Care Med 1998;26:1650-9. [PMID: 9781721 DOI: 10.1097/00003246-199810000-00016] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 732 |
Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, Mahieu P, Malaise M, De Groote D, Louis R, Belaiche J. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-6. [PMID: 9737669 DOI: 10.1046/j.1365-2249.1998.00662.x] [Cited by in Crossref: 436] [Cited by in F6Publishing: 468] [Article Influence: 17.4] [Reference Citation Analysis]
|
| 733 |
Makhatadze NJ. Tumor necrosis factor locus: genetic organisation and biological implications. Hum Immunol 1998;59:571-9. [PMID: 9757913 DOI: 10.1016/s0198-8859(98)00056-1] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 734 |
Hanauer SB, Cohen RD, Becker RV 3rd, Larson LR, Vreeland MG. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther 1998;20:1009-28. [PMID: 9829451 DOI: 10.1016/s0149-2918(98)80082-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 735 |
Nakada MT, Tam SH, Woulfe DS, Casper KA, Swerlick RA, Ghrayeb J. Neutralization of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells. Cell Adhes Commun 1998;5:491-503. [PMID: 9791729 DOI: 10.3109/15419069809005606] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 736 |
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63. [PMID: 9751087 DOI: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W] [Cited by in Crossref: 1073] [Cited by in F6Publishing: 1206] [Article Influence: 42.9] [Reference Citation Analysis]
|
| 737 |
Noguchi M, Hiwatashi N, Liu Z, Toyota T. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut 1998;43:203-9. [PMID: 10189845 DOI: 10.1136/gut.43.2.203] |
